‹łŽşĐ‰îAƒXƒ^ƒbƒtĐ‰îAŒ¤‹†A‹ĆŃ“™A‡“V“°‘ĺŠw‘ĺŠw‰@Šá‰ČŠw‚ÉŠÖ‚ˇ‚é—lX‚ȏî•ń‚đ‚˛ˆÄ“ŕ‚ľ‚Ü‚ˇB


‹ĆŃ


@

Ą‰ß‹Ž10”NŠÔ‚Ě‹ĆŃ‚đŽŚ‚ľ‚Ü‚ˇBIF, ƒCƒ“ƒpƒNƒgƒtƒ@ƒNƒ^[

@ 2018”N
yŒ´’˜‰p•śz
  1. Morimoto Y, Hirahara K, Kiuchi M, Wada T, Ichikawa T, Kanno T, Okano M, Kokubo K, Onodera A, Sakurai D, Okamoto Y, Nakayama TFAmphiregulin-Producing Pathogenic Memory T Helper 2 Cells Instruct Eosinophils to Secrete Osteopontin and Facilitate Airway FibrosisDImmunity, 2018; 49(1): 134-150 (IF: 19.734)
  2. Suto H, Nambu A, Morita H, Yamaguchi S, Numata T, Yoshizaki T, Shimura E, Arae K, Asada Y, Motomura K, Kaneko M, Abe T, Matsuda A, Iwakura Y, Okumura K, Saito H, Matsumoto K, Sudo K, Nakae S: IL-25 enhances Th17 cell-mediated contact dermatitis by promoting IL-1b production by dermal dendritic cells. J Allergy Clin Immunol, 2018; 142: 1500-1509 (IF: 13.258)
  3. Matsuda A, Asada Y, Suita N, Iwamoto S, Hirakata T, Yokoi N, Ohkawa Y, Okada Y, Yokomizo T, Ebihara N.FTranscriptome profiling of refractory atopic keratoconjunctivitis by RNA sequencing. J Allergy Clin Immunol, 2018 Nov 21. pii: S0091-6749(18)31639-7. [Epub ahead of print], 2018 (IF: 13.258)
  4. Takamori A, Izawa K, Kaitani A, Ando T, Okamoto Y, Maehara A, Tanabe A, Nagamine M, Yamada H, Uchida S, Uchida K, Isobe M, Hatayama T, Watanabe D, Ando T, Ide T, Matsuzawa M, Maeda K, Nakano N, Tamura N, Ikeda K, Ebihara N, Shimizu T, Ogawa H, Okumura K, Kitaura J.FIdentification of inhibitory mechanisms in pseudo-allergy involving Mrgprb2/MRGPRX2-mediated mast cell activation. J Allergy Clin Immunol, 2018; Nov 8. pii: S0091-6749(18)31574-4. [Epub ahead of print], 2018D(IF: 13.258)
  5. Vu CHV, Kawashima M, Yamada M, Suwaki K, Uchino M, Shigeyasu C, Hiratsuka Y, Yokoi N, Tsubota K: Dry Eye Cross-Sectional Study in Japan Study Group. Influence of Meibomian Gland Dysfunction and Friction-Related Disease on the Severity of Dry Eye. Ophthalmology, 2018; 125(8): 1181-1188 (IF: 7.479)
  6. Inomata T, Nakamura M, Iwagami M, Shiang T, Yoshimura Y, Fujimoto K, Okumura Y, Eguchi A, Iwata N, Miura M, Hori S, Hiratsuka Y, Uchino M, Tsubota K, Dana R and Murakami A: Risk Factors for Severe Dry Eye Disease: Crowdsourced Research Using DryEyeRhythm. Ophthalmology (in press) (IF: 7.479)
  7. Kuribayashi H, Baba Y, Iwagawa T, Arai E, Murakami A, Watanabe S: Roles of Nmnat1 in the survival of retinal progenitors through the regulation of pro-apoptotic gene expression via histone acetylation. Cell Death Dis 2018, ; 9(9):891. doi: 10.1038/s41419-018-0907-0. (IF: 5.638)
  8. Hirakata T, Lee HC, Ohba M, Saeki K, Okuno T, Murakami A, Matsuda A, Yokomizo T: Dietary omega-3 fatty acids alter the lipid mediator profile and alleviate allergic conjunctivitis without modulating Th2 immune responses. FASEB J. (in press) (IF: 5.595)
  9. Tan X, Chen Y, Foulsham W, Amouzegar A, Inomata T, Liu Y, Chauhan SK, Dana R: The immunoregulatory role of corneal epithelium-derived thrombospondin-1 in dry eye disease. Ocul Surf, 2018; 16(4): 470-477 (IF: 5.53)
  10. Inomata T, Iwagami M, Hiratsuka Y, Fujimoto K, Okumura Y, Shiang T, Murakami A: Maximum blink interval is associated with tear film breakup time: A new simple, screening test for dry eye disease. Sci Rep, 2018; 8(1): 13443. doi: 10.1038/s41598-018-31814-7 (IF: 4.122)
  11. Inomata T, Shiang T, Iwagami M, Sakemi F, Fujimoto K, Okumura Y, Ohno M, Murakami A: Changes in Distribution of Dry Eye Disease by the New 2016 Diagnostic Criteria from the Asia Dry Eye Society. Sci Rep, 2018; 8(1): 1918 (IF: 4.122)
  12. Inoue S, Kawashima M, Hiratsuka Y, Nakano T, Tamura H, Ono K, Murakami A, Tsubota K, Yamada M: Assessment of physical inactivity and locomotor dysfunction in adults with visual impairment. Sci Rep, 2018; 8(1): 12032. doi: 10.1038/s41598-018-30599-z. (IF: 4.122)
  13. Hua J, Inomata T, Chen Y, Foulsham W, Stevenson W, Shiang T, Bluestone JA, Dana R: Pathological conversion of regulatory T cells is associated with loss of allotolerance. Sci Rep, 2018; 8(1): 7059 (IF: 4.122)
  14. Hiraishi Y, Nambu A, Yamaguchi S, Shimura E, Takamori A, Narushima S, Nakanishi W, Asada Y, Sugita J, Yoshizaki T, Suzukawa M, Yamauchi Y, Matsuda A, Arae K, Morita H, Suto H, Okumura K, Matsumoto K, Saito H, Sudo K, Iikura M, Nagase , Nakae S: IL-33, IL-25 and TSLP contribute to development of fungal-associated protease-induced innate-type airway inflammation. Sci Rep. (in press) (IF: 4.122)
  15. Asada Y, Okano M, Ishida W, Iwamoto S, Fukuda K, Hirakata T, Tada N, Fukushima A, Ebihara N, Kudo A, Matsuda A: Periostin deletion suppresses late-phase response in mouse experimental allergic conjunctivitis. Allergol Int, 2018 Nov 9. pii: S1323-8930(18)30144-8. [Epub ahead of print], 2018 (IF: 4.045)
  16. Matsuno T, Toyoshima S, Sakamoto-Sasaki T, Kashiwakura J, Matsuda A, Watanabe Y, Azuma H, Kawana K, Yamamoto T, Okayama Y: Characterization of human decidual mast cells and establishment of a culture system. Allergol Int. (in press) (IF: 4.045)
  17. Kawamura Y, Suga A, Fujimaki T, Yoshitake K, Tsunoda K, Murakami A, Iwata T: LRRTM4-C538Y novel gene mutation is associated with hereditary macular degeneration with novel dysfunction of ON-type bipolar cells. J Hum Genet, 2018; 63(8): 893-900. doi: 10.1038/s10038-018-0465-4. Epub 2018 May 14. (IF: 2.942)
  18. Inomata T, Mizuno J, Iwagami M, Kawasaki S, Shimada A, Inada E, Shiang T, Amano A: The impact of Joint Commission International accreditation on time periods in the operating room: A retrospective observational study. PLoS ONE, 2018 13(9): e0204301 (IF: 2.766)
  19. Niihata K, Fukuma S, Hiratsuka Y, Ono K, Yamada M, Sekiguchi M, Otani K, Kikuchi S, Konno S, Fukuhara S: Association between vision-specific quality of life and falls in community-dwelling elderly people: LOHAS. PLoS ONE, 2018 Apr 24; 13(4):e0195806. doi: 10.1371/journal.pone. 0195806. eCollection 2018 (IF: 2.766)
  20. Ohta T, Ichikawa K, Matsuzaki Y, Toshida H, Murakami A: L-pocket scleral incision. J Cataract Refract Surg, (in press) (IF: 2.68)
  21. Toshida H, Suto C: Preganglionic parasympathetic denervation rabbit, model for innervation studies. Cornea, 2018; 37(Suppl 1); s106-s112 (IF; 2.464)
  22. Inomata T, Hua J, Nakao T, Shiang T, Chiang H, Amouzegar A, Dana R: Corneal Tissue From Dry Eye Donors Leads to Enhanced Graft Rejection. Cornea, 2018 Jan;37(1):95-101. doi: 10.1097/ICO.0000000000001400 (IF:2.464)
  23. Shigeyasu C, Yamada M, Kawashima M, Suwaki K, Uchino M, Hiratsuka Y, Yokoi N, Tsubota K: DECS-J study group. Quality of life measures and health utility values among dry eye subgroups. Health Qual Life Outcomes, 2018; 16(1): 170. doi: 10.1186/s12955-018-0999-3 (IF; 2.278)
  24. Nomura Y, Toida H , Fukui C , Kai S , Nakaoka R , Kato R , Uematsu M , Ono K , Kanai A , Haishima Y: Evaluation of Pigment Distribution and Depth Analysis Methods for Decorative Soft Contact Lenses. Eye & Contact lens, 2018; 44: S105-S112(IF: 1.813)
  25. Iwatake A, Murakami A, Ebihara NFThe expression of matrix metalloproteinases and their inhibitors in corneal fibroblasts by alarmins from necrotic corneal epithelial cellsDJpn J Ophthalmol, 2018; 62(1): 92-100 (IF: 1.775)
  26. Hamada M, Ohkoshi K, Inagaki K, Ebihara N, Murakami A: Visualization of microaneurysms using optical coherence tomography angiography: comparison of OCTA en face, OCT B-scan, OCT en face, FA, and IA imagesDJpn J Ophthalmol, 2018; 62(2): 168-175 (IF: 1.775)
  27. Hamada M, Ohkoshi K, Inagaki K, Ebihara N, Murakami A: Correction to: Visualization of microaneurysms using optical coherence tomography angiography: comparison of OCTA en face, OCT B-scan, OCT en face, FA, and IA images. Jpn J Ophthalmol,2018; 62(2): 176-178 (IF: 1.775)
  28. Takei M, Obana A, Inomata T, Tanaka T, Shiang T, Bae Y, Takemura T, Murakami A: Fundus changes in type III membranoproliferative glomerulonephritis: a case report. BMC Ophthalmol, 2018; 18(1): 72, https://doi.org/10.1186/s12886-018-0738-x (IF: 1.77)
  29. Hamada M, Ohkoshi K, Inagaki K, Ebihara N, Murakami A.FSubthreshold Photocoagulation Using Endpoint Management in the PASCAL® System for Diffuse Diabetic Macular EdemaDJ Ophthalmol, 2018; Jan 31;2018: 7465794 eCollection (IF: 1.68)
  30. Ichikawa K, Kambe T, Kurihara J, Hiratsuka Y, Murakami A: Visual Impairment Caused by an Intra-Orbital Dermoid Cyst in 9-Month-Old Infant, Ann Case Rep: ACRT-167, 2018. DOI: 10.29011/2574-7754/100067
  31. Miura-Karasawa, Toshida H, Ohta T, Murakami A: Papilloma and sebaceous gland hyperplasia of the lacrimal caruncle: a case report. Int Med Case Rep J, 2018 Apr 27; 11: 91-95. doi: 10.2147/IMCRJ.S162528. eCollection 2018.
  32. Tamaki Y, Hiratsuka Y, Kumakawa T, Miura H: Relationship between the Necessary Support Level for Oral Hygiene and Performance of Physical, Daily Activity, and Cognitive Functions. International Journal of Dentistry, Vol 2018, Article ID 1542713, https://doi.org/10.1155/ 2018/1542713
  33. Qi H, Chen Y, Inomata T, Amouzegar A, Dana R: IL-10-Producing Th17 Cells: A Potentially Regulatory Cell Population in Dry Eye Disease. Journal of Immunology and Immunotherapy, 2018; 2(1): 1-5
  34. Ogawa M, Inomata T, Shiang T, Tsubota K, Murakami A: Method for selective quantification of immune and inflammatory cells in the cornea using flow cytometry. J Biol Methods, 2018; 5(4): e102. doi: 10.14440/jbm.2018.237
yŒ´’˜˜a•śz
  1. ŠC˜VŒ´Ls: Šá–ň—Œ¤‹†‚Ě‚˝‚ß‚ĚŠá‰Č—Տ° “ŤƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠł‚ĚŽĄ—Ð헪(ŽŸ˘‘ăƒV[ƒNƒGƒ“ƒT[‰đÍ‚Š‚ç‚í‚Š‚é‚ą‚Ć). Šá–ň—, 2018; 32(1): 59-62
  2. ź“c˛: ƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰Š‚É‚¨‚Ż‚éŠî‘bŒ¤‹†. ƒAƒŒƒ‹ƒM[E–Ɖu, 2018; 25(7): 880-885
  3. “yŽŠ“cG, ‘ž“cr•F, {“ĄŽjŽq, ‘şăť: •›ŒđŠ´_Œoœ_Œo‰Ć“eƒhƒ‰ƒCƒAƒCƒ‚ƒfƒ‹‚É‚¨‚Ż‚郌ƒ`ƒm[ƒ‹ƒpƒ‹ƒ~ƒ`ƒ“Ž_ƒGƒXƒeƒ‹“_Šá‰t‚ĚŽĄ—ĂŒř‰Ę. Šá–ň—, 2018; 32(1): 28-32
  4. •‹“Ö‰p, ‰ĄŽR—˜K: ‹­–Œ“ŕŒĹ’čp‚Ć–Ń—la–D’…p‚Ě”äŠr. Šá‰Č, 2018; 60(7): 733-741
  5. –{“c—•ô, t“úrŒő, ‘şăť, ź“c˛: ‘B“œ”A•a–Ô–ŒÇ‚ɍ‡•š‚ľ‚˝ŒŒŠÇVś—Γŕá‚ɑ΂ˇ‚éƒoƒ‹ƒxƒ‹ƒgƒCƒ“ƒvƒ‰ƒ“ƒg‚ĚŽčpŹŃ. Šá‰Č, 2018; 60(9): 957-962
  6. ˆÉ“Ą—z‰î, –Ř‘şŽŠ, ‹Ęé˜a”Í, –]ŒŽ—Sl, “n糌d, ŠC˜VŒ´LsFƒhƒ‰ƒCƒAƒC‡•š—ΓŕáŠłŽŇ‚É‚¨‚Ż‚郌ƒoƒ~ƒsƒh“_Šá‰t‚Ě—L—pŤ‚ĚŒŸ“˘. Šá‰Č, 2018; 60(2): 175-180
  7. ‹{ě—R‹NŽq, Šâ’|˛, ‘ĺŽR—S‰Ŕ—˘, Žćo—•, —é–Ř‹M‰p, •‹“Ö‰p, ‰ĄŽR—˜K: TS-1(5-FUŒnŒoŒűRŠŕ–ň)“ŕ•ž‰Á—Ă’†‚ÉŠp–Œă”çáŠQ‚đ”F‚ß‚˝2Ç—á. Šá—Ő‹I, 2018; 11(3): 176-180
  8. ’ˇ’Jě“ľ, M–؏rŹ, ŽRŒűš‘ĺ, ‘şăť: ƒIƒ‹ƒ\ƒPƒ‰ƒgƒƒW[ƒŒƒ“ƒY‘•—p’†‚ÉŠp–ŒŠ´őÇ‚đ‚Ť‚˝‚ľ‚˝–˘Ź”NŠłŽŇ‚Ě2—á. Šá—Ő‹I, 2018; 11(5): 339-343
  9. ‘ĺ–쐐, M–؏rŹ, ŽRŒűš‘ĺ, Šâ–{—ĺ, t“úrŒő, ‘şăť: ”’“ŕápŒă‚ÉŠp–ŒúE‚đ—ˆ‚ľ‚˝3Ç—á. “úŠá‰ďŽ, 2018; 122(4): 300-305
  10. •˝Œ`Žő•j, —›ŒŤú•, ‘ĺšĹ–ƒś, ˛”Œ˜aŽq, ‰œ–ě—˜–ž, ź“c˛, ‘şăť, ‰ĄaŠx•F: ƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰Š‚ɑ΂ˇ‚éƒIƒƒK3Ž‰–bŽ_‚ĚŒř‰Ę‚ĚŒŸŘ. Ž‰Žżś‰ťŠwŒ¤‹†, 2018, 60: 34-36
  11. ‘ĺ’J—mŠö, “yŽŠ“cG, ”–؍LĆ, źč—LC, ŹX—ƒ, ’Š‰ŞšŽq, Žsě_•˝, —Ń—Y‰î, ŒK–ź—ş•ă, ‘ž“cr•F: “řĘŽîᎂ̊p–ŒŒă–ʐڐG‚É‚ć‚鐅ávŤŠp–ŒÇ‚ɑ΂ľŠp–Œ“ŕ”çˆÚAp‚Ş—LŒř‚Ĺ‚ ‚Á‚˝1—á. —ŐŠá, 2018; 72(3): 359-362
  12. ‘şăŒb”ü, ŞŠÝ‹MŽu, ŕ_”¨“O–ç, ‘şăť: F‘fŽ¸’˛Ç‚É‚¨‚Ż‚錌ŠÇ•ÂÇ‚̐is‚Ć–Ô–ŒŒő‹ĂŒĹ. Šá—Ő‹I, 2018; 11(5): 372-376
  13. “ěç’q: ‰Š”Á‘O–Œ‚ɑ΂ˇ‚é25GA27GÉŽq‘ĚŽčp‚Ě”äŠr. —ŐŠá, 2018; 72(10): 1373-1377
  14. ‹Ęé–ƒ‰Ä, ‘ĺ“ŕˆŸ—R”ü, âź—ǐm, —›ˆŸ”ü, ŠC˜VŒ´Ls: ŽĄ—ĂŠJŽnŒă‚É”xŒ‹Šj‚Ö‚ĚœëŠł‚Ş”ť–ž‚ľ‚˝“œ”A•a–Ô–ŒÇ3—á. —ŐŠá, 2018; 72(8): 1161-1167
  15. ‘ĺŽR—S‰Ŕ—˘, t“úrŒő, –{“c—•ô, ź“c˛, ‘şăť: “–‰@‚É‚¨‚Ż‚éEx-PRESS‘}“üp‚̏pŒăŹŃ. Šá‰ČŽčp, 2018; 31(4): 603-606
  16. ‘ƒŽRˆŸ‹IŽq, •˝’Ë‹`@, ‘şăť: –Ô–ŒF‘f•ĎŤ‚ĚŒoŽž“I•]‰ż‚É‚¨‚Ż‚éFunctional Vision Score‚Ě—L—pŤ‚ɂ‚˘‚Ä. Šá‰Č, 2018; 60(11): 1393-1400
  17. ˛“Ą”ü•Ű, ‰Á“ĄŒőL, “c“‡•qL, ě‘şF, m‰ČKŽq, ŞŠÝ‹MŽu, Š`Œ´Š°Žq, ‰ě‰Ăˆę, ź‘ş–], ŽO–؏~Ži, Ž›ˆä•üŽq, ‰ĄŽR—˜K, X“c—R, ŽOŒ´”ü°, –ě‘şkŽĄ, •x“c, —ŃŽv‰š, ˆéŠLł’q, –x“cŠě—T: ’†ŠuŽ‹_ŒoˆŮŒ`ŹÇ‚ĚŠá‰Čf—Ă‚ÉŠÖ‚ˇ‚錤‹†. Šá—Ő‹I, 2018; 11(5): 395-400
  18. ‘ž“ě‹MŽq, •ˆäłl, ´“cáÁ—Žq, âV“Ą—Y‘ž, “Œ”͍s, m‰ČKŽq, ŠŰŽqˆę˜N, ŞŠÝ‹MŽu, –ě“c‰pˆę˜Y, ‘ĺŒFNO, ‹g“cŒ\, “ĄŠŞ‘ń˜Y, ź–{’ź, “n粌b”üŽq, âV“Ą˝: ’´’áoś‘̏dŽ™‚É‚¨‚Ż‚é–˘nŽ™–Ô–ŒÇ@“Œ‹ž“s‘˝Ž{ÝŒ¤‹†. “úŠá‰ďŽ, 2018; 122(2) : 103-113
  19. ›IłM, –Ľ—Ö—LŽq, ˆîŠ_Œ\Ži, ŕ_“c^Žj, ‘ĺ‰z‹MŽuŽq: –Ô–ŒĂ–Ź•ŞŽ}•ÂÇÇ‚̉Š”Á•‚Žî‚ɑ΂ˇ‚錌ŠÇ“ŕ”瑝BˆöŽq‘jŠQ–ňÉŽq‘Ě’ŽË—Ă–@‚Ć’áNP‰Š”ÁŒő‹ĂŒĹp‚Ě•š—p—Ă–@‚ĚŒŸ“˘. —ŐŠá, 2018; 72(10): 1413-1419
  20. “ż‰i‹`˜Y, ź‘ş‰hˆę, ŽOˆäç’U, –űˆäˆęŒh, ‹g“cŒ’–ç, ™ŽR“Ţ’ĂŽq, ‘“cŒőF, ‘ž“cr•F, ‚‹´t’j: ‹­–ŒL-ƒ|ƒPƒbƒgŘŠJ–@‚É‚ć‚čŠá“ŕƒŒƒ“ƒY‚Ě“EoA–Ń—la–D’…p‚đŽ{s‚ľ‚˝“ń—á. IOL&RS, 2018; 32(1): 79-84
y‘ŕz
  1. Tahvildari M, Inomata T, Amouzegar A, Dana R (Co-first author): Regulatory T Cell Modulation of Cytokine and Cellular Networks in Corneal Graft Rejection. Curr Ophthalmol Rep, 2018; 6(4): 266-274
  2. Takamura Y, Ohkoshi K, Murata T: New strategies for treatment of diabetic macular edema. J Opthalmol, 2018; Aug 19;2018:4292154. doi: 10.1155/2018/4292154. eCollection 2018.
  3. ‘şăť: y‚ŕ‚Á‚Ć’m‚č‚˝‚˘ƒIƒ‹ƒ\ƒPƒ‰ƒgƒƒW[z ƒIƒ‹ƒ\ƒPƒ‰ƒgƒƒW[ƒKƒCƒhƒ‰ƒCƒ“. OCULISTA, 2018; 59-62
  4. ‘şăť: yuŠá‰Čˆă‚Ş’m‚Á‚Ä‚¨‚­‚ׂŤ•ŰŒŻ‚ƎЉď•Űá‚Ě˜bvz f—Ă•ńV‰ü’č‚ĚŽd‘g‚Ý. “ú–{‚ĚŠá‰Č, 2018; 89i7j: 891-894
  5. ‘ž“cr•F: ‚ą‚ž‚í‚č‚̐f—ĂŠí‹ď@‚ ‚˝‚ç‚ľ‚˘‘˝–Ú“IŠj•ŞŠ„ƒfƒBƒoƒCƒ_[iJƒ`ƒ‡ƒbƒp[ji‰đŕj. IOL&RS, 2018; 32(3): 535-538
  6. ‘ž“cr•F: Šá“ŕƒŒƒ“ƒY–D’…A‹­–Œ“ŕŒĹ’č‚Ě“K‰ž‚Ćƒ|ƒCƒ“ƒg‚ɂ‚˘‚Ä‹ł‚Ś‚ĉş‚ł‚˘. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č, 2018; 35(—Ő‘): 193-200
  7. ŠC˜VŒ´Ls, ‘ĺ“ŕˆŸ—R”ü: Šá‚Ě•a‹C‚Ć‚­‚ˇ‚č ‚Ô‚Ç‚¤–Œ‰Š. –ň‹Ç, 2018; 69(4): 1617-1618
  8. ŠC˜VŒ´Ls, ‘ĺ“ŕˆŸ—R”üFŠá‚Ě•a‹C‚Ć‚­‚ˇ‚č Œ‹–Œ‰Š.  –ň‹Ç, 2018; 69(4): 1616-1617
  9. ŠC˜VŒ´Ls: –Ú‚Ě‚Š‚ä‚Ý‚Ć”’“ŕáE–Ô–Œ”—Ł. ŹŽ™“ŕ‰Č, 2018; 50(7): 1158-1160
  10. ŠC˜VŒ´Ls: uÔ‚ż‚á‚ń‚Ć‚¨•ę‚ł‚ń‚Ě‚˝‚ß‚ĚƒAƒŒƒ‹ƒM[“Ç–{vt‹GƒJƒ^ƒ‹‚Á‚Ä‚Č‚ń‚Ĺ‚ˇ‚Š. ŽüŽYŠúˆăŠw, 2018; 48 ‘Š§†: 426-427
  11. ŠC˜VŒ´Ls: uÔ‚ż‚á‚ń‚Ć‚¨•ę‚ł‚ń‚Ě‚˝‚ß‚ĚƒAƒŒƒ‹ƒM[“Ç–{v–Ú‚Şáy‚˘‚Ě‚Š‚ć‚­–Ú‚đ‚ą‚ˇ‚Á‚˝‚č’@‚˘‚˝‚č‚ľ‚Ä‚˘‚Ü‚ˇB‚Ç‚¤‚ľ‚˝‚ç‚悢‚Ĺ‚ˇ‚Š. ŽüŽYŠúˆăŠw, 2018; 48 ‘Š§†: 428-429
  12. ŠC˜VŒ´Ls: uÔ‚ż‚á‚ń‚Ć‚¨•ę‚ł‚ń‚Ě‚˝‚ß‚ĚƒAƒŒƒ‹ƒM[“Ç–{vƒXƒeƒƒCƒh“_Šá–ň‚đŽg—p‚ˇ‚é‚Ć‚Ť‚Ě’ˆÓ“_‚đ‹ł‚Ś‚Ä‚­‚ž‚ł‚˘. ŽüŽYŠúˆăŠw, 2018; 48 ‘Š§†: 430-431
  13. ŠC˜VŒ´Ls: uÔ‚ż‚á‚ń‚Ć‚¨•ę‚ł‚ń‚Ě‚˝‚ß‚ĚƒAƒŒƒ‹ƒM[“Ç–{v–Ɖu—}§–ň“_Šá–ň‚Ş‚ ‚é‚Ć•ˇ‚Ť‚Ü‚ľ‚˝B‚ć‚­Œř‚Ť‚Ü‚ˇ‚Š. ŽüŽYŠúˆăŠw, 2018; 48 ‘Š§†: 432
  14. ŠC˜VŒ´Ls: ƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠłŠłŽŇ‚̗܉t‚Š‚ç‰đ‚鎖i—܉t’†ƒoƒCƒIƒ}[ƒJ[‚̐V‚ľ‚˘’n•˝j. ƒAƒŒƒ‹ƒM[‚Ě—Ő°, 2018; 38i10j: 16
  15. •˝’Ë‹`@: ˘ŠE‚ĚŽ¸–ž‚Í‚Ç‚¤‚Č‚Á‚Ä‚˘‚é‚Ě‚Š@2018 updates. “úŠá‰ďŽ, 2018; 122(7): 537-545
  16. “yŽŠ“cG, ŽR‰Ş—TŽq, “c•ŁĆl: yRŽ_‰ťƒrƒ^ƒ~ƒ“‚ĆŽžŠł‚ĚŠÖŒWzƒrƒ^ƒ~ƒ“A‚Ćƒhƒ‰ƒCƒAƒC. H‚Ćˆă—Ă, 2018; 6: 69-77
  17. “yŽŠ“cG: yƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY—pŒęW‘ć22‰ńzƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚Ě–@—Ľă‚Ě•Ş—Ţ. “úƒRƒŒŽ, 2018; 60: 48-49
  18. “yŽŠ“cG: y‚ŕ‚Á‚Ć’m‚č‚˝‚˘ƒIƒ‹ƒ\ƒPƒ‰ƒgƒƒW[zƒIƒ‹ƒ\ƒPƒ‰ƒgƒƒW[‚Ě‹üÜ‹¸łŒ´—‚ĆŠp–Œ‚ւ̉e‹ż. Monthly Book OCULISTA, 2018; 66: 13-19
  19. “yŽŠ“cG: ‰“‹ß—ź—pCL‚ĚŠî‘b‚Ɖž—p|˜VŽ‹‘΍ô‚Š‚ç‹ßŽ‹—}§‚܂Ł\. Šá‰ČƒOƒ‰ƒtƒBƒbƒN, 2018; 7: 541
  20. “yŽŠ“cG: ‰“‹ß—ź—p‚ĚŠT˜_. Šá‰ČƒOƒ‰ƒtƒBƒbƒN, 2018; 7: 542-548
  21. ŞŠÝ‹MŽu:  yŠá‹…‰^“ŽáŠQ‚Ě‚ˇ‚ׂāz –ƒáƒŤŽÎŽ‹‚ĚŽčpŽĄ—Ă. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 35(3): 343-348, 2018
  22. ŞŠÝ‹MŽu: yƒCƒ`‚Š‚ç‚Í‚ś‚ß‚é_ŒoŠá‰Čf—Áz Šá‹…‰^“ŽáŠQ‚ĚŽĄ—Ă. OCULISTA 61, 51-54, 2018.
  23. ŞŠÝ‹MŽu: ‰şŽÎ‹ŘŘœp. https://iseminar.net/e05200146, 2018
  24. ŞŠÝ‹MŽu: ŒĹ’č“ŕŽÎŽ‹@‰ĄŽR–@. https://iseminar.net/e05200145, 2018
  25. ŞŠÝ‹MŽu: ‰~ŠW•”ŹŘŠJ‚É‚ć‚éŠO’ź‹Ř“]p. https://iseminar.net/e05200144, 2018
  26. ŞŠÝ‹MŽu: ƒoƒbƒNƒŠƒ“ƒOE—ΓŕáŽčp‚Ŗ𗧂 oŒŒ‚ľ‚Č‚˘Œ‹–ŒŘŠJ. ttps://iseminar.net/e05200143, 2018
  27. ŞŠÝ‹MŽu: g‘̏áŠQŽŇŽč’ ˆÓŒŠ‘‚̏‘‚Ť•ű@2018”N‰üłŒă. https://iseminar.net/e07100198, 2018
  28. ŞŠÝ‹MŽu: ŽÎŽ‹–ň•¨ŽĄ—Á\ Pharmacologic treatment of strabismus \. https://ophthalmology- update.jp/reviews/review/201804r01, 2018
  29. ŞŠÝ‹MŽu: •ĄŽ‹‚đ‘i‚Ś‚˝Ç—á. https://ophthalmology-update.jp/reviews/casereport/201804c01, 2018
  30. ’––“•”Í: ResearchKit‚đ—p‚˘‚č쐬‚ľ‚˝iPhoneƒAƒvƒŠƒP[ƒVƒ‡ƒ“uƒhƒ‰ƒCƒAƒCƒŠƒYƒ€v‚É‚ć‚éƒhƒ‰ƒCƒAƒC‚ĚŒ[”­‚ƐV‚ľ‚˘‘ĺ‹K–Í—Ő°Œ¤‹†. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č, 2018; 35(7): 871-877
  31. ’––“•”Í: §ŒäŤT×–E(Treg)‚ɂ‚˘‚Ä. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č, 2018; 35(9): 1255
  32. ‘ĺ“ŕˆŸ—R”ü, ŠC˜VŒ´Ls: Šá‚Ě•a‹C‚Ć‚­‚ˇ‚č –Ô–ŒF‘f•ĎŤÇ –ň‹Ç, 2018 69(4):  1618-1619
  33. ‘ĺ“ŕˆŸ—R”ü, ŠC˜VŒ´Ls: Šá‚Ě•a‹C‚Ć‚­‚ˇ‚č ”’“ŕá. –ň‹Ç, 2018; 69(4): 1613-1615
  34. źč—LC, ‘ž“cr•F: y‚ą‚ę‚Ĺ‚í‚Š‚éŠá“ŕƒŒƒ“ƒY“x”Œˆ’č‚ĚƒRƒcz‘O–[[“x‚Š‚ç‚Ý‚˝IOL“x”ŒvŽZ‚ĚƒRƒc. MB OCULISTA, 2018; 63: 66-71
  35. źč—LC: ”’“ŕáE‹üÜŽčp‚Ě˜_“_ –D’…‘΋­–Œ“ŕŒĹ’či‹­–Œ“ŕŒĹ’č‚ĚŽ‹“_j. IOL&RS, 2018; 32(3): 485-491
  36. •˝Œ`Žő•j, —›ŒŤú•, ‰ĄaŠx•F: Ž‰–bŽ_—R—ˆ‚ĚŽ‰ŽżƒƒfƒBƒG[ƒ^[‚É‚ć‚éƒAƒŒƒ‹ƒM[‰ŠÇ‚̐§Œä. —Տ°–ƉuEƒAƒŒƒ‹ƒM[‰Č, 2018; 69(9): 569-575
  37. ‰Fˆä–qŽq, ŞŠÝ‹MŽu: yŽĺ‘i‚ƏŠŒŠ‚Š‚ç‚Ý‚˝Šá‰Č common diseasezŠŒŠ‚Š‚ç‚Ý‚˝f’f‚̐i‚ß•ű ŠáˆĘˆŮí@ŠOŽÎŽ‹. Šá‰Č, 2018; 60(10): 1151-1156
  38. ‘ĺ‰z‹MŽuŽq: ‘B“œ”A•a–Ô–ŒÇ‚ɑ΂ˇ‚éƒAƒtƒŠƒxƒ‹ƒZƒvƒgÉŽq‘Ě’ŽË‚ƔĖԖŒŒő‹ĂŒĹ‚Ě52T‚É‚¨‚Ż‚éĹ‚‹¸łŽ‹—͂ɑ΂ˇ‚é—Տ°Œř‰Ę‚Ě”äŠriCLARITYj: ‘˝Ž{Ý’P–ÓŒŸƒ‰ƒ“ƒ_ƒ€‰ťPhase2b”ń—ňŤŽŽŒą. “ú–{‚ĚŠá‰Č, 2018; 88(12): 1583-1584
  39. ‘ĺ‰z‹MŽuŽq: –Ť’†SŤŸ÷‰tŤ–Ź—–Œ–Ô–ŒÇ‚ɑ΂ˇ‚鉊Fi577nmjƒ}ƒCƒNƒƒpƒ‹ƒXƒŒ[ƒU[‚Ć”ź—Ęƒxƒ‹ƒeƒ|ƒ‹ƒtƒBƒ“Œőü—ÍŠw“I—Ă–@‚Ě”äŠr:ƒpƒ“ƒAƒƒŠƒJƒ“‹¤“Ż–Ô–ŒŒ¤‹†(PACORES)ƒOƒ‹[ƒv‚ĚŒ¤‹†Œ‹‰Ę. “ú–{‚ĚŠá‰Č, 2018; 89(8): 1095-1096
  40. ˆîŠ_Œ\Ži, ‘ĺ‰z‹MŽuŽq: “œ”A•a‰Š”Á•‚Žî‚ɑ΂ˇ‚郌[ƒU[‚Ć–ň•¨ŽĄ—Ă‚ĚŽg‚˘•Ş‚Ż. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č, 2018; 35(9): 1207-1216
  41. ‰i“c–œ—R”ü, ŽRŞ^, ‘ž“cr•F, ”Ń“c‰Ă•F, XŽR—Á: ƒRƒ“ƒTƒ‹ƒe[ƒVƒ‡ƒ“ƒR[ƒi[@ƒGƒLƒXƒp[ƒg‚É•ˇ‚­. IOL&RS, 2018; 32(3): 539-545
  42. ź“‡”Ž”V, ŞŠÝˆę”T, ‘ž“cr•F, ź‘ş‰hˆę, XŽR—Á: Žčp‘Š’kŽş@‘˝Ĺ“_Šá“ŕƒŒƒ“ƒY‚Ě’E‰PÇ—á. Šá‰ČŽčp, 2018; 31(4): 585-589
y’˜‘z
  1. Negishi T, Murakami A. Surgical outcomes of early treatment for infantile esotropia.  39th meeting of the European Strabismological Association transactions. Cioplean D. Corint books. Romania, 2018; 247-249
  2. ‘ž“cr•F: IOL‹­–Œ“ŕŒĹ’čp‚ĚŠî–{. Šá‰ČƒOƒ‰ƒtƒBƒbƒN2018”N•Ęű Šá‰ČƒXƒS‹Z ”’“ŕáŽčp-WEB“Ž‰ć•t‚Ť75–{ ‘ćˆęü‚ĹŠˆ–ô‚ˇ‚éƒT[ƒWƒƒƒ“‚ĚŽč‹ZAĹVƒfƒoƒCƒX‚Ş•Ş‚Š‚éI. ‘厭“N˜YE{“ĄŽjŽqiŠÄCj, ƒƒfƒBƒJƒ‹o”Ĺ, 2018; 105-112
  3. ‘ž“cr•F: IOL‹­–Œ“ŕŒĹ’čp(T-fixation technique). Šá‰ČƒOƒ‰ƒtƒBƒbƒN2018”N•Ęű Šá‰ČƒXƒS‹Z ”’“ŕáŽčp-WEB“Ž‰ć•t‚Ť75–{ ‘ćˆęü‚ĹŠˆ–ô‚ˇ‚éƒT[ƒWƒƒƒ“‚ĚŽč‹ZAĹVƒfƒoƒCƒX‚Ş•Ş‚Š‚éI. ‘厭“N˜YE{“ĄŽjŽqiŠÄCj, ƒƒfƒBƒJƒ‹o”Ĺ, 2018; 134-142
  4. ŠC˜VŒ´Ls: ƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠł. f—ĂƒKƒCƒhƒ‰ƒCƒ“UP-TO-DATE2018-2019, –ĺ˜eF, ŹŽşˆęŹ, ‹{’n—ÇŽ÷ŠÄC, ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽĐ, ‘ĺă, 2018, 740-745
  5. ’––“•”Í: •a‰@‹@”\Œüă‚ƐśŽYŤ‚̉ü‘P‚É‚ć‚芳ŽŇ‚É‚ŕƒXƒ^ƒbƒt‚É‚ŕ—Ç‚˘•a‰@‚đ–ÚŽw‚ˇ. OPERAAtimes, 2018”N7(14-17).
  6. ‰Á“Ą_W (•Ş’S: ’––“•”Í): ˆă—Ă4.0 ‘ć‚SŽŸŽY‹ĆŠv–˝Žž‘ă‚Ěˆă—Ă. “úŒoBPŽĐ, 2018”N6ŒŽ23“ú
  7. IoMTŠw‰ď•ŇWˆĎˆő‰ď (•Ş’S: ’––“•”Í): Journal of Internet of Medical Things Vol.1 No.1. ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽĐ, 2018”N5ŒŽ16“ú.
  8. ’––“•”Í: Šw‰ďŒ¤‹†‰ďFront Lineuˆă—Ă‚É“Á‰ť‚ľ‚˝IoT‚ĚŒ¤‹†‚đ s‚¤‚˝‚ß‚Ěƒvƒ‰ƒbƒgƒtƒH[ƒ€v. W’†. 2018”N10ŒŽ21“ú
  9. ‘ĺ‰z‹MŽuŽq: śŠU‹łˆçƒVƒŠ[ƒY-94@‚í‚Š‚č‚₡‚˘Š´ŠoŠíŽžŠł V Š´ŠoŠíŽžŠł‚ĚŽĄ—Á@Ž‹Šo@1–Ô–ŒŽžŠł|”ńŠĎŒŒ“IŽĄ—Ă. “ú–{ˆăŽt‰ďŽGŽ, 2018: 147(1), s240-241
y•ńE‚ť‚Ě‘źz
  1. Ohkoshi K: EpM TISSUE-SPARING LASER THERAPY-ADISCUSSION WITH PASCAL EXPERTS. Retina Today, 2018 Marcy; 13(2): 6-8
  2. ‘ž“cr•F: Šá‰ČŽčp‚ĚĹ‹ß‚Ěi•ŕ. “c•űˆăŽt‰ď•ń, 2018; 88: 2025-2026
  3. •˝’Ë‹`@: Šá‚ĚŒŸ¸‚Ĺ‘ź‚Ě•a‹C‚Ş‚í‚Š‚é. TŠÔ’Š“úMOOK@Šá‚Ě•a‹C&˜VŠá‚Ş‚Ü‚é‚˛‚Ć‚í‚Š‚é2018@’Š“úV•ˇo”Ĺ, 68-71, 2018@
  4. •˝’Ë‹`@: lś100”NŽž‘ă‚ĚƒƒKƒl‘I‚Ń. TŠ§’Š“ú,@2018”N10ŒŽ5“ú†, 151-155
  5. •˝’Ë‹`@: î•ń’ń‹Ÿ‚ľŽx‰‡‚ɂ‚Ȃ°‚é@L‚Ş‚éƒXƒ}[ƒgƒTƒCƒg@Ž‹ŠoáŠQ‚Ě‘‹ŒűĐ‰î. 2018”N5ŒŽ31“ú, “ú–{ŠCV•ˇ
  6. •˝’Ë‹`@: î•ń’ń‹Ÿ‚ľŽx‰‡‚ɂ‚Ȃ°‚é@L‚Ş‚éƒXƒ}[ƒgƒTƒCƒg@Ž‹ŠoáŠQ‚Ě‘‹ŒűĐ‰î. 2018”N6ŒŽ3“ú, ç—t“ú•ń
  7. •˝’Ë‹`@: Ž‹ŠoáŠQ‚̐l‚ɏî•ń’ń‹Ÿ@L‚Ş‚éƒXƒ}[ƒgƒTƒCƒg@ŠeŽí‘Š’k‘‹Œű‚đĐ‰î. 2018”N6ŒŽ4“ú, ‘ĺ•Ş‡“ŻV•ˇ
  8. •˝’Ë‹`@: Ž‹ŠoáŠQ‚ą‚ą‚É‘Š’k@L‚Ş‚éuƒŠ[ƒtƒŒƒbƒgvěŹ. 2018”N6ŒŽ4“ú, ŽRŒ`V•ˇ
  9. •˝’Ë‹`@: Ž¸–ž‚⃍[ƒrƒWƒ‡ƒ“‚̐l‚ց@Šá‰Čˆă‚ŞŽx‰‡î•ń’ń‹Ÿ. 2018”N6ŒŽ5“ú, ‹ž“sV•ˇ
  10. •˝’Ë‹`@: Ž‹ŠoáŠQŽŇ‚đ•ŸŽƒ‚ɂ‚Ȃ°. 2018”N6ŒŽ6“ú, ŒF–{“ú“úV•ˇ
  11. •˝’Ë‹`@: Ž‹ŠoáŠQŽŇ‚Ě‘Š’k‘‹ŒűĐ‰î@L‚Ş‚éuƒXƒ}[ƒgƒTƒCƒgvěŹ. 2018”N6ŒŽ16“ú, Šň•ŒV•ˇ
  12. •˝’Ë‹`@: Ž‹ŠoáŠQ@Žx‰‡‚Ö‘Š’k‘‹Œű. 6ŒŽ19“ú, ˛‰ęV•ˇ
  13. •˝’Ë‹`@: Ž‹ŠoáŠQ‚Ě‘Š’kćĐ‰î@Šá‰Čˆă@•ŸŽƒŽx‰‡‚ɂ‚ȂŽ. 2018”N6ŒŽ15“ú, ‚’mV•ˇ
  14. •˝’Ë‹`@: Ž‹Šoá‚Ş‚˘ŽŇ‚ɏî•ń’ń‹Ÿ@ƒŠ[ƒtƒŒƒbƒguƒXƒ}[ƒgƒTƒCƒgv. 2018”N6ŒŽ14“ú, ‰Ť“ęƒ^ƒCƒ€ƒX
  15. •˝’Ë‹`@: •śÍ‚đ‰šş‚ɃnƒCƒeƒNŠá‹ž@ƒIƒgƒ“ƒOƒ‰ƒXŽ‹ŠoáŠQŽŇ‚đŽx‰‡. 2018”N9ŒŽ19“ú, ’†š V•ˇ
  16. •˝’Ë‹`@: Šá‹žŒ^––’[‚ŏáŠQŽŇŽx‰‡@ƒIƒgƒ“ƒOƒ‰ƒXŽ‹ŠoáŠQŽŇ‚đŽx‰‡. 2018”N9ŒŽ13“ú, ‹{č“ú“úV•ˇ
  17. •˝’Ë‹`@: Šá‹žŒ^“Ç‚Ýă‚°––’[@áŠQŽŇ‚Ş‹Ś—͐ť•i‰ť. 2018”N9ŒŽ26“ú, é‹ĘV•ˇ
  18. •˝’Ë‹`@: Šá‹ž––’[‚Ĺ•śŽš‚𐺂Ɂ@–Ú‚ĚáŠQŽx‰‡ƒIƒgƒ“ƒOƒ‰ƒX. 2018”N9ŒŽ21“ú, ‰ş–ěV•ˇ
  19. •˝’Ë‹`@: Šá‹žŒ^––’[‚Ĺ•śŽš‚đ‰šş‚Ɂ@áŠQ‚Ě‚ ‚él‚Ş‹Ś—Í‚ľť•i‰ť. 2018”N9ŒŽ13“ú, “ú–{ŠCV•ˇ
  20. •˝’Ë‹`@: Šá‹žŒ^––’[‚Ĺ•śŽš→‰šş‚Ɂ@áŠQŽŇ‚Ş‹Ś—Í‚ľť•i‰ť. 2018”N9ŒŽ18“ú, ‹ž“sV•ˇ
  21. •˝’Ë‹`@: Šá‹žŒ^––’[‚Ĺ•śŽš‚đ‰šş‚Ɂ@áŠQŽŇ‚Ş‹Ś—Í‚ľť•i‰ť. 2018”N9ŒŽ17“ú, ŽR‰A’†‰›V•ń
  22. •˝’Ë‹`@: Šá‹žŒ^––’[‚Ĺ•śŽš‚đ‰šş‚Ɂ@áŠQŽŇ‚Ş‹Ś—Í‚ľť•i‰ť. 2018”N10ŒŽ2“ú, ˛‰ęV•ˇ
  23. •˝’Ë‹`@: Šá‹žŒ^––’[•śŽš‚đ‰šş‚Ɂ@“Œ‹ž‚ĚŠé‹ĆŠJ”­uƒIƒgƒ“ƒOƒ‰ƒXv. 2018”N9ŒŽ30“ú, ŽR—zV•ˇ
  24. •˝’Ë‹`@: Šá‹žŒ^––’[‚Ĺ•śŽš‚đ‰šş‚Ɂ@áŠQŽŇ‚Ş‹Ś—Í. 2018”N10ŒŽ4“ú, ’†•”ŒoĎV•ˇ
  25. •˝’Ë‹`@: Šá‹žŒ^––’[•śŽš‚đ‰šş‚Ɂ@áŠQŽŇ‚ŕ‹Ś—Í‚ľť•i‰ť. 2018”N10ŒŽ8“ú, ŽRŒ`V•ˇ
  26. •˝’Ë‹`@: Šá‹žŒ^––’[•śŽš‚đ‰šş•ĎŠˇ@Ž‹ŠoáŠQŽŇ‚Ě‹Ś—͂Őť•i‰ť. 2018”N9ŒŽ27“ú, ŽR—œ“ú“úV•ˇ
  27. “yŽŠ“cG: ‘S‘wŠp–ŒˆÚApŒă‚ÉŠp–Œ“ŕ”çˆÚAp‚đŽ{s‚ľ‚˝1—á. Ă‰ŞŒ§Šá‰Čˆă‰ďŽ, 2018; 35: 1
  28. Ź–ě_ˆę: ‚—îŽŇ‚É‘˝‚˘–Ú‚Ě•a‹C. “Œ‹ćˆăŽt‰ď‹ć–ŻŒöŠJuŔ, “Œ‹ž, 5ŒŽ26“ú, 2018
  29. ”~‰Ž—ćŽq: “–ƒZƒ“ƒ^[‚É‚¨‚Ż‚é–Ô–ŒŒŒŠÇŒa‚ĚŒ¤‹†Ź‰Ę. Microvascular Research Conference `Ophthalmology & Nephrology`, “Œ‹ž, 3ŒŽ8“ú, 2018
  30. _•”—F: “ű—cŽ™Œ’f‚ĹŒŠ‚‚Ż‚é‚ą‚Ç‚ŕ‚ĚŠá‚ĚˆŮí. é‹ĘŒ§ŹŽ™•ŰŒ’‹Ś‰ď‘ć88‰ńŒ¤‹†‰ď, 2018”N6ŒŽ23“ú
  31. ’––“•”Í: ‰Ô•˛ÇƒAƒvƒŠ. Tarzan, 2018”N2ŒŽ28“ú†
  32. ’––“•”Í: uŽ¸”s‚ľ‚Ä‚ŕAŠć’Ł‚č‘ą‚Ż‚évBŽüˆÍ‚Ə•‚Ż‡‚˘‚Č‚Ş‚çƒ`ƒƒƒŒƒ“ƒW‚đĎ‚ݏd‚Ë‚élś‚đ‘I‚ń‚žŠá‰Čˆă‚Ě‚Í‚Č‚ľ. ƒƒNƒXƒ^, http://workstudy.jp/interview/63, 2018”N1ŒŽ31“ú
  33. ’––“•”Í: ŒÂlę—p‚̉ԕ˛Ç—\•ń. “úŠ§H‹ĆV•ˇ, 2018”N1ŒŽ31“ú
  34. ’––“•”Í: ˘ŠE‰‚̉ԕ˛Ç—\–hƒAƒvƒŠ‚đŠJ”­. Medical Tribune, https://medical-tribune.co.jp/news/2018/0228513235/
  35. ’––“•”Í: 2018‰Ô•˛Ç“ÁW. J-WAVE TOKYO MORNING RADIO, 2018”N3ŒŽ6“ú
  36. ’––“•”Í: ƒJƒ‰ƒ_‚̓Xƒ}ƒz‚ĹŠÇ—‚ĚŽž‘ă‚Ĺ‚ˇ. anan, 2018”N3ŒŽ14“ú†
  37. ’––“•”Í: ƒAƒvƒŠ‚ŞŘ‚č‘ń‚­ˆęlˆęl‚Ě‚˝‚߂̉ԕ˛‘΍ôŽ–‹Ć. Mac Fac, 2018”N5ŒŽ†
  38. ’––“•”Í: ‹ł‚Ś‚ăˆƒ~ƒhƒbƒN. “Ç”„V•ˇ, 2018”N1ŒŽ25“ú—[Š§, 2018”N4ŒŽ1“ú’ŠŠ§
  39. ’––“•”Í: ˆăŽt‚Ě“­‚Ť•ű‰üŠv‚ɂ‚˘‚Ä. ŒŽŠ§ƒŠƒNƒ‹[ƒgƒhƒNƒ^[ƒYƒLƒƒƒŠƒA2018”N5ŒŽ†
  40. ’––“•”Í: ƒhƒ‰ƒCƒAƒC‚ɂ‚˘‚Ä. “ú–{ŒoĎV•ˇ2018”N7ŒŽ16“ú’ŠŠ§
  41. ’––“•”Í: ¸ŽqŒŸ¸Eƒhƒ‰ƒCƒAƒCE’_“š•Â˝Ç…@Œ’NƒAƒvƒŠi‰ť’†. ’Š“úV•ˇDEGITAL, https://www.asahi.com/articles/ASLCG77D7LCGUBQU01V.html
  42. ’––“•”Í: Vƒhƒ‰ƒCƒAƒCf’fŠî€‚É‚ć‚čuƒhƒ‰ƒCƒAƒCŠm’čvŠłŽŇ‚Ş3Š„‘‰Á. ‡“V“°‘ĺŠwƒvƒŒƒXƒŠƒŠ[ƒX,2018”N4ŒŽ6“ú
  43. ’––“•”Í: ƒhƒ‰ƒCƒAƒC‚ĚƒZƒ‹ƒtƒ`ƒFƒbƒN‚É—L—p‚ČĹ‘ĺŠJáَžŠÔ‚đŒŸŘ. ‡“V“°‘ĺŠwƒvƒŒƒXƒŠƒŠ[ƒX, 2018”N10ŒŽ10“ú
  44. ’––“•”Í:ƒAƒvƒŠ‚đŽg‚Á‚ĉԕ˛Ç‚đƒ`ƒFƒbƒNI ‰Ô•˛Ç—\–hƒAƒvƒŠuƒAƒŒƒ‹ƒT[ƒ`v‚đƒŠƒŠ[ƒX. ‡“V“°‘ĺŠwƒvƒŒƒXƒŠƒŠ[ƒX, 2018”N2ŒŽ1“ú
  45. š •ŞF“š: ”ńŠOŠá‚É‚¨‚Ż‚郌ƒ“ƒY—Ž‰ş‚ƊᎲ’ˇ‚ĚŠÖŒW‚ɂ‚˘‚Ä. JON‚̉ď, “Œ‹ž, 2018”N6ŒŽ23“ú
  46. ‚–ěr”V: Fusion®ENTƒiƒrƒQ[ƒVƒ‡ƒ“ƒVƒXƒeƒ€‚đ—p‚˘‚˝—Ü”X•@o•Ť‡p‚ɂ‚˘‚āD‘ć31‰ńé‹ĘŒ§Šá‰ČŽčp’k˜b‰ď, é‹ĘŒ§, 2018”N7ŒŽ8“ú
  47. ‹g“c—Il: ”F’mÇŠłŽŇ‚É‚¨‚Ż‚é”’“ŕáŽčp‘OŒă‚Ě”F’m‹@”\‚̕ωť. ‘ć798‰ń“Œ‹ž“sŠá‰ČW’k‰ď, “Œ‹ž, ç‘ă“c•ú‘—‰ďŠŮ, 2018”N8ŒŽ9“ú
  48. ŽđŒŠˆčŒ\: Šp–ŒˆÚAŠá‚ɑ΂ˇ‚éŽÎŽ‹ŽĄ—Ă‘I‘đ. ‡“V“°‘ĺŠwŠá‰ČÇ—ጟ“˘‰ď, “Œ‹ž, 2018”N3ŒŽ28“ú
  49. ŽđŒŠˆčŒ\: “–‰@‚É‚¨‚Ż‚é‘I‘đ“IƒŒ[ƒU[üˆŰ’Œ‘ŃŒ`Źp‚ĚŽĄ—ÐŹŃ. ‡“V“°‘ĺŠwŠá‰ČÇ—ጟ“˘‰ď, “Œ‹ž, 2018”N3ŒŽ28“ú
  50. rˆäéŽq: RƒAƒNƒAƒ|ƒŠƒ“4R‘Ě—zŤŽ‹_Œo‰Š‚Ě’ˇŠúŒo‰ß. ]“ŒŠá‰ČŠwpŒ¤‹†‰ď, “Œ‹ž, 2018”N7ŒŽ26“ú
  51. ŽRŒű’B•v: V”N‚ĚŒäˆĽŽA. “Œ‹ž“sŠá‰Čˆă‰ď‰ď•ń, 2018: 242
  52. ŽRŒű’B•v, ’ˇ’Jěˆę˜Y, –ě’n’B, ź‘ş”ü‘ă, •˝–ěkŽĄ, ‹ß“Ąť: “ú–{Šá‰Čˆă‰ď—Ď—j—́E—Ď—‹K’č‚̉ü’č. “ú–{‚ĚŠá‰Č, 2018; 89(1), 5-6
  53. ŽRŒű’B•v: Ž„‚Ě—š—đ‘uˆęŠúˆę‰ďv. “Œ‹ž“sŠá‰Čˆă‰ď‰ď•ń, 2018H
  54. ‘ĺ‰z‹MŽuŽq: ƒrƒfƒI DVD ÉŽq‘Ě”’“ŕá“ŻŽžŽčpiW-60RŽg—pj2Ç—á‡@Cataract+ERM+SDR‡ACataract+DME. ŽQ“Vť–ň, 2018
  55. ‘ĺ‰z‹MŽuŽq: ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď ŽQ“Vť–ň‹¤Ăƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[@ÉŽq‘ĚŽčpAŠeX‚ĚŒ´“_@‡WÉŽq‘ĚŽčp-’áNPŽĄ—Ă‚Ö‚Ě’Ç‹y. ŽQ“Vť–ňƒŠ[ƒ_[ƒYƒ{ƒCƒX, 2018; 87
  56. ˆŔ“c–žO: Žqˆç‚āE‹łˆçuƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚͉˝Î‚Š‚çH‹¸łŽčp‚̉”\Ť‚́v. “úŒoDUALA“úŒoBPŽĐ, 2018”N8ŒŽ29“ú
2017”N
yŒ´’˜‰p•śz
  1. Miyazaki D, Fukushima A, Ohashi Y, Ebihara N, Uchio E, Okamoto S, Shoji J, Takamura E, Nakagawa Y, Namba K, Fujishima H.FSteroid-Sparing Effect of 0.1% Tacrolimus Eye Drop for Treatment of Shield Ulcer and Corneal Epitheliopathy in Refractory Allergic Ocular Diseases. Ophthalmology, 2017; 124(3): 287-294 (IF: 8.204)
  2. Nakama T, Yoshida S, Ishikawa K, Kubo Y, Kobayashi Y, Zhou Y, Nakao S, Hisatomi T, Ikeda Y, Takao K, Yoshikawa K, Matsuda A, Ono J, Ohta S, Izuhara K, Kudo A, Sonoda KH, Ishibashi T. Therapeutic effect of novel single-stranded RNA interference agent targeting periostin in eyes with retinal neovascularization. Mol Ther - Nucl Acids, 2017; 6: 279-289 (IF: 6.392)
  3. Chen Y, Chauhan SK, Shao C, Omoto M, Inomata T, Dana R: IFN-γ-Expressing Th17 Cells Are Required for Development of Severe Ocular Surface Autoimmunity. J Immunol, 2017 Aug 1; 199(3):1163-1169 (IF: 4.856)
  4. Iwamoto S, Koga T, Ohba M, Okuno T, Koike M, Murakami A, Matsuda A, Yokomizo T. Non-steroidal anti-inflammatory drug delays corneal wound healing by reducing production of 12-hydroxyheptadecatrienoic acid, a ligand for leukotriene B4 receptor 2. Sci Rep, 2017G 7(1): 13267 (IF: 4.259)
  5. Di Zazzo A, Tahvildari M, Subbarayal B, Yin J, Dohlman TH, Inomata T, Mashaghi A, Chauhan SK, Dana R: Proangiogenic Function of T Cells in Corneal Transplantation. Transplantation, 2017 Apr; 101(4): 778-785 (IF: 3.678)
  6. Arai R, Usui-Ouchi A, Ito Y, Mashimo K, Murakami A Ebihara NFEffects of Secreted Mast Cell Mediators on Retinal Pigment Epithelial Cells: Focus on Mast Cell TryptaseDMediat Inflamm, 2017; 2017:3124753. 2017 JunD[Epub ahead of print] (IF: 3.232)
  7. Takamura E, Uchio E, Ebihara N, Ohno S, Ohashi Y, Okamoto S, Kumagai N, Satake Y, Shoji J, Nakagawa Y, Namba K, Fukagawa K, Fukushima A, Fujishima H: Japanese Society of Allergology.FJapanese guidelines for allergic conjunctival diseases 2017DAllergol Int, 2017; 66(2): 220-229 (IF: 3.194)
  8. Usui-Ouchi A, Ouchi Y, Ebihara N.FThe peroxisome proliferator-activated receptor pan-agonist bezafibrate suppresses microvascular inflammatory responses of retinal endothelial cells and vascular endothelial growth factor production in retinal pigmented epithelial cells. Int Immunopharmacol, 2017; 52: 70-76 (IF: 2.956)
  9. Toshida H, Funaki T, Ono K, Tabuchi N, Watanabe S, Seki T, Otake H, Kato T, Ebihara N, Murakami A: Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye: a Japanese Phase II clinical trial. Drug Des Devel Ther, 2017; 11: 1871-1879 (IF: 2.822)
  10. Inomata T, Mashaghi A, Hong J, Nakao T, Dana R.: Scaling and maintenance of corneal thickness during aging. PLoS One, 2017 Oct 6; 12(10): e0185694 (IF:2.806)
  11. Sasaki M, Kato Y, Fujinami K, Hirakata T, Tsunoda K, Watanabe K, Akiyama K, Noda T: Advanced quantitative analysis of the sub-retinal pigment epithelial space in recurrent neovascular age-related macular degeneration. PLoS One, 2017 Nov 2; 12(11): e0186955 (IF:2.806)
  12. Kawashima M, Yamada M, Suwaki K, Shigeyasu C, Uchino M, Hiratsuka Y, Yokoi N, Tsubota K, DECS-J Study Group (Hiratsuka Y). A Clinic-based Survey of Clinical Characteristics and Practice Pattern of Dry Eye in Japan. Adv Ther, 2017 Mar; 34(3):732-743. doi: 10.1007/s12325-017-0487-x. Epub 2017 Feb 8 (IF:2.709)
  13. Hirata M, Kamatani Y, Nagai A, Kiyohara Y, Ninomiya T, Tamakoshi A, Yamagata Z, Kubo M, Muto K, Mushiroda T, Murakami Y, Yuji K, Furukawa Y, Zembutsu H, Tanaka T, Ohnishi Y, Nakamura Y; BioBank Japan Cooperative Hospital Group (Hiratsuka Y), Matsuda K: Cross-sectional analysis of BioBank Japan clinical data: A large cohort of 200,000 patients with 47 common diseases. J Epidemiol, 2017 Mar; 27(3S):S9-S21. doi: 10.1016/j.je.2016.12.003. Epub 2017 Feb 9 (IF:2.447)
  14. Yokomichi H, Nagai A, Hirata M, Kiyohara Y, Muto K, Ninomiya T, Matsuda K, Kamatani Y, Tamakoshi A, Kubo M, Nakamura Y; BioBank Japan Cooperative Hospital Group(Hiratsuka Y), Yamagata Z. Serum glucose, cholesterol and blood pressure levels in Japanese type 1 and 2 diabetic patients: BioBank Japan. J Epidemiol, 2017 Mar; 27(3S):S92-S97. doi: 10.1016/j.je.2016.12.013. Epub 2017 Feb 3 (IF:2.447)
  15. Nakatani S, Murakami A: Descemet stripping automated endothelial keratoplasty using corneas from elderly donors. Graefes Arch Clin Exp Ophthalmol, 2017; 255(1), 209-210. doi: 10.1007/s00417-016-3495-7 (IF:2.349)
  16. Arai E, Parmar VM, Sahu B, Perusek L, Parmar T, Maeda A: Docosahexaenoic acid promotes differentiation of photoreceptor cells in three-dimensional neural retinas. Neurosci Res, 2017 Oct; 123:1-7 (IF:2.060)
  17. Inomata T, Mashaghi A, Di Zazzo A, Lee SM, Chiang H, Dana R: Kinetics of Angiogenic Responses in Corneal Transplantation. Cornea, 2017; 36(4): 491-496 (IF:2.010)
  18. Tabuchi N, Toshida H, Koike D, Odaka A, Suto C, Ohta T, Murakami A. Effect of Retinol Palmitate on Corneal and Conjunctival Mucin Gene Expression in a Rat Dry Eye Model after Injury. J Ocul Pharmacol Ther, 2017, 33(1): 24-33 (IF:1.679)
  19. Kasuga T, Aruga F, Ono K, Hiratsuka, Murakami A: Visual impairment as an independent risk factor for falls in hospitalized patients. Can J ophthalmol, 2017; 52(6): 559-563 (IF:1.543)
  20. Inomata T, Ono K, Matsuba T, Shiang T, Di Zazzo A, Nakatani S, Yamaguchi M, Ebihara N, Murakami A: Pre-banking microbial contamination of donor conjunctiva and storage medium for penetrating keratoplasty. Jpn J Ophthalmol, 2017; 61(5): 369-377 (IF:1.519)
  21. Iwatake A, Murakami A, Ebihara NFThe expression of matrix metalloproteinases and their inhibitors in corneal fibroblasts by alarmins from necrotic corneal epithelial cells. Jpn J Ophthalmol, 2017 Nov. [Epub ahead of print] (IF:1.519)
  22. Hiratsuka Y, Tamaki Y, Okamoto E, Tsubaki H, Kumakawa T; Relationships between medical expenditures and the Specific Health Checkups scheme in Japan: A Study of outpatient medical expenditures and questionnaire responses concerning lifestyle that form part of the Specific Health Checkups scheme in Japan. Journal of the National Institute of Public Health, 2017; 66(1): 75-84
  23. Sugita J, Asada Y, Ishida W, Iwamoto S, Sudo K, Suto H, Matsunaga T, Fukuda K, Fukushima A, Yokoi N, Ohno T, Azuma M, Ebihara N, Saito H, Kubo M, Nakae S, Matsuda A.FContributions of Interleukin-33 and TSLP in a papain-soaked contact lens-induced mouse conjunctival inflammation model. Immun Inflamm Dis, 2017; 5(4): 515-525
  24. Sakanishi Y, Usui-Ouchi A, Tamaki K, Mashimo K, Ito R, Ebihara N.FShort-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab. Clin Ophthalmol, 2017; 11: 829-834
  25. Nagasako Y, Inagaki K, Serizawa S, Hamada M, Echizen N, Takahashi O, Deshpande. AG, Ohkoshi K: Risk Factors Associated with Retinal Lesions Resulting from Widespread Systemic Infection. Ophthalmology Retina, 2017; 1(4), 333-338
  26. Kase S, Chin S, Hamanaka T, Shinmei Y, OhguchiT, Kijima R, Matsuda A, Ishida S. Histological Findings in the Trabecular Meshwork of a Patient with Atopic Glaucoma. Open Opthalmol J, 2017; 11: 103-106
yŒ´’˜˜a•śz
  1. ŞŠÝ‹MŽu: ŠáŽčpŠÖ˜A–ň•¨ŽĄ—Ă AŒ^ƒ{ƒcƒŠƒkƒX“Ĺ‘f‚Ě–ň—ě—p‚ĆŽÎŽ‹ŽĄ—ĂŒř‰Ę. Šá–ň—, 2017; 31(1): 48-49
  2. ŽRŒűš‘ĺ, Ž…ˆä‘fƒ, •˝’Ë‹`@, M–؏rŹ, ‘şăťF‰~Šp–Œ‚É‚¨‚Ż‚éƒn[ƒhƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‘•—p‚É‚ć‚éŠp–ŒŒ`ó•Ď‰ť. “úƒRƒŒŽ, 2017; 59(1): 24-28
  3. Vˆä‰p‰îA‘O“cˆŸŠóŽqA‘şăť: Stargardt•a‚ÉŠÖ˜A‚ľ‚˝–Ô–Œ•ĎŤŽžŠł‚ƐV‚ľ‚˘ŽĄ—Ẩ”\Ť. “úŠá‰ďŽ, 2017; 121(1); 7-16
  4. ó“c—m•ă: ƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰Š‚É‚¨‚Ż‚éILC2. ƒAƒŒƒ‹ƒM[‚Ě—Ő°, 2017; 37(6): 574-578
  5. ‹{ě—R‹NŽq: TS-1®i5-FUŒnŒoŒűRŠŕÜj“ŕ•ž‰Á—Ă’†‚ÉŠp–Œă”çáŠQ‚đ”F‚ß‚˝2Ç—á. Šá—Ő‹I@iˆóü’†j@
  6. “n糌d, –Ř‘şŽŠ, ’†ŕV—LŒá, ŠC˜VŒ´LsFƒ`ƒ…[ƒuƒVƒƒƒ“ƒgŽčp(EX-PRESS)‚ƐüˆŰ’Œ‘ѐ؏œp‚̏pŒă2”NŠÔ‚ĚŽĄ—ÐŹŃ‚ĚŒŸ“˘DŠá‰Č, 2017; 59(13): 1605-1612
  7. ´…“Žq, ´ěł•q, ˆÉ“Ą—ć, ˛‹vŠÔr˜Y, ŠC˜VŒ´Ls: “űŠŕŒ´”­‚Ě—źŠá“]ˆÚŤ–Ź—–ŒŽîᇂɕúŽËü—Ă–@‚Ć–ň•¨—Ă–@‚Ě•š—p—Ă–@‚Ş‘tŒř‚ľ‚˝1Ç—á. —ŐŠá, 2017; 71(7): 1001-1006
  8. Žsě_•˝, Ź—эG–ž, M–؏rŹ, —é–؍N•v, ‘şăť: ’×ᇐŤ‘ĺ’°‰Š‚ɑ΂ľ‚Äadalimumab“Š—^’†‚ÉŽ‹_Œo‰Š‚đ”­Ç‚ľ‚˝1—á. _ŒoŠá‰Č, 2017; 33(3): 254-258
  9. ‘ĺŽR—S‰Ŕ—˘, t“úrŒő, –{“c—•ô, ź“c˛, ‘şăť: “–‰@‚É‚¨‚Ż‚éEx-PRESS®‘}“üp‚̏pŒăŹŃ. Šá‰ČŽčp@iˆóü’†j
  10. ’Š‰ŞšŽq, –{“c—•ô,@ŽRŒűš‘ĺ, M–؏rŹ, ‘şăť, ź“c˛: ƒoƒ‹ƒxƒ‹ƒg—ΓŕáƒCƒ“ƒvƒ‰ƒ“ƒg‚É‚¨‚Ż‚éƒ`ƒ…[ƒu‚Ě‚ć‚ś‚ę‚𐎕œ‚ľ‚˝1—á. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č, 2017; 34(6): 899-902
  11. ’Š‰ŞšŽq, ŞŠÝ‹MŽu, ‘şăť: ŹŽ™ăŽÎ‹Ř–ƒáƒ‚ɑ΂ˇ‚éăŽÎ‹Ř–Dkp‚ĚŒř‰Ę. Šá—Ő‹I, 2017; 10(3): 215-217
  12. ‹{–{Ă‰Ř, ’––“•”Í, ’†’J’q, •˝’Ë‹`@, ‘şăť: ƒAƒCƒoƒ“ƒN’ń‹ŸŠá‚ĚŠá‹…•Ű‘ś‰t‚É‚¨‚Ż‚éMRSA‰˜ő‚ĚŒŸ“˘. —ŐŠá, 2017; 71(10): 1549-1555
  13. ˆî—tŽu”ż, H’J‚Đ‚ë‚Ý, ŞŠÝ‹MŽu, ‘şăť; ŽüŠúŤŠOŽÎŽ‹‚Ě1—á. Šá—Ő‹I, 2017; 10(4): 300-302
  14. ˆ˘‹vŞ—zŽq, ě“‡‘fŽq, •˝’Ë‹`@, ŽR“cš˜a: Źl‚đ‘ÎŰ‚Ć‚ľ‚˝ŠáŽžŠłƒXƒNƒŠ[ƒjƒ“ƒO‚Ě—\ŽZ‰e‹ż•ŞÍ. “ú–{‚ĚŠá‰Č, 2017; 88(1)•t˜^: 58-62
  15. ŽR“cš˜a, •˝’Ë‹`@, Ź–ě_ˆę, “c‘şŠ°, ’†–싧, ěč—Ç, ˆ˘‹vŞ—zŽq, ě“‡‘fŽq: •ďŠ‡“IƒXƒNƒŠ[ƒjƒ“ƒO‚Ć‚ľ‚Ă̐ŹlŠá‰ČŒŸf‚ĚŒř‰Ę. “ú–{‚ĚŠá‰Č, 2017; 88(1)•t˜^: 50-57
  16. ’†–싧, •˝’Ë‹`@: ‘‡Œ’f‚É‚¨‚Ż‚é—ΓŕáƒXƒNƒŠ[ƒjƒ“ƒO. “ú–{‚ĚŠá‰Č, 2017; 88(1)•t˜^: 42-49
  17. ěč—Ç, ˆ˘‹vŞ—zŽq, •˝’Ë‹`@, ŽR“cš˜a: Źl‚đ‘ÎŰ‚Ć‚ľ‚˝“œ”A•a–Ô–ŒÇŒŸfƒvƒƒOƒ‰ƒ€‚Ě”ď—p‘ÎŒř—p•ŞÍ. “ú–{‚ĚŠá‰Č, 2017; 88(1)•t˜^: 33-41
  18. “c‘şŠ°, Œă“Ą—ă, ŽR“cš˜a, •˝’Ë‹`@, ˆ˘‹vŞ—zŽq: Źl‚đ‘ÎŰ‚Ć‚ľ‚˝‰Á—”Á•ĎŤŒŸfƒvƒƒOƒ‰ƒ€‚Ě—Ő°‰uŠwAˆă—ĂŒoĎŠw“I•]‰ż. “ú–{‚ĚŠá‰Č, 2017; 88(1)•t˜^: 23-32
  19. ˆŔ“c–žO, —`…ƒŽq, ‘ĺ‰z‹MŽuŽq: ŒőŠąÂ’f‘wŒv‚Ĺ‘Ş’č‚ľ‚˝Œă–[Œ^—L…ť‘ĚŠá“ŕƒŒƒ“ƒYpŒă‚Ě–Ô–ŒŒú‚Ć–Ź—–ŒŒú•Ď‰ť. —ŐŠá, 2017; 71(9); 1393-1398
  20. ’Šˆä’m‰ŔŽq, Źě‰ŔŽq, ě“‡‘fŽq, •˝’Ë‹`@, ŽR“cš˜a: Ž‹ŠoáŠQ‚ĚŽž•a•‰’S‚ɂ‚˘‚Ä‚ĚŒŸ“˘@—źŠáŤ‚ƕЊᐍ‚Ě”äŠr. Šá—Ő‹I, 2017; 10(11): 891-896
y‘ŕz
  1. Hiratsuka Y: Visual Impairment as a Public Health Problem. Juntendo Medical Journal, 2017; 63(3): 201-203
  2. Inomata T: A New Immunotherapy Using Regulatory T-Cells for High-Risk Corneal Transplantation. Juntendo Medical Journal, 2017; 63(1): 2-7
  3. ‘şăť, ‹g–ě Œ’ˆę, A“c Šěˆę, ŒÜ“Ą ’qŽq, ”’Î “Ö, •B“c –q, •˝‰Ş F_, ‘O“c ’ź”V, ‹{–{ —TŽq, “ú–{ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYŠw‰ďƒIƒ‹ƒ\ƒPƒ‰ƒgƒƒW[ƒKƒCƒhƒ‰ƒCƒ“ˆĎˆő‰ď: ƒIƒ‹ƒ\ƒPƒ‰ƒgƒƒW[ƒKƒCƒhƒ‰ƒCƒ“(‘ć2”Ĺ). “úŠá‰ďŽ, 2017; 121(12): 936-938
  4. ‘ž“cr•F: uŠá“ŕƒŒƒ“ƒY‹­–Œ“ŕŒĹ’čp‚đŹŒ÷‚ł‚š‚éƒRƒcv-T-fixation technique-. Šá‰ČƒOƒ‰ƒtƒBƒbƒN, 2017; 6(1), 45-53
  5. ‘ž“cr•F; —Ž‹űÇŒóŒQ‚Ő…ť‘Ě’E‰PEˆŸ’E‰P‚𐜂ś‚Ä‚˘‚銳ŽŇ‚Ş‚˘‚Ü‚ˇ.‘Ήž‚đ‹ł‚Ś‚ĉş‚ł‚˘. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č, 2017; 34i—Ő‘j: 197-201
  6. ‘ž“cr•F; L-ƒ|ƒPƒbƒg‹­–ŒŘŠJ. ‚ ‚˝‚ç‚ľ‚˘Šá‰Čiˆóü’†j
  7. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠł‚ĆŒ‹–ŒƒoƒŠƒA[‹@\DƒAƒŒƒ‹ƒM[A2017; 66(8): 1001-1006
  8. ŠC˜VŒ´LsFŒ‹–ŒEŠp–Œă”ç×–E‚ĚƒoƒŠƒA‹@\‚ĆƒAƒŒƒ‹ƒM[Ť‰ŠÇDƒAƒŒƒ‹ƒM[E–Ɖu, 2017: 24(6): 778-786
  9. ŠC˜VŒ´LsFƒAƒgƒs[ŤŠááٔ畆‰Š‚É‚ć‚éŠá‡•šÇ‚ĆŽĄ—ÁD“ú–{‚ĚŠá‰Č, 2017; 88(8): 1027-1028
  10. ŠC˜VŒ´LsFƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYƒZƒ~ƒi[@‰Ô•˛Ç‚ĆƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYD‚ ‚˝‚ç‚ľ‚˘Šá‰Č, 2017; 34(9): 1277-1278
  11. ŠC˜VŒ´LsFáy‚Ý‚Ě‹­‚˘ŹŠwś‚̏t‹GƒJƒ^ƒ‹‚ɑ΂ˇ‚鎥—Ă–@‚đ‹ł‚Ś‚Ä‚­‚ž‚ł‚˘D‚ ‚˝‚ç‚ľ‚˘Šá‰Č, 34(—Ő‘): 171-173
  12. ŠC˜VŒ´LsC‘ĺ“ŕˆŸ—R”üFŠ´ŠoŠíE”畆‚Ě•a‹C‚Ć‚­‚ˇ‚č ŠáŽžŠł@Œ‹–Œ‰ŠD–ň‹Ç, 2017; 68(4): 1611-1612
  13. ŠC˜VŒ´LsC‘ĺ“ŕˆŸ—R”üFŠ´ŠoŠíE”畆‚Ě•a‹C‚Ć‚­‚ˇ‚č ŠáŽžŠł@‚Ô‚Ç‚¤–Œ‰ŠD–ň‹Ç, 2017; 68(4): 1612-1613
  14. ŠC˜VŒ´LsC‘ĺ“ŕˆŸ—R”üFŠ´ŠoŠíE”畆‚Ě•a‹C‚Ć‚­‚ˇ‚č ŠáŽžŠł@–Ô–ŒF‘f•ĎŤÇD–ň‹Ç, 2017; 68(4): 1614
  15. •˝’Ë‹`@: Ž‹ŠoáŠQ‘΍ô‚ĹŒ’NŽő–˝‰„L‚đ-‰îŒě—\–h‚É‚¨‚Ż‚éŠá‰Čˆă—Ă‚Ě–đŠ„-. “Œ‹ž“sŠá‰Čˆă‰ď•ń, 2017; 239: 2-7
  16. •˝’Ë‹`@AŹ–ě_ˆę: Ž‹ŠoáŠQ‚ÍŒöO‰qś–â‘č‚Ĺ‚ ‚é@“ú–{‚É‚¨‚Ż‚鎋ŠoáŠQEŽ¸–ž‚ĚŒťó‚ĆŒ´ˆö‚Ě•Ď‘J. ŒöO‰qś, 2017; 81(5): 364-371
  17. •˝’Ë‹`@, Ź–ě_ˆę, ’†–싧, “c‘şŠ°, Œă“Ą—ă, ěč—Ç, ě“‡‘fŽq, ŽR“cš˜a: Źl‚đ‘ÎŰ‚Ć‚ľ‚˝Šá‰ČŒŸf‚ĚŒťó‚Ć’nˆć“ĆŽŠ‚ĚŽć‚č‘g‚Ý. “ú–{‚ĚŠá‰Č, 2017; 8(1)•t˜^ : 3-22
  18. •˝’Ë‹`@, Ź–ě_ˆę: Ž‹ŠoáŠQ‚̉uŠw@“ú–{‚É‚¨‚Ż‚鎋ŠoáŠQ“Œv‚ĚŒťó‚Ɖۑč. —ŐŠá , 2017; 71(1): 12-18
  19. •˝’Ë‹`@, Ź–ě_ˆę: Ž‹ŠoáŠQ‚ÍŒöO‰qś–â‘č‚Ĺ‚ ‚é@“ú–{‚É‚¨‚Ż‚鎋ŠoáŠQEŽ¸–ž‚ĚŒťó‚ĆŒ´ˆö‚Ě•Ď‘J. ŒöO‰qś, 2017; 81(5): 364-371
  20. •˝’Ë‹`@: ƒXƒ}[ƒgƒTƒCƒgiƒ[ƒrƒWƒ‡ƒ“ƒPƒAĐ‰îƒŠ[ƒtƒŒƒbƒgj‚É‚ć‚郍[ƒrƒWƒ‡ƒ“ƒPƒA˜AŒgƒVƒXƒeƒ€‚̍\’z. “ú–{‚ĚŠá‰Č, 2017; 88(11): 1457-1466
  21. •˝’Ë‹`@, Ź–ě_ˆę: ŠáŽžŠł‚ĚˆęŽŸ—\–h‚Ć“ńŽŸ—\–h-ŠáŽžŠł‚Í‚Ç‚ą‚Ü‚Ĺ—\–h‰Â”\‚Š? Ž‹ŠoáŠQ‚̉uŠw@“ú–{‚É‚¨‚Ż‚鎋ŠoáŠQ“Œv‚ĚŒťó‚Ɖۑč. —ŐŠá, 2017; 71i1j: 12-18
  22. ŞŠÝ‹MŽu: ŽÎŽ‹‚Ǝ㎋‚ĚABCŠOŤ”]_ŒoáŠQ‚É‚ć‚éŽÎŽ‹. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č, 2017; 34(7): 1011-1012
  23. ŞŠÝ‹MŽu: ŹŽ™Šá‰ČEŽÎŽ‹—Ěˆć‚É‚¨‚Ż‚錤‹†‚Ě•űŒüŤ‚Ć–˘—ˆ. “úŠá‰ďŽ, 2017; 121(7): 519-520
  24. ŞŠÝ‹MŽu: yŠá‰Č‚É‚¨‚Ż‚é–ň•¨—Ă–@ƒp[ƒtƒFƒNƒgƒKƒCƒhz Šá•t‘ŽŠíEŠOŠá‹Ř@ƒ{ƒcƒŠƒkƒX“Ĺ‘fŽĄ—Á@ŠááŮázš. OCULISTA, 2017; 48: 1-4
  25. ŞŠÝ‹MŽu: AŒ^ƒ{ƒcƒŠƒkƒX“Ĺ‘f‚É‚ć‚éŽÎŽ‹ŽĄ—Ă. “Œ‹ž“sŠá‰Čˆă‰ď•ń, 2017; 241: 2-6
  26. ŞŠÝ‹MŽu: Minimally Invasive Strabismus Surgery. Šá‰ČŽčp‚Ě“K‰ž ĹVî•ń. Šá‰Č, 2017; 59(10)—Ő‘: 1047-1051
  27. ŞŠÝ‹MŽu: y•ĄŽ‹‚đf‚˝‚ç‚Ç‚¤‚ˇ‚é‚Šz •ĄŽ‹‚ĚŽĄ—Á@Žčp—Ă–@. Oculista, 2017; 53: 64-67
  28. ŞŠÝ‹MŽu: ŹŽ™Šá‰Č‚ĚUnmet Medical Needs. https://iseminar.net/e05100180, 2017
  29. ŞŠÝ‹MŽu: ŽÎŽ‹Žčp‚ĚŠî–{. https://iseminar.net/e05100181, 2017
  30. ŞŠÝ‹MŽu: Knot Assisted Hang-Back–@. https://iseminar.net/e05200142, 2017
  31. ŞŠÝ‹MŽu: g‘̏áŠQŽŇŽč’ ˆÓŒŠ‘‚̏‘‚Ť•ű. https://iseminar.net/e07100191, 2017
  32. _•”—F: ŠáˆĘ‚ĚˆŮí|Ž‹ü‚ލ‡‚í‚Č‚˘ŽÎŽ‹. ŹŽ™‰Č, 2017; 58(9): 1047-1052, 2017
  33. ŽRŒűš‘ĺ: yŠá‰Č‚ĹŒŠ‚‚Ż‚é!‘SgŽžŠłz ŠpŒ‹–ŒŠŒŠ‚Š‚猊‚‚Ż‚é‘SgŽžŠł. OCULISTA, 2017; 50 : 24-30
  34. ŽRŒűš‘ĺ, M–؏rŹ: yƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‘“_ŒŸz ƒn[ƒhƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY. Šá‰ČƒOƒ‰ƒtƒBƒbƒN, 2017; 6(2): 160-165
  35. ŽRŒűš‘ĺ: CLf—Ă‚É•K—v‚ČŠî‘b’mŽŻ(‘ć40‰ń)“K‰ž‚Ć‘I‘đ ‰~Šp–Œ•Ň(‹…–ĘHCL vs “ÁŽęHCL). “úƒRƒŒŽ, 2017; 59(‚P): 39-41
  36. ’––“•”Í, –{“c”üŽ÷: ÉŽq‘Ě’ŽË‚Ě“ú•ÄƒKƒCƒhƒ‰ƒCƒ“‚Ě”äŠr. Šá‰ČŽčp, 2017; 30: 5-11.
  37. ’––“•”Í: ˘ŠE‚Ěƒhƒ‰ƒCƒAƒC‚̍l‚Ś•ű‚Ě”äŠr. V‚ľ‚˘Šá‰Č, 2017; 34: 371-80.
  38. ’––“•”Í: 2045”N‚́gƒnƒCƒuƒŠƒbƒhƒƒfƒBƒVƒ“h‚Ě–‹ŠJ‚Ż IoTŽž‘ă“ž—ˆI@‚ť‚Ě‚Ć‚ŤA•a‰@‚Í‚Ç‚¤•Ď‚í‚é?. Nursing BUSINESS, 2017, 9ŒŽ†, 65-73
  39. ‘ĺ“ŕˆŸ—R”üCŠC˜VŒ´LsFŠ´ŠoŠíE”畆‚Ě•a‹C‚Ć‚­‚ˇ‚č ŠáŽžŠł@”’“ŕáD–ň‹Çi“ěŽR“°j68(4):1608-1610, 2017D
  40. źč—LC, ‘ž“cr•F: yHow to …ť‘ĚÄŒšz‚ć‚萳Šm‚ČCCCěŹ‚ĚƒRƒci‰đŕ/“ÁWj. MB OCULISTA, 2016; 45, 26-34
  41. Žsě_•˝, ‘ž“cr•F: y‚ą‚ń‚Č‚Ć‚Ť‚Ç‚¤‚ˇ‚é@ŠáŠOz‹÷Šp‰đ—ŁA“řĘ—Ł’fA–Ń—l‘̉đ—Ł. MB OCULISTA, 2017; 56: 15-23
  42. ‘ĺ‰z‹MŽuŽq: ‹~‹}ŽžŠł‚˛‚Ć‚ĚŠî–{“I‚Č‘Îˆ–@ 8 ÉŽq‘́E–Ô–Œ Q3 –Ô–Œ’†S“Ž–Ź•ÂÇÇ‚Ö‚Ě‘Îˆ–@‚đ‹ł‚Ś‚Ä‚­‚ž‚ł‚˘. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č, 2017; 34—Ő‘: 233-237
  43. ‘ĺ‰z‹MŽuŽq: “œ”A•a‰Š”Á•‚Žî‚ĚŽĄ—Á|Œő‹ĂŒĹ‚Ě“K‰ž‚Ć•ű–@. “ú–{‚ĚŠá‰Č, 2017; 88(5): 567-573
  44. ‘ĺ‰z‹MŽuŽq: “œ”A•a‰Š”Á•‚Žî‚É‚¨‚Ż‚éƒ}ƒCƒNƒƒpƒ‹ƒX@ƒ_ƒCƒI[ƒhƒŒ[ƒU[臒l‰ş‹ĂŒĹ: ƒ‰ƒ“ƒ_ƒ€‰ť”äŠrŽŽŒą‚Ěƒƒ^‰đÍ. “ú–{‚ĚŠá‰Č, 2017; 88(5): 584-585
  45. ‘ĺ‰z‹MŽuŽq:Šá‰ČŽĄ—Ă‚ĚŒťÝ ƒŒ[ƒU[‚ƍRVEGF—Ă–@. MEDICAL PHOTONICS, 2017; 24: 41-46
  46. ˆîŠ_Œ\Ži: 臒l‰şƒŒ[ƒU[‚ֈڍs‚ˇ‚éƒ^ƒCƒ~ƒ“ƒO‚ĆŽĄ—Ă‚ĚŽŔŰ@‚˘‚‚܂őą‚Ż‚éH“œ”A•a‰Š”Á•‚Žî臒l‰şƒŒ[ƒU[‚ֈڍs‚ˇ‚éƒ^ƒCƒ~ƒ“ƒO‚ĆŽĄ—Ă‚ĚŽŔŰ. Šá‰ČƒOƒ‰ƒtƒBƒbƒN, 2017; 6(5): 436-442
  47. ˆîŠ_Œ\Ži: RVEGF—Ă–@Žž‘ă‚É‚¨‚Ż‚é‘źŽĄ—Ă‚ĚˆĘ’u‚Ă‚Ż DME•Ň: ƒŒ[ƒU[‚ɂ‚˘‚āARVEGF—Ă–@‚Ć‚ĚŽg‚˘•Ş‚Ż‚â•š—p—Ă–@‚ɂ‚˘‚Ä. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č, 2017; 34(6): 837-838
  48. ŽR“cš˜a, •˝’Ë‹`@, Ź–ě_ˆę, “c‘şŠ°, ’†–싧, ěč—Ç, ˆ˘‹vŞ—zŽq, ě“‡‘fŽq: •ďŠ‡“IƒXƒNƒŠ[ƒjƒ“ƒO‚Ć‚ľ‚Ă̐ŹlŠá‰ČŒŸf‚ĚŒř‰Ę. “ú–{‚ĚŠá‰Č, 2017; 88i1j•t˜^: 50-55
  49. ŽR“cš˜a, ˆ˘‹vŞ—zŽq, •˝’Ë‹`@: Źl‚đ‘ÎŰ‚Ć‚ľ‚˝Šá‰ČŒŸf‚̉”\Ť. —ŐŠá, 2017; 71(1) : 62-67
y’˜‘z
  1. ‘ž“cr•F: ZinnŹ‘ѐƎ㔒“ŕá. Šá‰Čf—Ăƒ}ƒCƒXƒ^[2ŠŞ, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, 128-131, 2017
  2. ‘ž“cr•F: –ł…ť‘ĚŠá‚ɑ΂ˇ‚éŠá“ŕƒŒƒ“ƒY–D’…p‚Ć‹­–Œ“ŕŒĹ’čp. Šá‰Čf—Ăƒ}ƒCƒXƒ^[3ŠŞ, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, 2017
  3. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠł. Ą“ú‚ĚŽĄ—ĂŽwj2017i‘•ŇWj•ŸˆäŽŸ–î, ‚–ؐ˝, ŹŽşˆęŹiˆăŠw‘‰@j1433-1435,2017
  4. “yŽŠ“cG: ‡•š‚ˇ‚é‘SgŽžŠł. ‚Ç‚¤f‚Ä‚Ç‚¤ŽĄ‚ˇ? ‰~Šp–Œ. “‡čE‘O“c’ź”VE‰Á“Ą’źŽqi•Ňj, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, 12-13, 2017
  5. ŞŠÝ‹MŽu: ”ń‹üÜŤ’˛ßŤ“ŕŽÎŽ‹. ŽÎŽ‹ŽĄ—Ă‚ĚƒXƒgƒ‰ƒeƒW[. •ŇW ˛“Ą”ü•Ű. ŽO—֏‘“X, “Œ‹ž, 45-48, 2017
  6. ŞŠÝ‹MŽu: ŠÔŒ‡ŤŠOŽÎŽ‹(ŽÎˆĘ‹ßŽ‹). ŽÎŽ‹ŽĄ—Ă‚ĚƒXƒgƒ‰ƒeƒW[. •ŇW ˛“Ą”ü•Ű. ŽO—֏‘“X, “Œ‹ž, 100-102, 2017
  7. ŞŠÝ‹MŽu: dÇ‹Ř–ł—͏Ç. ŽÎŽ‹ŽĄ—Ă‚ĚƒXƒgƒ‰ƒeƒW[. •ŇW ˛“Ą”ü•Ű. ŽO—֏‘“X, “Œ‹ž, 168-170, 2017
  8. ŞŠÝ‹MŽu: ŹŠp“x‚Ěă‰şŽÎŽ‹. ŽÎŽ‹ŽĄ—Ă‚ĚƒXƒgƒ‰ƒeƒW[. •ŇW ˛“Ą”ü•Ű. ŽO—֏‘“X, “Œ‹ž, 216-218, 2017
  9. ŞŠÝ‹MŽu: ŠáˆĘŤŠáU. ŽÎŽ‹ŽĄ—Ă‚ĚƒXƒgƒ‰ƒeƒW[. •ŇW ˛“Ą”ü•Ű. ŽO—֏‘“X, “Œ‹ž, 244-247, 2017
  10. ŞŠÝ‹MŽu: Šááقُ̈í. ĹVƒKƒCƒhƒ‰ƒCƒ“€‹’@ŹŽ™‰Čf’fEŽĄ—ĂŽwj@‰ü’ů‘ć‚Q”Ĺ. ‘•ŇW ‰““Ą•ś•v. ’†ŽR‘“X, “Œ‹ž, 1069-1072, 2017
  11. ŞŠÝ‹MŽu: Œ‹–Œ‰Š. ĹVƒKƒCƒhƒ‰ƒCƒ“€‹’@ŹŽ™‰Čf’fEŽĄ—ĂŽwj@‰ü’ů‘ć‚Q”Ĺ. ‘•ŇW ‰““Ą•ś•v. ’†ŽR‘“X, “Œ‹ž, 1072-1076, 2017
  12. ŞŠÝ‹MŽu: ć“VŤ•@—܊ǕÇ. ĹVƒKƒCƒhƒ‰ƒCƒ“€‹’@ŹŽ™‰Čf’fEŽĄ—ĂŽwj@‰ü’ů‘ć‚Q”Ĺ. ‘•ŇW ‰““Ą•ś•v. ’†ŽR‘“X, “Œ‹ž, 1076-1077, 2017
  13. ŞŠÝ‹MŽu: ć“VFŠoˆŮí. ĹVƒKƒCƒhƒ‰ƒCƒ“€‹’@ŹŽ™‰Čf’fEŽĄ—ĂŽwj@‰ü’ů‘ć‚Q”Ĺ. ‘•ŇW ‰““Ą•ś•v. ’†ŽR‘“X, “Œ‹ž, 1092-1095, 2017
  14. ’––“•”́A’†”ö•ŽjŠÄ–ó: ƒn[ƒo[ƒh‘ĺŠwŠá‰ČƒCƒ‰ƒXƒgƒŒƒCƒeƒbƒhƒ}ƒjƒ…ƒAƒ‹. ‹ŕŒ´o”ŁE 2017”N10ŒŽ
  15. ’––“•”Í: ƒn[ƒo[ƒh×MBA׈ăŽt “­‚­l‚Ě‚˝‚ß‚ĚĹ‹­‚Ě‹x‘§–@. ƒfƒBƒXƒJƒ”ƒ@[EƒgƒDƒGƒ“ƒeƒBƒƒ“E2017”N8ŒŽ
  16. ’––“•”Í: }‰đ ŒŔ‚ç‚ę‚˝ŽžŠÔ‚ĹĹ‘ĺ‚̐Ź‰Ę‚đ‚ ‚°‚éĹ‹­‚̕׋­–@. ƒfƒBƒXƒJƒ”ƒ@[EƒgƒDƒGƒ“ƒeƒBƒƒ“E2017”N2ŒŽ
y•ńE‚ť‚Ě‘źz
  1. ‘ž“cr•F: ”’“ŕá.@ƒAƒXƒeƒ‰ƒXť–ň, –ž“ú‚ŕŒł‹C, TBSƒ‰ƒWƒI, 2017”N1ŒŽ30“ú`2ŒŽ3“ú
  2. ‘ž“cr•F: ƒRƒ“ƒTƒ‹ƒe[ƒVƒ‡ƒ“ƒR[ƒi[@ƒGƒLƒXƒp[ƒg‚É•ˇ‚­. IOL&RS, 2017; 31(1), 144
  3. ŠC˜VŒ´LsFŒ‹–Œă”ç‚ĆŠáƒAƒŒƒ‹ƒM[DƒAƒŒƒ‹ƒM[‚Ě—Ő°i–k—˛ŠŮjĄ“ú‚ĚŒž—t492. (525)17, 2017.
  4. ŠC˜VŒ´LsF’Ę”NŤƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠDÎŠç9ŒŽ†i•ŰŒ’“ŻlŽĐj10-13, 2017.
  5. ŠC˜VŒ´LsF‰Ô•˛Ç‚É‚ć‚é–Ú‚Ě‚Š‚ä‚݁DŽYŒoV•ˇC2017”N3ŒŽ7“úD
  6. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠD•Ÿ“‡–Ż—FV•ˇC2017”N3ŒŽ6“úD
  7. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠDĂ‰ŞV•ˇi—[Š§jC2017”N3ŒŽ7“úD
  8. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠD’†‘V•ˇC2017”N3ŒŽ8“úD
  9. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠD“ż“‡V•ˇC2017”N3ŒŽ8“úD
  10. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠD“ú–{ŠCV•ˇC2017”N3ŒŽ9“úD
  11. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠDŽR—œ“ú“úV•ˇC2017”N3ŒŽ9“úD
  12. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠDVŠƒ“ú•ńC2017”N3ŒŽ10“úD
  13. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠDŠň•ŒV•ˇC2017”N3ŒŽ11“úD
  14. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠDç—t“ú•ńC2017”N3ŒŽ12“úD
  15. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠD˛‰ęV•ˇC2017”N3ŒŽ14“úD
  16. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠD—Ž‹…V•ˇC2017”N3ŒŽ14“úD
  17. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠDŠâŽč“ú•ńC2017”N3ŒŽ15“úD
  18. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠD_ŒËV•ˇC2017”N3ŒŽ16“úD
  19. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠD‚’mV•ˇC2017”N3ŒŽ17“úD
  20. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠDŒF–{“ú“úV•ˇC2017”N3ŒŽ17“úD
  21. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠD_“ސěV•ˇC2017”N3ŒŽ19“úD
  22. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠDŽRŒ`V•ˇC2017”N3ŒŽ20“úD
  23. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠD’†•”ŒoĎV•ˇC2017”N3ŒŽ21“úD
  24. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠDˆ¤•QV•ˇC2017”N3ŒŽ21“úD
  25. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠD“ě“ú–{V•ˇC2017”N3ŒŽ22“úD
  26. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠDˆďéV•ˇC2017”N3ŒŽ23“úD
  27. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠD‰ş–ěV•ˇC2017”N3ŒŽ24“úD
  28. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠDŽR—zV•ˇi—[Š§jC2017”N3ŒŽ28“úD
  29. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰ŠD‹ž“sV•ˇC2017”N3ŒŽ28“úD
  30. •˝’Ë‹`@, •Ÿ‰şŒöŽq: ƒ[ƒrƒWƒ‡ƒ“ƒPƒA‚ĹŒŠ‚Ś‚é—Í‚đĹ‘ĺŒŔ‚É”­Šö‚ˇ‚é. TŠÔ’Š“úMOOK@Šá‚Ě‚˘‚˘•a‰@2017@˜VŠá&”’“ŕáŠŽ‘SƒKƒCƒh@’Š“úV•ˇo”Ĺ 2017; 80-85
  31. •˝’Ë‹`@: Ž‹ŠoáŠQ‘΍ô‚ŞŒ’NŽő–˝‚đ‰„‚Î‚ˇ@Šá‚ĚŒŸ¸‚Ĺ‚í‚Š‚é”]‘˛’†ƒŠƒXƒN. TŠ§’Š“ú 2017”N8ŒŽ4“ú†; 86-87
  32. “yŽŠ“cG: CL‘•—p‚ĆŠ´őÇi‘ć39‰ńj. “úƒRƒŒŽ, 2017; 59(1), 42-43
  33. “yŽŠ“cG: ŒŁŠá‚Ě—‰đ[‚ß‚é Ŕ’Âŕ׋­‰ď. Ă‰ŞV•ˇ, 2017”N10ŒŽ12“ú, 23
  34. ’†’J’q: ”’“ŕáŽčp‚É‚¨‚Ż‚éƒ}ƒjƒ…ƒAƒ‹CCC ěŹ¸“x‚ÉŠÖ‚ˇ‚錟“˘. AMO Cataract Surgery SeminarE’鍑ƒzƒeƒ‹“Œ‹žE2017”N8ŒŽ28“ú
  35. ”~‰Ž—ćŽq: Ž‹ŠE‚Ş‹ˇ‚˘A‚Ü‚Ô‚˝‚ޏd‚˘…Šááىş‚‚Ĺ‚Í? Œ´ˆö‚ĆŽĄ—Ă–@‚Ě‚¨‚Í‚Č‚ľ. ‡“V“°“Œ‹ž]“Œ‚—îŽŇˆă—ĂƒZƒ“ƒ^[@‹ć–ŻŒ’NuŔ, “Œ‹ž@2017”N9ŒŽ16“ú
  36. ”~‰Ž—ćŽq: ƒJƒ‰ƒRƒ“‚̏”–â‘č. ‘ć1‰ń]“ŒŠá‰ČŠwpŒ¤‹†‰ď, “Œ‹ž, 2017”N7ŒŽ6“ú
  37. •ˆäłl: Žčp‘Š’kŽş ‰Š”Á‰şŒŒŽî‚ĚŽĄ—Ă‘I‘đ. Šá‰ČŽčp, 2017; 30(4): 667-671
  38. ŽRŒűš‘ĺF”’“ŕá. Tokyo Eye Festival, “Œ‹ž, 2017”N10ŒŽ8“ú
  39. ’––“•”Í: –Ú‚ĚŠŁ‚Ť‚͉Á—î‚Ě‚š‚˘HƒCƒPƒƒ“ƒhƒNƒ^[‚ށgƒhƒ‰ƒCƒAƒCh‚đ‚â‚ł‚ľ‚­‰đŕ‚ˇ‚éwƒIƒgƒi‚ĚƒJƒ‰ƒ_”Y‚Ý‘Š’kŽşx. ‚˛‚˛ƒiƒ}, NHK, 2017”N6ŒŽ27“ú
  40. ’––“•”Í: Œúś˜J“­ČAˆăŽt‚Ě“­‚Ť•ű‚ÉŠÖ‚ˇ‚錟“˘‰ďE\Źˆő. http://www.mhlw.go.jp/stf/shingi/other-isei.html?tid=469190
  41. ’––“•”Í: “Ž‚Ťo‚ľ‚˝gIoMTh\\ƒlƒbƒgŽĐ‰ď‚Ćˆă—Ă‚Ş—Z‡‚ˇ‚鎞‘ă‚É. “úŒoƒfƒWƒ^ƒ‹ƒwƒ‹ƒXA2017”N9ŒŽ19“ú, http://techon.nikkeibp.co.jp/atcl/column/15/327412/091800028/?ST=health
  42. ’––“•”Í: w—ŻŠw‚ĆMBA‚Š‚çŽn‚Ü‚Á‚˝ˆă—Ă”ĹIoT‚Ö‚Ě’§íIx. ŽŔŒąˆăŠw, 2017”N5ŒŽ†, vol.35, No.8
  43. ’––“•”Í: •a‰@‚̢’ˇ‚˘‘Ň‚żŽžŠÔ‚Í‚Č‚ş‰đÁ‚ľ‚Č‚˘‚Ě‚Š@Œo‰cŠw‚Ć–@—Ľ‚ĚŠĎ“_‚Š‚ç‰đŒˆô‚đl‚Ś‚é. “Œ—mŒoĎƒIƒ“ƒ‰ƒCƒ“, 2017”N2ŒŽ25“ú http://toyokeizai.net/articles/-/157392
  44. ’––“•”Í: IoMT‚͈ă—Ă‚É‚¨‚Ż‚éƒCƒmƒx[ƒVƒ‡ƒ“‚đ‹N‚ą‚š‚é‚Š? -ResearchKit‚đ—p‚˘‚˝—Տ°Œ¤‹†‚Ě—L—pŤ. ŽŔŒąˆăŠw, 2017”N3ŒŽ†, Vol.35 No.4
  45. ’––“•”Í: ResearchKit‚đ—p‚˘‚˝iPhoneƒAƒvƒŠ‚̉”\Ť - ‡“V“°‘ĺŠw‚ĚŒ¤‹†‚Š‚ç•Ş‚é‚ą‚Ć. ƒ}ƒCƒiƒrƒjƒ…[ƒX, 2017”N1ŒŽ24“ú, http://news.mynavi.jp/articles/2017/01/24/reserchkit/
  46. ’––“•”Í: Šá‰Čˆă‚ŞŽŽ‚ľ‚Ä‚Ý‚Ü‚ľ‚˝Iƒhƒ‰ƒCƒAƒCŠÖ˜AƒOƒbƒY. Frontier in Dry Eye. 2017. vol.12 No.2
  47. ’––“•”Í: 100Î‚܂Őś‚Ť‚é‚˝‚ß‚Ě–{100‘I. 2017; vol13, Mo.3
  48. ŽRŒű’B•v: Ž¸–ž—\–h@ŠŞ“ŞŒž. “ú–{Ž¸–ž—\–h‹Ś‰ď‰ď•ń, 2017, 30
  49. ‚–ěr”V:ƒWƒ‡[ƒ“ƒYƒ`ƒ…[ƒu‚đ—p‚˘‚˝Œ‹–Œ—Ü”X•@o•Ť‡p‚ɂ‚˘‚Ä. ‘ć30‰ńé‹ĘŒ§Šá‰ČŽčp’k˜b‰ď, é‹ĘŒ§,@2017”N7ŒŽ9“ú@
  50. ‘ĺ‰z‹MŽuŽq: ‚Ť‚傤‚ĚƒZƒJƒ“ƒhƒIƒsƒjƒIƒ“. –ˆ“úV•ˇ, 2017”N1ŒŽ22“ú
  51. ‘ĺ‰z‹MŽuŽq: “œ”A•a‚Ĺ•|‚˘‚Ě‚Í‡•šÇ‚Ĺ‚ˇ. “œ”A•a‚É‚˘‚˘‚ą‚ƁiŠÄCj, 2017”N7ŒŽ”­s
  52. ‘ĺ‰z‹MŽuŽq: “œ”A•a‰Š”Á•‚ŽîiDMEj‰ć‘œŠŒŠ‚É‚ć‚鎥—Ă•űj‚ĚŒˆ’č‚ĆŽĄ—ĂŠÇ—. EYLEA IMAGING REPORTiŠÄC, Ç—á’ńŽŚj,@2017”N8ŒŽ”­s
  53. ‘ĺ‰z‹MŽuŽq: ‚Š‚Š‚č‚‚Ż–ňÜŽt‚ށuŠá’ęŒŸ¸‚ĚŽóf§—ă‚đv“œ”A•a–Ô–ŒÇ‚Ě‘Šú”­ŒŠ. –ňŽ–“ú•ń, “Œ‹ž, 2017”N10ŒŽ20“ú
  54. ‘ĺ‰z‹MŽuŽq: “œ”A•a‚Ɛf’f‚ł‚ę‚˝•ű‚Ö. mealtaime2017“~†, 2017”N11ŒŽ@
  55. ‘ĺ‰z‹MŽuŽq: ‚ą‚̐l‚É’–ځ@„‘El‚Š‚ç‚ĚƒRƒƒ“ƒg. IOL•RS, 2017; 31(4): 402-409
  56. ˆŔ“c–žO, —`…ƒŽq, ‘ĺ‰z‹MŽuŽq: ƒtƒ‰ƒbƒvěť–@‚Ĺ”äŠr‚ľ‚˝LASIKpŒă‚Ě–Ô–Ź—–Œ‚¨‚ć‚яɮq‘̕ωť. “úŠá‰ďŽ, 2017; 121(10): 778
  57. ˆŔ“c–žO: ‚ą‚̐l‚É’–Ú. IOL•RS, 2017; 31(4): 402-409
  58. ‰Fm‚ ‚ł‚Đ, ˆîŠ_Œ\Ži, ŕ_“c^Žj, Ż–ěŠG—˘, ‘ĺ‰z‹MŽuŽq: “œ”A•aŠłŽŇ‚Ě–Ô–ŒÇ‘Šú”­ŒŠ‚É‚¨‚Ż‚éOCTAngiography‚Ě—L—pŤ. ‘ć11‰ńšƒ‹ƒJEƒAƒJƒfƒ~ƒAŒ¤Cˆă‹ĆŃW, 2017
  59. Kurihara T, Echizen N, Deshpande GA, Ohkoshi K: Real-World outcomes of treatment for polypoidal choroidal vasculopathy:The impact of intravitreal aflibercept injections. ‘ć11‰ńšƒ‹ƒJEƒAƒJƒfƒ~ƒAŒ¤Cˆă‹ĆŃW, 2017
  60. @@@@@@@@@@@@@@@@@@@@@
2016”N
yŒ´’˜‰p•śz
  1. Shimura S, Takai T, Iida H, Maruyama N, Ochi H, Kamijo S, Nishioka I, Hara M, Matsuda A, Saito H, Nakae S, Ogawa H, Okumura K, Ikeda S. Epicutaneous Allergic Sensitization by Cooperation between Allergen Protease Activity and Mechanical Skin Barrier Damage in Mice. J Invest Dermatol, 136: 1408-1417, 2016 iIF: 6.915j
  2. Inomata T, Hua J, Di Zazzo A, Dana R: Impaired Function of Peripherally Induced Regulatory T Cells in Hosts at High Risk of Graft Rejection. Sci rep, 2016 Dec 23;6:39924. doi: 10.1038/srep39924.(IF: 5.228)
  3. Ueno K, Iwagawa T, Kuribayashi H, Baba Y, Nakauchi H, Murakami A, Nagasaki M, Suzuki Y, Watanabe S: Transition of differential histone H3 methylation in photoreceptors and other retinal cells during retinal differentiation. Sci Rep, 2016 Jul 5;6:29264. doi: 10.1038/srep29264iIF: 5.228j
  4. Kamijo S, Suzuki M, Hara M, Shimura S, Ochi H, Maruyama N, Matsuda A, Saito H, Nakae S, Suto H, Ichikawa S, Ikeda S, Ogawa H, Okumura K, Takai T. Subcutaneous allergic sensitization to protease allergen is dependent on mast cells but not IL-33: Distinct mechanisms between subcutaneous and intranasal routes. J Immunol, 196: 3559-3569, 2016 iIF: 4.985j
  5. Palczewska G, Maeda A, Golczak M, Arai E, Dong Z, Perusek L, Kevany B, Palczewski P: Receptor tyrosine kinase MERTK is not required for transfer of bis-retinoids to the retinal pigmented epithelium. J Biol Chem, 291(52); 26937-26949,  2016iIF: 4.258j
  6. Kobayashi Y, Yoshida S, Zhou Y, Nakama T, Ishikawa K, Kubo Y, Arima M, Nakao S, Hisatomi T, Ikeda Y, Matsuda A, Sonoda K-H, Ishibashi T. Tenascin-C secreted by transdifferentiated retinal pigment epithelial cells promotes choroidal neovascularization via integrin αV. Lab Invest,  96: 1178-1188, 2016iIF: 4.202j
  7. Tahvildari M, Omoto M, Chen Y, Emami-Naeini P, Inomata T, Dohlman TH, Kaye AE, Chauhan SK, Dana R: In Vivo Expansion of Regulatory T Cells by Low-Dose Interleukin-2 Treatment Increases Allograft Survival in Corneal Transplantation. Transplantation, 100(3): 525-532, 2016iIF: 3.690j
  8. Di Zazzo A, Tahvildari M, Subbarayal B, Yin J, Dohlman TH, Inomata T, Mashaghi A, Chauhan SK, Dana R: Proangiogenic Function of T Cells in Corneal Transplantation. Transplantation, 2016 Aug 3. [Epub ahead of print] iIF: 3.690j
  9. Tamaki K, Usui-Ouchi A, Murakami A, Ebihara N: Fibrocytes and Fibrovascular Membrane Formation in Proliferative Diabetic Retinopathy. Invest Ophthalmol Vis Sci, 57(11): 4999-5005, 2016iIF: 3.427j
  10. Hamanaka T, Matsuda A, Sakurai T, Kumasaka T: Morphological abnormalities of schlemm’s canal in primary open-angle glaucoma from the aspect of aging. Invest Ophthalmol Vis Sci, 57(2): 692-706, 2016iIF: 3.427j
  11. Hua J, Stevenson W, Dohlman TH, Inomata T, Tahvildari M, Calcagno N, Pirmadjid N, Sadrai Z, Chauhan SK, Dana R: Graft Site Microenvironment Determines Dendritic Cell Trafficking Through the CCR7-CCL19/21 Axis. Invest Ophthalmol Vis Sci, 57(3): 1457-67. doi: 10.1167/iovs.15-17551, 2016iIF: 3.427j
  12. Parmar T, Parmar V, Arai E, Sahu B, Perusek L, and Maeda A: Acute stress responses are early molecular events of retinal degeneration in Abca4-/-Rdh8-/- mice after light exposure. Invest Ophthalmol Vis Sci, 57(7): 3257-3267, 2016 iIF: 3.427j
  13. Usui-Ouchi A, Ouchi Y, Kiyokawa M, Sakuma T, Ito R, Ebihara NFUpregulation of Mir-21 Levels in the Vitreous Humor Is Associated with Development of Proliferative Vitreoretinal DiseaseDPLoS One, 28; 11(6):e0158043, 2016iIF: 3.057j
  14. Tano T, Ono K, Hiratsuka Y, Otani K, Sekiguchi M, Konno S, Kikuchi S, Onishi Y, Takegami M, Yamada M, Fukuhara S, Murakami A: Retinal vessel diameters in a Japanese population: the Locomotive Syndrome and Health Outcome in Aizu Cohort Study. Acta Ophthalmol, 94(6): e432-441, 2016iIF: 3.032j
  15. Miyamichi D, Asahina M, Nakajima J, Sato M, Hosono K, Nomura T, Negishi T, Miyake N, Hotta Y,  Ogata T, Matsumoto N. Novel HPS6 mutations identified by whole-exome sequencing in two Japanese sisters with suspected ocular albinism. J Hum Genet, 61(9): 839-842, 2016iIF: 2.487j
  16. Inomata T, Honda M, Murakami A: Atypical VZV Retinitis in a Patient with Good Syndrome. Ocul Immunol Inflamm. Aug 5:1-5, 2016 [Epub ahead of print] iIF:2.481 j
  17. Kobayashi Y, Yoshida S, Zhou Y, Nakama T, Ishikawa K, Arima M, Nakao S, Sassa Y, Takeda A, Hisatomi T, Ikeda Y, Matsuda A, Sonoda KH, Ishibashi T. Tenascin-C promotes angiogenesis in fibrovascular membranes in eyes with proliferative diabetic retinopathy. Mol Vis, 22:436-445, 2016. iIF: 2.110j
  18. Yamaguchi M, Shima N, Kimoto M, Ebihara N, Murakami A, Yamagami S: Optimization of Cultured Human Corneal Endothelial Cell Sheet Transplantation and Post-Operative Sheet Evaluation in a Rabbit Model. Curr Eye Res, 41(9): 1178-1184, 2016iIF: 2.025j
  19. Serizawa S, Ohkoshi K, Minowa Y, Soejima K: Interdigitation zone band restoration after treatment of diabetic macular edema. Curr Eye Res, 41(9): 1229-1234, 2016iIF: 2.025j
  20. Nakatani S, Murakami A: Descemet stripping automated endothelial keratoplasty using corneas from elderly donors. Graefes Arch Clin Exp Ophthalmol, 254(6): 1135-1140, 2016iIF: 1.991j
  21. Watanabe S, Murakami A: Regulation of Retinal Development via the Epigenetic Modification of Histone H3. Adv Exp Med Biol, 854: 635-641, 2016iIF: 1.953j
  22. Kawashima M, Hiratsuka Y, Nakano T, Tamura T, Ono K, Murakami A, Inoue S, Tsubota K, and Yamada M. The association between legal Japanese visual impairment grades and vision related quality of life. Jpn J Ophthalmol, 60(3): 219-225, 2016iIF: 1.510j
  23. Shimazaki J, Maeda N, Hieda O, Ohashi Y, Murakami A, Nishida K, Tsubota K: Japan Pellucid Marginal Corneal Degeneration Study Group. National survey of pellucid marginal corneal degeneration in Japan. Jpn J Ophthalmol, 60(5): 341-8, 2016iIF: 1.510j
  24. Kawashima M, Hiratsuka Y, Nakano T, Tamura H, Ono K, Murakami A, Inoue S, Tsubota K, Yamada M: The association between legal Japanese visual impairment grades and vision-related quality of life. Jpn J Ophthalmol, 60(3): 219-25, 2016iIF: 1.510j
  25. Sakanishi Y, Lee A, Usui-Ouchi A, Ito R, Ebihara N: Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab. Clin Ophthalmol, 21; 10: 1161-1165, 2016
  26. Toride A, Toshida H, Matsui A, Matsuzaki Y, Honda R, Ohta T, Murakami A: Visual outcome after emergency surgery for open globe eye injury in Japan. Clin Ophthalmol, 10: 1731-1736, 2016
  27. Hirakata T, Fujinami K, Watanabe K, Sasaki M, Noda T, Akiyama K: One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement. Clin Ophthalmol, 10: 969-77, 2016
  28. Nakano T, Kawashima M, Hiratsuka Y, Tamura H, Ono K, Murakami A, Tsubota K, Yamada M: Assessment of quality of life in patients with visual impairments using a new visual function questionnaire: the VFQ-J11DClin Ophthalmol, 10: 1939-1944, 2016
  29. Hayashi Y, Toshida H, Matsuzaki Y, Matsui A, Ohta T. Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes. Int Med Case Rep J, May 9; 113-116, 2016
yŒ´’˜˜a•śz
  1. ’†’J@’qA‰Í–씎”VA‘şă@ťFŠp–Œ“ŕ”çáŠQŠá‚ɑ΂ľ‚ÄŽ{s‚ľ‚˝”’“ŕáŽčpÇ—á‚ĚŒŸ“˘. “úŠá‰ďŽ, 120(7): 481-486, 2016
  2. ŞŠÝ‹MŽuF–ƒáƒŤŽÎŽ‹@f’f‚ĆŽĄ—Â̐i•ŕ –ƒáƒŤŽÎŽ‹‚ĚŽčpŽĄ—Ă. Šá—Ő‹I, 9(1): 38-40, 2016
  3. —é–Ř‹M‰pF×–EŤ‹}ŤƒŠƒ“ƒpŤ”’ŒŒ•aŽĄ—Ă’†‚É”­Ç‚ľ‚˝Posterior reversible encephalopathy syndrome‚Ěˆę—áDJournal of the Eye, 33(6): 909-914, 2016
  4. âź—ǐmA‘ĺ“ŕˆŸ—R”üAˆÉ“Ą—ćAŠC˜VŒ´LsF–Ô–ŒĂ–Ź•ÂÇÇ‚É”ş‚¤‰Š”Á•‚Žî‚ɑ΂ˇ‚郉ƒjƒrƒYƒ}ƒuÉŽq‘Ě“ŕ’ŽË‚Ě‚U‚ŠŒŽŠÔŽĄ—ÐŹŃD“úŠá‰ďŽC120(1): 28-34, 2016
  5. ‰Ş–ě”üŽ÷Žq, —›ˆŸ”ü, ŠC˜VŒ´LsFŒ‹Šj‹Ű“ÁˆŮ“IINF-γ—V—ŁŽŽŒą‚ސf’f‚É—L—p‚Ĺ‚ ‚Á‚˝–Ź—–ŒŒ‹ŠjŽî‚Ě1Ç—áDŠá‰Č, 58(3): 313-318, 2016
  6. ‰Ş–ě”üŽ÷Žq, âź—ǐm, ŠC˜VŒ´LsFŽŠ‘R•Â˝‚ľ‚˝stage IV“Á”­Ť‰Š”Á‰~E‚Ş3”NŒă‚ɍĔ­‚ľ‚˝1—á. Šá—Ő‹I, 2016; 9(12): 1022-1027
  7. ’Ř“c’qŽqCŠC˜VŒ´LsF—Տ°•ń Œ€ÇŒ^‚Ě”L‚Đ‚Á‚Š‚Ť•a‚Ě1—á. —ŐŠá, 70(7): 1059-106, 2016
  8. Vˆä—ćCŠC˜VŒ´LsC•x“c–ÎŽ÷FŠááىş‚‚É‚ć‚č”­ŒŠ‚ł‚ę‚˝Œ‹–ŒƒAƒ~ƒƒCƒh[ƒVƒX‚Ě‚QÇ—á. “úŠá‰ďŽ120: 797-801, 2016D
  9. Žsě_•˝AŹ—эG–žAM–؏rŹA—é–؍N•vA‘şăťF’×ᇐŤ‘ĺ’°‰Š‚ɑ΂ľ‚Äadalimumab“Š—^’†‚ÉŽ‹_Œo‰Š‚đ”­Ç‚ľ‚˝1—á. _ŒoŠá‰Č, 33: 254-258, 2016.
y‘ŕz
  1. ‘şăťF–Ô–ŒF‘f•ĎŤD“Œ‹ž“sˆăŽt‰ďŽGŽ, 69i7j: 624-627, 2016
  2. ‘ž“cr•FFŠá“ŕƒŒƒ“ƒY‹­–Œ“ŕŒĹ’čp|T-fixation technique|. Šá‰ČŽčp Vol 29 No.1 24-31, ƒƒfƒBƒJƒ‹ˆ¨o”Ĺ, 2016
  3. ŠC˜VŒ´LsFt‹GƒJƒ^ƒ‹. “ú–{—Տ°•Ęű–ƉuÇŒóŒQi‘ć2”Łj 33-38, 2016
  4. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠł‚̓Ç—á‚Ö‚ĚŽĄ—Ð헪. ƒAƒŒƒ‹ƒM[, 65(8): 994-998, 2016
  5. ŠC˜VŒ´LsFŒ‹–Œ‘gD‚ĚƒAƒŒƒ‹ƒM[”˝‰ž‚Ě“ÁŽęŤ. “ú–{ˆăŽt‰ďŽGŽ, 145: S70-S71, 2016
  6. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŠááىŠ. OCULISTA, 24: 39-42, 2016D
  7. ŠC˜VŒ´LsFƒAƒgƒs[ŠááىŠFŠá‰Č‚Ě—§ę‚Š‚ç. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č, 33(3): 357-361, 2016D
  8. ŠC˜VŒ´Ls, ‘ĺ“ŕˆŸ—R”üFŒ‹–Œ‰Šy•a‹C‚Ć‚­‚ˇ‚č20169@Šî‘b‚ĆŽŔ‘HExpert's Guidez Š´ŠoŠíE”畆‚Ě•a‹C‚Ć‚­‚ˇ‚č@ŠáŽžŠł. –ň‹Ç, 67(4):1449-1450, 2016
  9. ŠC˜VŒ´Ls, ‘ĺ“ŕˆŸ—R”üF‚Ô‚Ç‚¤–Œ‰Šy•a‹C‚Ć‚­‚ˇ‚č2016@Šî‘b‚ĆŽŔ‘HExpert's Guidez Š´ŠoŠíE”畆‚Ě•a‹C‚Ć‚­‚ˇ‚č@ŠáŽžŠł. –ň‹Ç, 67(4):1450-1451, 2016
  10. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–Œ‰Š@“ŕ‰Čˆă‚É‚Ĺ‚Ť‚é‘΍ô‚ĆŽĄ—ÁD“ŕ‰Č, 2016; 118(6): 1077-1080
  11. •˝’Ë‹`@A•Ÿ“c•q‰ëFƒ[ƒrƒWƒ‡ƒ“EƒPƒAĹ‘ĺ‚Ě–â‘č‚̓AƒNƒZƒX‚Ĺ‚ ‚é. “ú–{‚ĚŠá‰Č 87(4): 499-503, 2016
  12. •˝’Ë‹`@FÇóEŽžŠł•ĘƒgƒŠƒA[ƒW5u•ĐŠá‚Ş‹}‚ÉˆĂ‚­‚Č‚č‚Ü‚ľ‚˝v“ÁW@‚ą‚ę‚Ĺƒoƒbƒ`ƒŠ!@Šá‚ĚŒ’N–â‘č@‘Ž‡f—Ă, 12: 2-7, 2016
  13. “yŽŠ“cGF“ÁŽę—p“r‚ĚƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY. Šá‰Č, 58(10); 1063-1072, 2016.
  14. “yŽŠ“cGF_Œo‚Ćƒhƒ‰ƒCƒAƒC. Frontiers in Dry Eye. 11H† 22-26, 2016
  15. ŞŠÝ‹MŽuFyŹŽ™Šá‰ČQ and Az ’˛ßŽ…–@‚É‚ć‚éŽÎŽ‹Žčp‚đ‹ł‚Ś‚ĉş‚ł‚˘. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č33, —Ő‘: 129-132, 2016
  16. ŞŠÝ‹MŽuFyŹŽ™”’“ŕá‚Ş—ˆ‚˝‚çz ŹŽ™”’“ŕáEp‘OŒŸ¸‚Ěƒ|ƒCƒ“ƒg. IOL & RS, 30(2): 178-180, 2016
  17. ŞŠÝ‹MŽuFy“K‰žŠg‘ĺ:ƒ{ƒgƒbƒNƒXŽÎŽ‹‚ւ̉ž—pzŽŠŒą—á‚É‚¨‚Ż‚éƒRƒc‚Ć’ˆÓ“_(1). Šá‰ČƒOƒ‰ƒtƒBƒbƒN 5(3): 256-259, 2016
  18. ŞŠÝ‹MŽuA_‘O‚ ‚˘AŠ`č—T•FA’r“cŽjŽqFŽčp‘Š’kŽş@Ç—á’掌@‹@ŠB“IŽÎŽ‹‚đ‚Ť‚˝‚ľ‚˝bó‘BŠáÇ(Q&A). Šá‰ČŽčp, 29(2): 279-282, 2016
  19. ŞŠÝ‹MŽuFy–ƒáƒŤŽÎŽ‹z –ƒáƒŤŽÎŽ‹‚ĚŽčpŽĄ—Ă. _ŒoŠá‰Č 33(1): 23-26,2016
  20. ŞŠÝ‹MŽuF‹ÉŹŘŠJŽÎŽ‹Žčp MISS Plication [•ŇWĎE‰đŕ•t]. https://iseminar.net/e05200141
  21. ŞŠÝ‹MŽuF‚ł‚ç‚ɏă‚ĚŽčp‚đ‚ß‚´‚ˇŠá‰Čˆă‚Ě‚˝‚ß‚ĚŽÎŽ‹Žčp. https://iseminar.net/e05200140
  22. ŞŠÝ‹MŽuFŽÎŽ‹Žčp Mini Tenotomy m•ŇWĎE‰đŕ•tn. https://iseminar.net/e05200139
  23. ŞŠÝ‹MŽuFŽÎŽ‹Žčp Plication m•ŇWĎE‰đŕ•tn. https://iseminar.net/e05200138
  24. ŽRŒű’B•vFŠáŠ´őÇ‚ĚŒXŒü‚Ć‘Îô|ŠŽ‘Sƒ}ƒjƒ…ƒAƒ‹‡VDŽžŠł•ĘFf’fEŽĄ—Â̐i‚ß•ű‚Əˆ•ű—á@7.pŒăŠ´őÇ@LASIKŠÖ˜AŠ´őÇ. —ŐŠá 70(11): 296-299, 2016
  25. ‘ĺ‰z‹MŽuŽqFŸřoŒ^‰Á—”Á•ĎŤ‚ɑ΂ˇ‚éRVEGF—Ă–@‚Ě5”NŹŃ. “ú–{‚ĚŠá‰Č 87(8): 1087-1088, 2016
  26. ‘ĺ‰z‹MŽuŽqF‚í‚Š‚č‚₡‚˘—Տ°uŔ@–Ô–ŒŒő‹ĂŒĹ@‰ß‹Ž@ŒťÝ@–˘—ˆ. “ú–{‚ĚŠá‰Č 87(11): 1485-1491, 2016
  27. ‘ĺ“ŕˆŸ—R”ü, ŠC˜VŒ´LsF”’“ŕáy•a‹C‚Ć‚­‚ˇ‚č2016@Šî‘b‚ĆŽŔ‘HExpert's Guidez Š´ŠoŠíE”畆‚Ě•a‹C‚Ć‚­‚ˇ‚č@ŠáŽžŠł. –ň‹Ç, 67(4):1446-1448, 2016D
  28. ‘ĺ“ŕˆŸ—R”ü, ŠC˜VŒ´LsF–Ô–ŒF‘f•ĎŤÇy•a‹C‚Ć‚­‚ˇ‚č2016@Šî‘b‚ĆŽŔ‘HExpert's Guidez Š´ŠoŠíE”畆‚Ě•a‹C‚Ć‚­‚ˇ‚č@ŠáŽžŠł. –ň‹Ç, 67(4): 1452, 2016D
  29. ’––“•”́Fˆă—Ă‚Ě–˘—ˆ‚đl‚Ś‚é`ˆăŽt‚ĆMBA‚̉”\Ť‚ɂ‚˘‚ā`. https://iseminar.net/e07100176
  30. źč—LC, ‘ž“cr•F: Šá“ŕƒŒƒ“ƒY“ńŽŸ‘}“üp‚É‚¨‚Ż‚éŠá“ŕƒŒƒ“ƒY‚Ě‘I‘đ. —ŐŠá, 70(1); 68–77,  2016
  31. źč—LC,@‘ž“cr•F: yHow to…ť‘ĚÄŒšz ‚ć‚萳Šm‚ČCCCěŹ‚ĚƒRƒc (‰đŕ/“ÁW). MB OCULISTA, 45; 26-34, ‘S“ú–{•a‰@o”ʼnď, 2016
  32. ó“c—m•ăCŠC˜VŒ´LsFt‹GƒJƒ^ƒ‹‚ɑ΂ˇ‚éƒ^ƒNƒƒŠƒ€ƒX“_ŠáŽĄ—ÁDƒAƒŒƒ‹ƒM[‚Ě—Ő°, 36:743-746, 2016
y’˜‘z
  1. ‘şăťF•W€Šá‰ČŠwDˆăŠw‘‰@A“Œ‹žA2016”N
  2. ‘şăťF–Ô–Œ•ĎŤŽžŠłf—Ă‚Ě‚ˇ‚ׂāDˆăŠw‘‰@A“Œ‹žA2016”N
  3. ‰ĄŽR—˜KFŠá‰ČŽžŠł‚̍ŐV‚ĚŽĄ—Ă2016-2018@ŠŠŽÔ_Œo–ƒáƒD‘ĺ‹´—TˆęA”’_Žj—YA‘şăť(•Ň)A“ě]“°A2016
  4. ‘ž“cr•FFŠá‰Čf—Ăƒ}ƒCƒXƒ^[2ŠŞ ƒ`ƒ“Ź‘ѐƎ㔒“ŕá@128-131, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, 2016
  5. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠłsŠá‰Č—Տ°ƒGƒLƒXƒp[ƒgtŠpŒ‹–ŒŽžŠł‚ĚŽĄ—Ð헪C“‡č(•Ň)CˆăŠw‘‰@C“Œ‹žA137-151, 2016D
  6. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠłDf—ĂƒKƒCƒhƒ‰ƒCƒ“UP-TO-DATEC–ĺ˜eFCŹŽşˆęŹC‹{’n—ÇŽ÷ŠÄCCƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽĐC‘ĺăC704-707, 2016D
  7. ŠC˜VŒ´LsFRƒAƒŒƒ‹ƒM[“_Šá‰t‚ĚŽí—Ţ‚ĆŽg‚˘•űD–Ú‚Ě‚Ü‚í‚č‚Ě•a‹C‚Ć‚ť‚ĚŽĄ—ÁCŠO‰€çŒbC‰Á“Ą‘Ľl(•Ň)CGŽĐC“Œ‹žC188-191, 2016D
  8. ŠC˜VŒ´LsFƒAƒgƒs[ŤŠpŒ‹–Œ‰ŠDĄ“ú‚̊᎞ŠłŽĄ—ĂŽwjC‘ĺ˜HłlCŒă“Ą_CŽR“cš˜aC–ě“c“O(•Ň)CˆăŠw‘‰@C“Œ‹žC292-294, 2016D
  9. ŠC˜VŒ´LsFƒAƒgƒs[Ť”畆‰ŠDĄ“ú‚̊᎞ŠłŽĄ—ĂŽwjC‘ĺ˜HłlCŒă“Ą_CŽR“cš˜aC–ě“c“O(•Ň)CˆăŠw‘‰@C“Œ‹žC751, 2016D
  10. ŠC˜VŒ´LsFTerrienŠp–Œ•Ó‰•ĎŤDŠá‰ČŽžŠłĹV‚ĚŽĄ—Ă2016-2018C‘ĺ‹´—TˆęC”’_Žj—YC‘şăť(•Ň)C“ě]“°C“Œ‹žC139, 2016D
  11. ŠC˜VŒ´LsF‘O•”ŠááىŠDŠá‰ČŽžŠłĹV‚ĚŽĄ—Ă2016-2018C‘ĺ‹´—TˆęC”’_Žj—YC‘şăť(•Ň)C“ě]“°C“Œ‹žC79, 2016D
  12. ŠC˜VŒ´LsFƒAƒgƒs[ŤŠpŒ‹–Œ‰ŠDˆę–Ú‚Ĺ‚í‚Š‚éŠáŽžŠł‚ĚŒŠ•Ş‚Ż•ű[ŠpŒ‹–ŒŽžŠłA—ΓŕáCˆäăKŽŸCŽR–{“N–çC‘ĺ˜HłlC–ĺ”V‰€ˆę–ž(•Ň)CƒƒWƒJƒ‹ƒrƒ…[ŽĐC“Œ‹žC53-54, 2016D
  13. ŠC˜VŒ´LsF‹‘ĺ“ű“ŞŒ‹–Œ‰ŠDˆę–Ú‚Ĺ‚í‚Š‚éŠáŽžŠł‚ĚŒŠ•Ş‚Ż•ű[ŠpŒ‹–ŒŽžŠłA—ΓŕáCˆäăKŽŸCŽR–{“N–çC‘ĺ˜HłlC–ĺ”V‰€ˆę–ž(•Ň)CƒƒWƒJƒ‹ƒrƒ…[ŽĐC“Œ‹žC55, 2016D
  14. “yŽŠ“cGFƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚É‚ć‚éŠp–ŒáŠQ. Ą“ú‚̊᎞ŠłŽĄ—ĂŽwj: 341-342, ˆăŠw‘‰@, 2016”N.
  15. “yŽŠ“cGF–ňÜŽg—p‚ĚƒCƒƒn. Šá‰ČŽžŠł@ĹV‚ĚŽĄ—Á@2016-2018: 69-78, “ě]“°, 2016”N.
  16. ŞŠÝ‹MŽuFŒŸ‰e–@. Šá‰ČŒŸ¸ƒKƒCƒh@‘ć2”Ĺ.Ş–؏ş(ŠÄC), ”Ń“c’mO, ‹ß“Ą•ôś, ’†‘ş˝, ŽR“cš˜a(•Ň). •śŒő“°, “Œ‹ž, 63-67, 2016.9@
  17. ŞŠÝ‹MŽuFŹŽ™‚̊᎞ŠłCŽÎŽ‹C‰“Ž‹. ŹŽ™‰ČŠO—ˆ‚̊ӕʐf’fp. –Ŕ‚Á‚˝‚Ć‚Ť‚Ě“š‚ľ‚é‚×. ‹{“cÍŽq, •y–{˜a•F(•Ň).. ’†ŽR‘“X, “Œ‹ž, 255-256, 2016.5
  18. ŞŠÝ‹MŽuFŠá‹…‰^“Ž‚̐_ŒoŽx”z. Šá‚Ě”­ś‚Ɖđ–UE‹@”\ Šá‰Čf—ĂƒNƒIƒŠƒtƒ@ƒC30.‘厭“N˜Y(•Ň).. ’†ŽR‘“X, “Œ‹ž, 71-76, 2016.5
  19. ŞŠÝ‹MŽuFć“V–ł“řĘ. Ą“ú‚̊᎞ŠłŽĄ—ĂŽwj ‘ć3”Ĺ.@‘ĺ˜Hłl, Œă“Ą_, ŽR“cš˜a, –ě“c“O(•Ň). ˆăŠw‘‰@, “Œ‹ž, 715-716, 2016.10
  20. ŞŠÝ‹MŽu: ”’”çÇ. Ą“ú‚̊᎞ŠłŽĄ—ĂŽwj ‘ć3”Ĺ.@‘ĺ˜Hłl, Œă“Ą_, ŽR“cš˜a, –ě“c“O(•Ň).. ˆăŠw‘‰@, “Œ‹ž, 716-718, 2016.10
  21. ŞŠÝ‹MŽu: ‰Š”Á’áŒ`Ź. Ą“ú‚̊᎞ŠłŽĄ—ĂŽwj ‘ć3”Ĺ. ‘ĺ˜Hłl, Œă“Ą_, ŽR“cš˜a, –ě“c“O(•Ň).. ˆăŠw‘‰@, “Œ‹ž, 718, 2016.10
  22. ŞŠÝ‹MŽu: ŽăŽ‹. Šá‰ČŽžŠłĹV‚ĚŽĄ—Ă 2016-2018. ‘ĺ‹´—Tˆę, ”’_Žj—Y, ‘şăť(•Ň). “ě]“°, “Œ‹ž, 287, 2016.3
  23. ŽRŒű’B•vFŠá‰ČŽžŠłĹV‚ĚŽĄ—Ă2016-2018@Šp–ŒŽžŠł@D.•ĎŤƒWƒXƒgƒƒtƒB@3Šp–Œă”çƒWƒXƒgƒƒtƒBiReis-Buckler‚¨‚ć‚ŃThiel-BehnkeŠp–ŒƒWƒXƒgƒƒtƒB‚đŠÜ‚ށjD“ě]“°A142-143A2016
  24. Šá‰ČŽžŠł‚̍ŐV‚ĚŽĄ—Ă2016-2018@ŠŠŽÔ_Œo–ƒáƒD‘ĺ‹´—TˆęA”’_Žj—YA‘şăť(•Ň).A“ě]“°A2016
  25. ‘ĺ‰z‹MŽuŽqF–Ú‚ĆŒ’N51@’m‚Á‚Ä‚¨‚Ť‚˝‚˘‰Á—”Á•ĎŤ|ŽĄ—Ă‚Ć—\–h|D“ú–{Šá‰Čˆă‰ď
  26. ‘ĺ‰z‹MŽuŽqF“§ÍŠłŽŇf—Âɖ𗧂@f’f‚ƏdÇ”ť’č‚Ě‚˝‚ß‚ĚƒAƒvƒ[ƒ`‘ŸŠí•Ę‚ĚƒAƒvƒ[ƒ`ŠáŽžŠł@“œ”A•a–Ô–ŒÇD“ú–{ƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[A6A293-295A2016
  27. _•”—FFŠá‰Č—Տ°ƒGƒLƒXƒp[ƒg@–Ô–Œ•ĎŤŽžŠłf—Ă‚Ě‚ˇ‚ׂāD‘şăťA‹g‘ş’ˇ‹v(•Ň)AˆăŠw‘‰@A“Œ‹žA2016”N
  28. ’––“•”Í: ƒn[ƒo[ƒh×MBA׈ăŽt –Ú•W‚đŽŸX‚É’BŹ‚ˇ‚él‚ĚĹ‹­‚̕׋­–@. ƒfƒBƒXƒJƒ”ƒ@[EƒgƒDƒGƒ“ƒeƒBƒƒ“A2016”N2ŒŽ
  29. ŒK–ź—ş•ă, ‘ž“cr•F: Œă”­”’“ŕá. Šá‰ČŽžŠłĹV‚ĚŽĄ—Ă2016-2018, 187, “ě]“°, 2016”N.
  30. ˆîŠ_Œ\ŽiFŠá‰ČƒPƒA@ę–Ę‚˛‚Ć‚ÉƒPƒA‚Ě—v“_‚Ş‚í‚Š‚éI“œ”A•a–Ô–ŒÇ‚ĚŠłŽŇ‚ł‚ń‚ĚŽóf‚Š‚çŽčpŒă‚܂Łi5j–Ô–ŒŒő‹ĂŒĹDƒƒfƒBƒJo”ŁA35-39A2016
y•ńE‚ť‚Ě‘źz
  1. Nakatani S, Murakami A: Descemet stripping automated endothelial keratoplasty using corneas from elderly donors. Graefes Arch Clin Exp Ophthalmol. Published online Sep 2016.
  2. ‘şăťF‚ˇ‚ׂĂނ킊‚é˜VŠá‘΍ôDTŠ§’Š“úMOOK  Šá‚Ě‚˘‚˘•a‰@@˜VŠá•Šá‚Ě•a‹CŠŽ‘SƒKƒCƒh
  3. ‘ž“cr•F: ĐŠQo“Ž‚ÖˆăŽt“o˜^§`Šá‰ČˆăŽt‚Í“ĆŽŠŽwj‚Ĺ˜A—–ԁ`. “Ç”„V•ˇ’ŠŠ§, 2016”N3ŒŽ13“ú.
  4. ‘ž“cr•F: Šw‰ď‚֍s‚ą‚¤EƒCƒ“ƒ^[ƒiƒVƒ‡ƒiƒ‹A@IOL&RS 30(4) :602-604, 2016
  5. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠł‚Ě•a‘Ô‚ĆŽĄ—Ă 2016DK-ƒlƒbƒgƒJƒ“ƒtƒ@ƒŒƒ“ƒXEWEBu‰‰‰ďEƒLƒbƒZƒC–ň•ii2016”N1ŒŽ20“úE“Œ‹žj
  6. ŠC˜VŒ´LsFŠá‰ČˆČŠO‚̐搜‚É’m‚Á‚Ä‚˘‚˝‚ž‚Ť‚˝‚˘‰Ô•˛ŤŒ‹–Œ‰Š‚̐f’f‚ĆŽĄ—ÁDWEBu‰‰‰ďEŽQ“Vť–ňi2016”N11ŒŽ24“úE‹ž“sj
  7. •˝’Ë‹`@Fˆă—Ă’ń‹ŸƒVƒXƒeƒ€‚Ě‘ĺ“]ŠˇF’nˆć•ďŠ‡ƒPƒAƒVƒXƒeƒ€‚É‚¨‚Ż‚éŠá‰Č‚Ě–đŠ„@Šw‰ďƒgƒsƒbƒNƒX@“ú–{Šá‰ČŠw‰ďŽGŽ2016;120: 130-133, 2016
  8. •˝’Ë‹`@F‚ą‚ę‚Á‚Ä•a‹C? ‹C‚É‚Č‚éŠá‚Ě•s’˛@TŠ§’Š“úMOOK@Šá‚Ě‚˘‚˘•a‰@@˜VŠá•Šá‚Ě•a‹CŠŽ‘SƒKƒCƒh@’Š“úV•ˇo”Ł@2016 14-17
  9. “yŽŠ“cG: CL‘•—p‚ĆŠ´őÇ35. “úƒRƒŒŽ 58, 43-44, 2016.
  10. ‘ĺ‰z‹MŽuŽqFƒi[ƒX‚Ěˆ×‚Ě‚‹‰f—ÏpAš˜H‰Á‘Ű•a‰@A“Œ‹žA2016”N1ŒŽ12“ú
  11. ‘ĺ‰z‹MŽuŽqFƒhƒNƒ^[ƒCƒ“ƒ^ƒrƒ…[uƒsƒ…ƒAƒCƒGƒ[EƒŒ[ƒU[Œő‹ĂŒĹ‘•’uIQ577‚Ćƒ}ƒCƒNƒƒpƒ‹ƒX臒l‰ş‹ĂŒĹvDTOMEY FocusA2016”N9ŒŽ10“ú
  12. ‘ĺ‰z‹MŽuŽqFˆăŽt‚Ćˆă—Ï]Ž–ŽŇ‚Ě‚˝‚ß‚Ěî•ńŽuƒxƒCv@BAY  2017 WINTER “œ”A•aŠłŽŇ‚Ě5l‚É1l‚Ş”­Ç‚ˇ‚éu“œ”A•a–Ô–ŒÇv‚Ƃ́DƒoƒCƒGƒ‹–ň•iŠ”ŽŽ‰ďŽĐ, 5-6, 2016
  13. ‘ĺ‰z‹MŽuŽqF•ŇW‚ž‚ć‚čD“ú–{‚ĚŠá‰Č 87(9): 1304, 2016
  14. ‘ĺ‰z‹MŽuŽq:@‰ˇŒĚ’mVI“œ”A•a‰Š”Á•‚Žî‚ĚƒŒ[ƒU[ŽĄ—Ă. ŽQ“Vť–ňŠ”ŽŽ‰ďŽĐƒGƒLƒXƒp[ƒg‚É’Ž‚­, 2017; Vol1, 2016”N12ŒŽ15“ú
  15. Takenori Inomata: Tear Film & Ocular Surface Society TFOS Travel Awards 2016. 2016, July
  16. ’––“•”Í: ˘ŠE‰I ƒXƒ}ƒzƒAƒvƒŠ‚Ĺƒhƒ‰ƒCƒAƒCŽw”‚đƒ`ƒFƒbƒN`‡“V“°‘ĺŠwŠá‰Č×iPhone‚Ĺƒhƒ‰ƒCƒAƒC‚ĚƒrƒbƒOƒf[ƒ^‰đÍ`. 2016.11.2 ‡“V“°‘ĺŠwƒvƒŒƒXƒŠƒŠ[ƒX
  17. ’––“•”Í: 10‰­l‚Ě•auƒhƒ‰ƒCƒAƒCvAiPhone‚Ĺ–ž‚Š‚ˇ. 2016.11.4 “úŒoƒfƒWƒ^ƒ‹ƒwƒ‹ƒX
  18. ’––“•”Í: ƒhƒ‰ƒCƒAƒC‚đƒ`ƒFƒbƒN‚ˇ‚éƒAƒvƒŠ‚Ş“oę. Tarzan (ƒ^[ƒUƒ“) 2016”N 11ŒŽ24“ú†
  19. ’––“•”Í: ‡“V“°‘ĺAƒhƒ‰ƒCƒAƒC‚ƐśŠˆKŠľ‚ĚŠÖ˜AŤ‚đ–ž‚ç‚Š‚É‚ˇ‚éƒXƒ}ƒzƒAƒvƒŠ‚đ”­•\. ƒ}ƒCƒiƒrƒjƒ…[ƒX. 2016.11.4
  20. ’––“•”Í: R FGF2 ƒAƒvƒ^ƒ}[ˆă–ň•i‚ĚŠJ”­‚ÉŠÖ‚ľ‚āAŒcœä‹`m‘ĺŠwˆăŠw•”A ‘ĺă‘ĺŠwˆăŠw•”A‚Č‚ç‚Ń‚É‡“V“°‘ĺŠwˆăŠw•”‚Ć‹¤“ŻŒ¤‹†Œ_–ń‚đ’÷Œ‹EŽŔŽ{. (Š”)ƒŠƒ{ƒ~ƒbƒN@ƒvƒŒƒXƒŠƒŠ[ƒX 2016.9.27
  21. ’––“•”́A–Řƒm“ŕ@‹P: ‘Î’kzƒn[ƒo[ƒh—Źu’§í‚ľ‘ą‚Ż‚é—́v. Forbes, 2016”N11ŒŽ27“ú, https://forbesjapan.com/articles/detail/14348
  22. Vˆä‰p‰îFPRPH2•ĎˆŮ‚É‚ć‚éStargardt•a‚Ě•a‘ԉ𖞂ƐV‚˝‚ČŽĄ—Ă–@‚ĚŠJ”­‚ÉŒü‚Ż‚āD“Œ‹ž‘ĺŠwˆă‰ČŠwŒ¤‹†ŠÄśŠî‘bˆă‰ČŠw‘ŰŒ¤‹†‹’“_VisitorsƒZƒ~ƒi[.“Œ‹ž‘ĺŠwˆă‰ČŠwŒ¤‹†Š‡“Żƒ‰ƒ{“3ŠK;“Œ‹ž“s`‹ć”’‹ŕ‘ä 4-6-1. 2016/10/28.
  23. •“c~Žj: ŽčpŽŔŃ‚Ĺ’T‚ˇ–źˆă‚Ě‚˘‚é•a‰@@ŠÖ“Œ•Ň2017, (Š”)ˆă—ÐV•ˇŽĐ, 2016”N12ŒŽ10“ú
  24. ˆîŠ_Œ\ŽiFqf—Ă‚ ‚ę‚ą‚ęr“œ”A•a‰Š”Á•‚Žî‚ɑ΂ˇ‚é’áNP‚ČƒŒ[ƒU[ŽĄ—ÁD“ŒŠáˆă‰ď•ń 236: 65, 2016
  25. ŽR“cš˜aA‚–ě”ɁA•˝’Ë‹`@A‘ę–{ŽŸ—FAŽR‘ş‹`şF’´‚—îŽĐ‰ď‚É‚¨‚Ż‚éQOLˆŰŽ‚Ě‚˝‚ß‚ĚŠá‰Č—Ěˆć‚Ĺ‚Ě—\–hˆăŠw‚đi‚ß‚é@Ŕ’k‰ď~Šá‰ČŒŸf~JOIA 2016 Annual Report “ú–{Šá‰Čˆă—Ă‹@Ší‹Ś‰ď p4-9, 2016.
  26. ŒFě Žő˜YA‰Ş–{ ‰xŽiAŹ–Ř OŽqA•Ÿ“c ŒhA‹Ę’u —mAŹ—Ń Œ’ˆęAXě”üŠGAź”É ‘ěĆA”’Šâ Œ’A‘ĺšę‰ę ­şA•˝’Ë ‹`@GƒGƒrƒfƒ“ƒX‚ÉŠî‚Ă‚­’nˆć•ďŠ‡ƒPƒAƒVƒXƒeƒ€\’z‚Ě‚˝‚ß‚ĚŽs’Ź‘şî•ńŠˆ—pƒ}ƒjƒ…ƒAƒ‹ěŹ‚Ɖ^—p‚ÉŠÖ‚ˇ‚錤‹†@ˆĎ‘ő‹Ć–ąŹ‰Ę•ńi‘Š‡jF“ú–{ˆă—ĂŒ¤‹†ŠJ”­‹@\ˆĎ‘ő”ď@’ˇŽőEáŠQ‘‡Œ¤‹†Ž–‹ĆuƒGƒrƒfƒ“ƒX‚ÉŠî‚Ă‚­’nˆć•ďŠ‡ƒPƒAƒVƒXƒeƒ€\’z‚Ě‚˝‚ß‚ĚŽs’Ź‘şî•ńŠˆ—pƒ}ƒjƒ…ƒAƒ‹ěŹ‚Ɖ^—p‚ÉŠÖ‚ˇ‚錤‹†vi‹Ć–ąŽĺ”CŽŇ@ŒFěŽő˜Yj•˝Ź27”N“x@ˆĎ‘ő‹Ć–ąŹ‰Ę•ń‘F2016
  27. ‰Ş–{@‰xŽiA‹Ę’u —mAŹ—Ń Œ’ˆęA”’Šâ Œ’A•˝’Ë ‹`@A•Ÿ“c ŒhAŒFě Žő˜Y@’nˆć•ďŠ‡Žx‰‡ƒZƒ“ƒ^[E’nˆćƒPƒA‰ď‹c‚Ě‚˝‚ß‚ĚKDBŠˆ—pƒ}ƒjƒ…ƒAƒ‹ěŹF“ú–{ˆă—ĂŒ¤‹†ŠJ”­‹@\ˆĎ‘ő”ď@’ˇŽőEáŠQ‘‡Œ¤‹†Ž–‹ĆuƒGƒrƒfƒ“ƒX‚ÉŠî‚Ă‚­’nˆć•ďŠ‡ƒPƒAƒVƒXƒeƒ€\’z‚Ě‚˝‚ß‚ĚŽs’Ź‘şî•ńŠˆ—pƒ}ƒjƒ…ƒAƒ‹ěŹ‚Ɖ^—p‚ÉŠÖ‚ˇ‚錤‹†vi‹Ć–ąŽĺ”CŽŇ@ŒFěŽő˜Yj•˝Ź27”N“x@ˆĎ‘ő‹Ć–ąŹ‰Ę•ń‘F2016
  28. ˆŔ“c–žOFŽŸ˘‘ă‚̋ߎ‹‹¸łpDƒSƒ‹ƒtŒŽŠ§ŽƒƒbƒOƒ‹@8:190|191, 2016
  29. ˆŔ“c–žOFŽq‹Ÿ‚ĚŽ‹—Í‚ĆŠá‚Ş‚Ë“ÁWi‘ć4‰ńjŤ—ˆ‚Ě‘I‘đŽˆ‚ĆƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY•ƒŒ[ƒVƒbƒNVŽ–îD“úŒoDUALF“úŒoBPŽĐA2016”N9ŒŽ23“ú
2015”N
yŒ´’˜‰p•śziIF:83.884j
  1. Morita H, Arae K, Unno H, Miyauchi K, Toyama S, Nambu A, Oboki K, Ohno T, Motomura K, Matsuda A, Yamaguchi S, Narushima S, Kajiwara N, Iikura M, Suto H, McKenzie A, Takahashi T, Karasuyama H, Okumura K, Azuma M, Moro K, Akdis CA, Galli SJ, Koyasu S, Kubo M, Sudo K, Saito H, Matsumoto K, Nakae S. An Interleukin-33-Mast Cell-Interleukin-2 Axis Suppresses Papain-Induced Allergic Inflammation by Promoting Regulatory T Cell Numbers. Immunity 43:175-186, 2015iIF: 21.561j
  2. Xu J, Hong J, Sun X, Liu Z, Mashaghi A, Inomata T, Lu, Y., Li, Y., Wu, D., Yang, Y., Wei, A., Zhao, Y. and Lu, C. Combined Lacrimal Passage Probing and Tobramycin/Dexamethasone Ophthalmic Ointment Infiltration: A Minimally Invasive Surgical Procedure for Incomplete Nasolacrimal Duct Obstruction. Medicine (Baltimore). 94(36): e1483, 2015 (IF: 5.723)
  3. Coppieters F, Todeschini AL, Fujimaki T, Baert A, De Bruyne M, Van Cauwenbergh C, Verdin H, Bauwens M, Ongenaert M, Kondo M, Meire F, Murakami A, Veitia RA, Leroy BP, De Baere E: Hidden Genetic Variation in LCA9-Associated Congenital Blindness Explained by 5'UTR Mutations and Copy-Number Variations of NMNAT1. Hum Mutat 36(12):1188-96, 2015 (IF:5.340)
  4. Perusek L, Sahu B, Parmar T, Maeno H, Arai E, Le YZ, Subauste CS, Chen Y, Palczewski K, Maeda A: Di-retinoid-pyridinium-ethanolamine (A2E) Accumulation and the Maintenance of the Visual Cycle Are Independent of Atg7-mediated Autophagy in the Retinal Pigmented Epithelium. J Biol Chem, 290(48): 29035-29044, 2015 iIF: 4.258j
  5. Matsuda A, Asada Y, Takakuwa K, Sugita J, Murakami A, Ebihara N. DNA methylation analysis of human trabecular meshwork cells during dexamethasone stimulation. Invest Ophthalmol Vis Sci. 56: 3801-3809, 2015 (IF: 3.40)
  6. Asada Y, Nakae S, Ishida W, Hori K, Sugita J, Sudo K, Fukuda K, Fukushima A, Suto H, Murakami A, Saito H, Ebihara N, Matsuda A: The roles of epithelial cell-derived type 2 initiating cytokines in experimental allergic conjunctivitis. Invest Ophthalmol Vis Sci. 56:5194-5202, 2015 (IF: 3.40)
  7. Iida A, Iwagawa T, Baba Y, Satoh S, Mochizuki Y, Nakauchi H, Furukawa T, Koseki H, Murakami A, Watanabe S: Roles of histone H3K27 trimethylase Ezh2 in retinal proliferation and differentiation. Dev Neurobiol 75(9):947-60, 2015 (IF:3.370)
  8. Tamura H, Goto R, Akune Y, Hiratsuka Y, Hiragi S, Yamada M. The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study. PLoS ONE, 2015;10(7) (IF: 3.234)
  9. Kakigi C, Kasuga T, Wang SY, Singh K, Hiratsuka Y, Murakami A, Lin SC. Hypothyroidism and Glaucoma in The United States. PLoS ONE, 31, 2015;10(7) (IF: 3.234)
  10. Nakama T, Yoshida S, Ishikawa K, Kobayashi Y, Zhou Y, Nakao S, Sassa Y, Oshima Y, Takao K, Shimahara A, Yoshikawa K, Hamasaki T, Ohgi T, Hayashi H, Matsuda A, Kudo A, Nozaki M, Ogura Y, Kuroda M, Ishibashi T. Inhibition of choroidal fibrovascular membrane formation by new class of RNA interference therapeutic agent targeting periostin. Gene Therapy 22: 127-137, 2015 (IF: 3.104)
  11. Ogura Y, Terasaki H, Gomi F, Yuzawa M, Iida T, Honda M, Nishijo K, Sowade O, Komori T, Schmidt-Erfurth U, Simader C, Chong VFEfficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 studyDBr J Ophthalmol. 99(1): 92–97, 2015 (IF: 2.976)
  12. Amari Y, Hamanaka T, Futa R: Pathologic investigation failure of trabeculotomy. J Glaucoma. 24(4): 316-322, 2015 (IF: 2.106)
  13. Takakuwa K, Hamanaka T, Mori K, Chin S, Shinmei Y, Funaki T, Ebihara N, Ono K, Murakami A, Matsuda A. Atopic Glaucoma: Clinical and Pathophysiological Analysis. J Glaucoma 24(9):662-668, 2015  (IF: 2.106)
  14. Lee RY, Chen RI, Kasuga T, Cui QN, Porco TC, Lin SC: The Effect of Cumulative Dissipated Energy on Changes in Intraocular Pressure After Uncomplicated Cataract Surgery by Phacoemulsification. J Glaucoma. 2015 Aug 27. [Epub ahead of print] (IF: 2.106)
  15. Arai E, Baba Y, Iwagawa T, Kuribayashi H, Mochizuki Y, Murakami A, Watanabe S: Ablation of Kcnj10 expression in retinal explants revealed pivotal roles for Kcnj10 in the proliferation and development of Müller glia. Mol Vis 21: 148-59, 2015 (IF:1.986)
  16. Okumura A, Arai E, Kitamura Y, Abe S, Ikeno M, Fujimaki T, Yamamoto T, Shimizu T: Epilepsy phenotypes in siblings with Norrie disease. Brain Dev 37(10): 978-982, 2015 (IF:1.785)
  17. Sawada M, Hikoya A, Negishi T, Hotta Y, Sato M.Characteristics and surgical outcomes of consecutive exotropia of different etiologies.  Jpn J Ophthalmol. 59(5) :335-40. 2015 (IF: 1.676)
  18. Inagaki K, Ohkoshi K, Ohde S, Deshpande GA, Ebihara N, Murakami AFComparative efficacy of pure yellow (577-nm) and 810-nm subthreshold micropulse laser photocoagulation combined with yellow (561-577-nm) direct photocoagulation for diabetic macular edema. Jpn J Ophthalmol 59(1):21-28, 2015 (IF: 1.676)
  19. Serizawa S, Ohkoshi K, Minowa Y, Takahashi O: Prognosis of patients with diabetic macular edema before Japanese approval of antivascular endothelial growth factor. Jpn J Ophthalmol 59: 244-251, 2015 (IF: 1.676)
  20. Yamaguchi M, Shima N, Kimoto M, Ebihara N, Murakami A, Yamagami SFMarkers for Distinguishing Cultured Human Corneal Endothelial Cells from Corneal Stromal Myofibroblasts. Curr Eye Res 40: 1211-1217 2015 (IF: 1.639)
  21. Serizawa S, Ohkoshi K, Minowa Y, Soejima K: Interdigitation zone band restoration after treatment of diabetic macular edema. Curr Eye Res (in press) (IF: 1.639)
  22. Inagaki K, Shuo T, Katakura K, Ebihara N, Murakami A, Ohkoshi K: Sub-lethal photothermal stimulation with a micropulse laser induces heat shock protein expression in ARPE-19 cells. J Ophthalmol, 2015;2015:729792. doi: 10.1155/2015/729792. Epub 2015 Nov 30 (IF: 1.463)
  23. Kawasaki R, Akune Y, Hiratsuka Y, Fukuhara S, Yamada M. Cost-utility analysis of screening for diabetic retinopathy in Japan: a probabilistic Markov modeling study. Ophthalmic epidemiology 12: 4-12: 2015 (IF: 1.148)
  24. Yokoyama T, Kanbayashi K, Yamaguchi T: Scleral buckling procedure with chandelier illumination for pediatric rhegmatogenous retinal detachment. Clin Ophthalmol 9: 69-73, 2015
  25. Inomata T, Mashaghi A, Di Zazzo A, and Dana R. Ocular surgical models for immune and angiogenic responses. J Biol Methods 2(3): e27, 2015
yŒ´’˜˜a•śz
  1. ’†’J@’qA‰Í–씎”VA‘şă@ť: Šp–Œ“ŕ”çáŠQŠá‚ɑ΂ľ‚ÄŽ{s‚ľ‚˝”’“ŕáŽčpÇ—á‚ĚŒŸ“˘.“úŠá‰ďŽAˆóü’†
  2. ‘ĺ‰z‹MŽuŽqF“œ”A•a‰Š”Á•‚Žî‚ɑ΂ˇ‚郉ƒjƒrƒYƒ}ƒuÉŽq‘Ě’ŽË‚Ě•š—p‚É‚¨‚Ż‚é‘ŚŽžƒŒ[ƒU[ŒQ‚Ć’x‰„ƒŒ[ƒU[ŒQ‚Ě”äŠrF–łěˆ×ŽŽŒą5”NŹŃD“ú–{‚ĚŠá‰Č 86: 473-474, 2015
  3. ‘ĺ‰z‹MŽuŽqF’áNPƒŒ[ƒU[‚Ě“K‰ž‚ĆŒŔŠED“ú–{‚ĚŠá‰Č 86: 1255-1262, 2015
  4. ”~‰Ž—ćŽqA‹ŕˆä~AŹ–ě_ˆęA“n•”•Ű’jAœAŁ—SŽqAŔ“c—LŠóAˇ•—R—˘A‘şăťF”ńŽ‹—͕␳—pF•tƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚Ě‚ą‚ˇ‚čô‚˘‘OŒă‚Ĺ‚ĚŠĎŽ@. “úƒRƒŒŽ, 57(4): 245-250, 2015
  5. ˛X–؁@GŒ›Aš •Ş@F“šFŠáŠŒŠ‚ć‚čf’f‚É‚˘‚˝‚Á‚˝čň“Ž–ŹŠC–ȐÖŹ“´á‘icarotid cavernous fistulaFCCFj‚Ě4Ç—áDŠá—Ő‹I@8F94-99,@2015
  6. “s’}ŒŤ‘ž˜YA—`…ƒŽqAÎ“c˝•vA‘ĺ‰z‹MŽuŽqAŽRŒű’B•vFintrastromal corneal ring segments (ICRS)pŒă‡•šÇ‚Ě2—áD‚ ‚˝‚ç‚ľ‚˘Šá‰Č 32: 92, 2015
  7. ‘ĺ“ŕˆŸ—R”ü, ´ěł•q, ˛‹vŠÔr˜Y, ˆÉ“Ą—ć, ŠC˜VŒ´LsF“ŕ‰Č‚¨‚ć‚ŃŠá‰Č“I–˘ŽĄ—Ă‚ĚdÇ‘B“œ”A•a–Ô–ŒÇ‚Ě—Ő°‘œ‚ĆŽčpŹŃD—ŐŠá 69F627-633, 2015D
  8. ó“c—m•ă, ‘ĺ—F —˘, M–Ř rŹ, ’†’J ’q, ŠC˜VŒ´ Ls, ‘şă ťF–Ɖu—}§–ň“ŕ•ž’†‚ĚŠłŽŇ‚É”­Ç‚ľ‚˝ŠpŒ‹–ŒG•˝ă”ç—R—ˆVś•¨‚Ě2—áD “úŠá‰ďŽ 119(4)F259-265, 2015
  9. ŒK–ź—ş•ă, ’†’J’q, ‘şăťF‡“V“°‘ĺŠwŠá‰Č‚É‚¨‚Ż‚é‰ß‹Ž10”NŠÔ‚ĚŠááوŤŤŽîᇂ̌Ÿ“˘D—ŐŠá69i5jF727-730C2015
  10. —›ˆŸ”üC•y“c–ÎŽ÷CŠC˜VŒ´LsFdÇƒAƒgƒs[Ť”畆‰ŠŠłŽŇ‚É”­Ç‚ľ‚˝Œ‹–ŒG•˝ă”çŠŕ‚Ě1Ç—áD—ŐŠá 69F1263-1267, 2015D
  11. ‹Ęé˜a”Í, Vˆä—ć, áÁ‰şŒ\‘ž˜Y, âź—ǐm, ŠC˜VŒ´LsFŒŒŸ÷ŒđŠˇ—Ă–@‚Ş’˜Œř‚ľ‚˝RƒAƒNƒAƒ|ƒŠƒ“4R‘̉AŤŽ‹_Œo‰Š‚Ě1Ç—áDŠá—Ő‹I 8F461-466, 2015D
  12. áÁ‰şŒ\‘ž˜YC˛‹vŠÔr˜Y, ˆÉ“Ą—ć, ´ěł•q, ŠC˜VŒ´LsF—ôEŒ´Ť–Ô–Œ”—Ł‚ɑ΂ˇ‚éÉŽq‘ĚŽčpŒă‚ĚŠá“ŕƒŒƒ“ƒY“ńŽŸ‘}“ü‚̏pŒă‹üÜ•Ď‰ťDŠá—Ő‹I 8F377-381, 2015D
  13. ˆÉ“Ą—z‰îC‘şˆä ŒbŽq, ŠC˜VŒ´ LsF”’“ŕápŒă‚ÉMunchausenÇŒóŒQ‚đ”­Ç‚ľ‚˝ˆę—áDŠá—Ő‹I 8F553-557, 2015D
y‘ŕz
  1. ‘şă@ťFyˆâ“`Ť–Ô–ŒŽžŠł‚Ěƒg[ƒ^ƒ‹ƒPƒAzŽĄ—ÂƑΉž –Ô–ŒƒWƒXƒgƒƒtƒB‚đ‚ŕ‚ŹŽ™‚ւ̑ΉžD—ŐŠá69i12jF1636-1640, 2015
  2. ‘ž“cr•F: ‹­–Œ“ŕŒĹ’čp‚Ě‚ˇ‚ׂā`T-fixation technique`. IOL&RS 29ŠŞ2† 162-168, 2015”N6ŒŽ.
  3. ‘ž“cr•F: yŠá“ŕƒŒƒ“ƒY‚Ěƒ|ƒCƒ“ƒg‚ƍ‡•šÇ‘΍ôzŠá“ŕƒŒƒ“ƒY‹­–Œ“ŕŒĹ’čp Intrascleral fixation of posterior chamber intraocular lenses (‰đŕ/“ÁW). MB OCULISTA No.33, ‘S“ú–{•a‰@o”ʼnď
  4. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠł‚É‚¨‚Ż‚é—܉t’†IgER‘Ě‚Ě•aˆöEf’fEŽĄ—Ă“IˆÓ‹`D—Տ°–ƉuEƒAƒŒƒ‹ƒM[‰Č 63(1)F52-54, 2015D
  5. ŠC˜VŒ´LsFƒAƒgƒs[ŠáÇ‚̐Źˆö‚ĆŽĄ—ÁDMebio 32(4)F76-80, 2015D
  6. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŠááىŠDOCULISTA 24F39-42, 2015D
  7. ŠC˜VŒ´LsFt‹GƒJƒ^ƒ‹ŽĄ—Ă‚ĚŒťÝE‹ß–˘—ˆDƒAƒŒƒ‹ƒM[E–Ɖu 22(5)F684-691, 2015D
  8. ŠC˜VŒ´LsF–Ɖu—}§–ň“_Šá‰t‚É‚ć‚ét‹GƒJƒ^ƒ‹ŽĄ—Ă‚ĚŒťó‚Ć–˘—ˆDƒAƒŒƒ‹ƒM[‚Ě—Ő° 35(7)F640-644, 2015D
  9. ŠC˜VŒ´LsFt‹GƒJƒ^ƒ‹‚̓Ç—á‚Ö‚ĚŽĄ—Ð헪DNANO OPHTHALMOLOGY 45:7-16, 2015.
  10. •˝’Ë ‹`@: —Տ°Œ¤‹†‚ĚPDCA (Plan Œv‰ć, Do ŽŔs, Check •]‰ż, Act‰ü‘P‚ł‚ę‚˝ŽŸ‚Č‚éŒv‰ć‚ÉŒü‚Ż‚Ä‚Ěs“Ž):—Տ°Œ¤‹†‚đ‚ß‚Ž‚é10‚Ě‹^–â‚ĆŒë‰đD“ú–{‚ĚŠá‰Č@2015;86:742-747.
  11. •˝’Ë‹`@AXě”üŠGA’ˇ‰ŽËŽqAŽR“cš˜aA•Ÿ“c•q‰ëFˆă—Ă’ń‹ŸƒVƒXƒeƒ€‚Ě‘ĺ“]ŠˇF’nˆć•ďŠ‡ƒPƒAƒVƒXƒeƒ€‚Ƃ́D“ú–{‚ĚŠá‰Č86F1309-1313, 2015
  12. •˝’Ë‹`@F‚—îŽŇŽ‹ŠoáŠQ‚ĚŒťó‚Ć’m‚Á‚Ä‚¨‚­‚ׂŤŽ‹ŠoáŠQ‚Ě’mŽŻD’nˆćƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ 11: 778-782, 2015.
  13. “yŽŠ“cGFƒIƒ‹ƒ\ƒPƒ‰ƒgƒƒW[@f—ĂƒKƒCƒhƒ‰ƒCƒ“DŠá‰Č 57:1019-1025, 2015.
  14. “yŽŠ“cGF—Ž‹‹¸ł—pƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYDMonthly book OCULISTA 29:47-54C2015.
  15. “yŽŠ“cGFƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYˆ•ű‚É‚ ‚˝‚Á‚Ä’m‚Á‚Ä‚¨‚­‚ׂŤŠî‘b“IŽ–€D‚P.ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚ĚŽí—ށD‚ ‚˝‚ç‚ľ‚˘Šá‰Č 32—ŐŽž‘Š§†:115-118, 2015.
  16. Ž…ˆä‘fƒA“yŽŠ“cGC–x@—TˆęC‹g–ěŒ’ˆęFƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚Ćƒhƒ‰ƒCƒAƒCDPharma Medica 33:99-101, 2015.
  17. Ź–ě_ˆęF—Տ°Œ¤‹†‚ĚC(CheckF•]‰ż)‚ĆAiActFŽŸ‚Č‚éŒ¤‹†Œv‰ć‚ÉŒü‚Ż‚Ä‚Ěs“ŽjF—Տ°Œ¤‹†‚Ě‚˝‚ä‚܂ʉü‘P‚Ě‚˝‚߁D“ú–{‚ĚŠá‰Č@86: 764-768, 2015
  18. ŞŠÝ‹MŽuFŹŽ™ŠłŽŇ‚ĚŽÎŽ‹f—Ă. Oculista 25: 1-6, 2015
  19. ŞŠÝ‹MŽuFŠááىş‚‚ĆŽÎŽ‹Žčp. Šá‰ČŽčp 28(2): 193-196, 2015
  20. ŞŠÝ‹MŽuFŽÎŽ‹‚̐f’f@Źl`‚—îŽŇ‚ĚŽÎŽ‹‚̐f’f. Šá‰ČƒOƒ‰ƒtƒBƒbƒN 4(4): 387-392. 2015
  21. ŞŠÝ‹MŽu: ƒ[ƒrƒWƒ‡ƒ“‚Ć’PŠá‹ž‚ɂ‚˘‚Ä. https://iseminar.net/e05100172 (2015.4)
  22. ŞŠÝ‹MŽu: ƒvƒŠƒYƒ€‚ɂ‚˘‚Ä. https://iseminar.net/e05100175 (2015.6)
  23. ŞŠÝ‹MŽu: Skiascopy‚ĚŒ´—‚ĆŽŔŰ [Šî‘b‚Š‚ç‚ĚŠáŒőŠw2]. https://iseminar.net/e05100176 (2015.7)
  24. ŞŠÝ‹MŽu: ƒNƒƒXƒVƒŠƒ“ƒ_[‚ĆPower Cross–@ [Šî‘b‚Š‚ç‚ĚŠáŒőŠw1]. https://iseminar.net/e05100177 (2015.7)
  25. ŞŠÝ‹MŽuFyŠá‹ž‚ĆƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚ĚŽŔŰ“Iˆ•űz ŽŔŰ“IŠá‹žˆ•ű@ŹŽ™‚ĚŠá‹žˆ•ű@ŹŽ™‚̉“Ž‹‹¸ł(ŽÎŽ‹‚Ě‚Č‚˘ę‡). ‚ ‚˝‚ç‚ľ‚˘Šá‰Č32, —Ő‘: 35-38, 2015
  26. ŞŠÝ‹MŽuF‹ßŽ‹‚Ěˆâ“`Ť‚Ɛis—\–h–@. “ú–{çΎ–V•ń, 4771; 65, 2015
  27. ‘ĺ‰z‹MŽuŽqFƒ‰ƒjƒrƒYƒ}ƒuŽĄ—Ă‚đŽ{s‚ľ‚˝“œ”A•a‰Š”Á•‚ŽîŠłŽŇ‚É‚¨‚Ż‚é‹@”\“I‰đ–UŠw“IƒAƒEƒgƒJƒ€—\‘ވöŽq. “ú–{‚ĚŠá‰Č 86(12): 1677-1678, 2015
  28. źˆä–ƒ‹I: ’YŽ_ƒKƒXƒŒ[ƒU[‚đ—p‚˘‚˝Šááىş‚Žčp. https://iseminar.net/e06200165 (2015.6)
  29. H“Ą‘ĺ‰îFŠá‹…‰^“Ž‚Ć“Ž‘ĚŽ‹—Í. i•Ňj–Ř’Ë’Š”ŽA‘Ěˆç‚̉Ȋw 65(12): 873-877, 2015
  30. ‚ŒK‰Á•cEŕ_’†‹P•FFƒoƒ‹ƒxƒ‹ƒg‚đ—p‚˘‚郁ƒŠƒbƒgEƒfƒƒŠƒbƒg‚Á‚Ä‚Č‚ń‚Ĺ‚ˇ‚ŠHD—Տ°Šá‰Č 69: 330-333, 2015
  31. Ź—эG–ž: AMD‚ɂ‚˘‚ā`—\–h‚𒆐S‚Ɂ`. https://iseminar.net/e04100163 (2015.1)
  32. Ź—эG–ž: ERG‚ɂ‚˘‚Ä. https://iseminar.net/e05100174 (2015.5)
  33. t“úrŒő: —Γŕá‚ĆƒŠƒXƒNƒtƒ@ƒNƒ^[. https://iseminar.net/e05100171 (2015.2)
  34. ŽR“cç‰Ä: Šá‹žˆ•ű. https://iseminar.net/e05100170 (2015.1)
  35. H’J‚Đ‚ë‚Ý: IOL‘}“üŠá‚ĚŠá‹žˆ•ű. https://iseminar.net/e02100154 (2015.5)
y’˜‘z
  1. ‰ĄŽR—˜KFŹŽ™Šá’ꎞŠł@Ą“ú‚ĚŽĄ—Ă•űj@2015”N”ŁiVol57jAŽRŒű“OE–kŒ´ŽO’jŠÄCA•ŸˆäŽŸ–îA‚–ؐ˝AŹŽşˆęŹ‘•ŇWAˆăŠw‘‰@A“Œ‹žA1386-1387A2015
  2. ŠC˜VŒ´LsF”’“ŕáE—ΓŕáDƒAƒgƒs[Ť”畆‰ŠŽĄ—Ă‚Ě‚˝‚ß‚ĚƒXƒeƒƒCƒhŠO—p–ňƒp[ƒtƒFƒNƒgƒuƒbƒNC‰–Œ´“N•v•ŇC“ěŽR“°C“Œ‹žC161-166, 2015
  3. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠłDŹŽ™“ŕ‰Č@ŹŽ™ŽžŠłf—Ă‚Ě‚˝‚ß‚Ě•a‘Ԑś—CuŹŽ™“ŕ‰ČvuŹŽ™ŠO‰Čv•ŇWˆĎˆő‰ď‹¤•ŇC“Œ‹žˆăŠwŽĐ“Œ‹žC837-841, 2015
  4. “ĄŠŞ‘ń˜Y@•ŇWF“Œ@”͍s@ŹŽ™Šá‰ČŠw@‘ć6Í@‹üÜˆŮí‚ĆŠá‹žEƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚ĚŠÇ—@ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚ĚŠÇ—@095-8@ŽO—֏‘“X@2015
  5. ‘ĺ‰z‹MŽuŽqF“ÁWE‡•šÇ‚ĚŠĎŽ@ƒ|ƒCƒ“ƒg‚Ɛę–ĺ‰Ć‚Ö‚ĚƒRƒ“ƒTƒ‹ƒg‚Ěƒ^ƒCƒ~ƒ“ƒO ‡ZŠáŽžŠł@Q15Šá’ęoŒŒ‚̂ւ̑Ήž@Šá’ęoŒŒ‚ĚŠů‰‚ ‚銳ŽŇ‚Ö‚Ě“§ÍˆăEƒXƒ^ƒbƒt‚Ě“úí“I”z—ś‚Ěƒ|ƒCƒ“ƒg‚́HD—Տ°“§Í@31F49-50C“ú–{ƒƒfƒBƒAƒJƒ‹ƒZƒ“ƒ^[C“Œ‹žC2015
  6. ‘ĺ‰z‹MŽuŽqF“ÁWE‡•šÇ‚ĚŠĎŽ@ƒ|ƒCƒ“ƒg‚Ɛę–ĺ‰Ć‚Ö‚ĚƒRƒ“ƒTƒ‹ƒg‚Ěƒ^ƒCƒ~ƒ“ƒO ‡ZŠáŽžŠł@Q15Šá’ęoŒŒ‚̂ւ̑Ήž@Šá‰Čˆă‚Ö‚ĚƒRƒ“ƒTƒ‹ƒg‚Ěƒ^ƒCƒ~ƒ“ƒO‚âA’čŠúŒŸ¸‚ĚƒXƒPƒWƒ…[ƒ‹‚́HD—Տ°“§Í@31F49-50C“ú–{ƒƒfƒBƒAƒJƒ‹ƒZƒ“ƒ^[C“Œ‹žC2015
  7. ‘ĺ‰z‹MŽuŽqF“ÁWE‡•šÇ‚ĚŠĎŽ@ƒ|ƒCƒ“ƒg‚Ɛę–ĺ‰Ć‚Ö‚ĚƒRƒ“ƒTƒ‹ƒg‚Ěƒ^ƒCƒ~ƒ“ƒO ‡ZŠáŽžŠł@Q15Šá’ęoŒŒ‚̂ւ̑Ήž@Œő‹ĂŒĹiÚ°ťŢ°ĆŽËj—Ă–@‚ÍŽ‹—Í‚đ‰ˇ‘ś‚Ĺ‚Ť‚é‚Ě‚ŠHD—Տ°“§Í@31F49-50C“ú–{ƒƒfƒBƒAƒJƒ‹ƒZƒ“ƒ^[C“Œ‹žC2015
  8. ‘ĺ‰z‹MŽuŽqFSurgical skills ŽžŠł•ĘŠá’ęƒŒ[ƒU[ŽĄ—Ă‚ĚŠî–{Žč‡|‹ęŽč•Ş–ě‚đŽ•ž‚ľ‚悤|<ƒvƒ‰ƒ“ƒi[>DŠá‰ČƒOƒ‰ƒtƒBƒbƒNƒX 4, MCƒƒfƒBƒJo”ŁC‘ĺăC2015
  9. “Y“cŽˆęF“ÁWE‡•šÇ‚ĚŠĎŽ@ƒ|ƒCƒ“ƒg‚Ɛę–ĺ‰Ć‚Ö‚ĚƒRƒ“ƒTƒ‹ƒg‚Ěƒ^ƒCƒ~ƒ“ƒO ‡ZŠáŽžŠł@Q16Šáˆłă¸‚Ě–â‘čD—Տ°“§Í@31C“ú–{ƒƒfƒBƒAƒJƒ‹ƒZƒ“ƒ^[C“Œ‹žC2015
  10. “Y“cŽˆęA‘ĺ‰z‹MŽuŽqF“§Í‚É‚¨‚Ż‚éŠáˆłă¸‚Ě–â‘čŒŒ‰tD—Տ°“§Í 2: 51-53, “ú–{ƒƒfƒBƒAƒJƒ‹ƒZƒ“ƒ^[A“Œ‹žA2015
  11. ˆŔ“c–žOF“ÁWE‡•šÇ‚ĚŠĎŽ@ƒ|ƒCƒ“ƒg‚Ɛę–ĺ‰Ć‚Ö‚ĚƒRƒ“ƒTƒ‹ƒg‚Ěƒ^ƒCƒ~ƒ“ƒO ‡ZŠáŽžŠł@Q17”’“ŕáD—Տ°“§Í@31C“ú–{ƒƒfƒBƒAƒJƒ‹ƒZƒ“ƒ^[C“Œ‹žC2015
  12. ˆîŠ_Œ\ŽiA‘ĺ‰z‹MŽuŽqFŽžŠł•ĘŠá’ęƒŒ[ƒU[ŽĄ—Ă‚ĚŠî–{Žč‡|‹ęŽč•Ş–ě‚đŽ•ž‚ľ‚悤|‰Š”ÁƒOƒŠƒbƒhF臒l‹ĂŒĹA臒l‰ş‹ĂŒĹDŠá‰ČƒOƒ‰ƒtƒBƒbƒNƒX 4F230-235, MCƒƒfƒBƒJo”ŁC‘ĺăC2015
y•ńE‚ť‚Ě‘źz
  1. ‹ŕˆä~AŹ–ě_ˆęFƒJƒ‰|ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚Ě‹KŠi“K‡Ť‚ÉŠÖ‚ˇ‚é’˛¸Œ¤‹†@Œ¤‹†”ǁ@Œ¤‹†‘ă•\ŽŇFú`“‡—R“ńFƒJƒ‰|ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚Ě‹KŠi“K‡Ť‚ÉŠÖ‚ˇ‚é’˛¸Œ¤‹†D•˝Ź26”N“x‘Š‡E•Ş’SŒ¤‹†•ń‘D•˝Ź26”N“xŒúś˜J“­‰ČŠwŒ¤‹†”ď•â•‹ŕ
  2. ‰ĄŽR—˜KFu‹Î–ąˆă‚̕Łv“Á•ĘŔ’k‰ď@RVEGF‚đŽć‚芪‚­Ĺ‹ß‚̏D“ú–{‚ĚŠá‰Č 86:1137-1151, 2015
  3. ‘ž“cr•F: —Γŕá‚Ƃ́H, news every. ‚ľ‚¸‚¨‚Š, Ă‰Ş‘ćˆęƒeƒŒƒr, 2015”N1ŒŽ28“ú.
  4. ‘ž“cr•F: –Ô–Œ”—Ł‚Ƃ́H, news every. ‚ľ‚¸‚¨‚Š, Ă‰Ş‘ćˆęƒeƒŒƒr, 2015”N4ŒŽ2“ú.
  5. ‘ž“cr•F: RVOŽĄ—Ð헪. ƒoƒCƒGƒ‹ŽĐ“ŕ•×‹­‰ď, Ŕ’ĂŽs, 2015”N8ŒŽ27“ú.
  6. ‘ž“cr•F: ‚—îŽŇ‚Ě–Ú‚Ě•a‹C‚ɂ‚˘‚Ä \f’f‚Š‚玥—ÁA—\–h‚܂Ł\. ‘ć36‰ń Žs–ŻŒöŠJuŔ, ‡“V“°Ă‰Ş•a‰@, 2015”N11ŒŽ30“ú.
  7. •˝’Ë‹`@EŹ–ě_ˆęE’†–싧E“c‘şŠ°EŒă“Ą—ăEěč—ǁEě“‡‘fŽqEŽR“cš˜aD@uŹl‚đ‘ÎŰ‚Ć‚ľ‚˝ŠáŒŸfvŒ¤‹†”Ç’†ŠÔ•ń‘  “ú–{‚ĚŠá‰Č2015:87:132-149.
  8. ŒFěŽő˜YA•˝’Ë‹`@A‹Ę’u—mA”’ŠâŒ’AŹ—ŃŒ’ˆęA›Œ´‘ô–A•Ÿ“cŒh. ’nˆćˆă—Í\‘zô’č‹y‚Ńˆă—ĂŒv‰ćPDCAƒTƒCƒNƒ‹‚̐„i‚ÉŽ‘‚ˇ‚é“s“š•{Œ§‚̐lŢˆçŹ“™Žč–@‚ÉŠÖ‚ˇ‚錤‹† ‘Š‡•ń‘@Œúś˜J“­‰ČŠwŒ¤‹†”ď•â•‹ŕ@Œúś˜J“­‰ČŠw“Á•ĘŒ¤‹†Ž–‹Ću’nˆćˆă—Í\‘zô’č‹y‚Ńˆă—ĂŒv‰ćPDCAƒTƒCƒNƒ‹‚̐„i‚ÉŽ‘‚ˇ‚é“s“š•{Œ§‚̐lŢˆçŹ“™Žč–@‚ÉŠÖ‚ˇ‚錤‹†viŒ¤‹†‘ă•\ŽŇFŒFěŽő˜YDH26-“Á•Ę-Žw’č-004) •˝Ź26”N“x@‘Š‡E•Ş’SŒ¤‹†•ń‘:2015
  9. ź”É‘ěĆAŒFěŽő˜YAXě”üŠGA‹Ę’u—mA•˝’Ë‹`@. ’n•űŽŠŽĄ‘Ě‚É‚¨‚Ż‚é‹qŠĎ“Iƒf[ƒ^‚đŠˆ—p‚ľ‚˝’nˆć‚̉ۑč”cˆŹ‚Ěó‹ľ‚ÉŠÖ‚ˇ‚éƒCƒ“ƒ^ƒrƒ…[’˛¸ Œúś˜J“­‰ČŠwˆĎ‘ő”ď ’ˇŽő‰ČŠwŒ¤‹†ŠJ”­Ž–‹ĆuƒGƒrƒfƒ“ƒX‚ÉŠî‚Ă‚­’nˆć•ďŠ‡ƒPƒAƒVƒXƒeƒ€\’z‚Ě‚˝‚ß‚ĚŽs’Ź‘şî•ńŠˆ—pƒ}ƒjƒ…ƒAƒ‹ěŹ‚Ɖ^—p‚ÉŠÖ‚ˇ‚錤‹†vi‹Ć–ąŽĺ”CŽŇ@ŒFěŽő˜YjH26”N“xˆĎ‘ő‹Ć–ąŹ‰Ę•ń‘F2015
  10. Xě”üŠGAŒFěŽő˜YAź”É‘ěĆA‹Ę’u—mA•˝’Ë‹`@.@’nˆć•ďŠ‡ƒPƒAƒVƒXƒeƒ€\’z‚Ě‚˝‚ß‚ĚŽs’Ź‘ş’nˆćƒPƒA‰ď‹c“™‚É‚¨‚Ż‚éî•ńŠˆ—pó‹ľ‚ÉŠÖ‚ˇ‚錤‹†@Œúś˜J“­‰ČŠwˆĎ‘ő”ď ’ˇŽő‰ČŠwŒ¤‹†ŠJ”­Ž–‹ĆuƒGƒrƒfƒ“ƒX‚ÉŠî‚Ă‚­’nˆć•ďŠ‡ƒPƒAƒVƒXƒeƒ€\’z‚Ě‚˝‚ß‚ĚŽs’Ź‘şî•ńŠˆ—pƒ}ƒjƒ…ƒAƒ‹ěŹ‚Ɖ^—p‚ÉŠÖ‚ˇ‚錤‹†vi‹Ć–ąŽĺ”CŽŇ@ŒFěŽő˜YjH26”N“xˆĎ‘ő‹Ć–ąŹ‰Ę•ń‘F2015
  11. •˝’Ë‹`@F‹Î–ąˆă‚ĆŠá‰Č‹Î–ąˆă‚Ćˆă—ĂŒoĎ@“ú–{‚ĚŠá‰Č2015;86:71-72
  12. •˝’Ë‹`@F‹Î–ąˆă‚ĆŠá‰Č‹Î–ąˆă‚Ćˆă—ĂŒoĎ@“ú–{Šá‰ČŠw‰ďŽGŽ2015;119F250-251
  13. •˝’Ë‹`@FŽ‹ŠoáŠQ‚̎Љď“IƒRƒXƒg‚Ć”’“ŕáŽčp‚Ě”ď—p‘ÎŒř‰Ę_Ž‹‹@”\ŠĹŒě‚̎Љď“IvŒŁ“x‚đ‘Ş‚é ‘ć30‰ń“ú–{Ž‹‹@”\ŠĹŒěŠw‰ďŠwp‘‰ďŽű˜^W@2015;22-24.
  14. “yŽŠ“cGDCL‘•—p‚ĆŠ´őÇ31@ƒwƒ‹ƒyƒXŤŠp–Œ‰Š‚¨‚ć‚ŃŠp–ŒZD“úƒRƒŒŽ57:43-44, 2015.
  15. ’†’J@’q:Šá‰ČŽžŠłĹV‚ĚŽĄ—Áu“ŕ”çˆŮíŠá‚Ě”’“ŕáv2016|2018A“ě]“°@ˆóü’†
  16. ‘ĺ‰z‹MŽuŽqF‘ć31‰ńŠázŠÂŠw‰ďƒVƒ“ƒ|ƒWƒEƒ€2@‰Š”ÁŽžŠł‚ɑ΂ˇ‚é臒l‰şƒŒ[ƒU[ŽĄ—ÁDŠázŠÂƒ^ƒCƒ€ƒY 5, 2015
  17. ‘ĺ‰z‹MŽuŽqAˆîŠ_Œ\ŽiF‚Ń‚Ü‚ńŤ‚Ě“œ”A•a‰Š”Á•‚Žî‚Ƀ‹ƒZƒ“ƒeƒBƒX‚đ“Š—^‚ľ‚˝1—áD‚c‚l‚dÇ—á‚Š‚ç“Ç‚ÝŽć‚é‰ü‘PŽ‹—ÍˆŰŽ‚ĚƒRƒciƒmƒoƒ‹ƒeƒBƒXEƒAƒ‹ƒRƒ“j, 2-4, 2015
  18. ‘ĺ‰z‹MŽuŽqFŽ‹ŠoŒn‚̍\‘˘‚Ć‹@”\iŒăŠá•”jD“Œ‹ž“sŠá‰Čˆă‰ď@‘ć37‰ńƒREƒƒfƒBƒJƒ‹uK‰ďA1ŒŽA“Œ‹ž
  19. ‘ĺ‰z‹MŽuŽqAˆîŠ_Œ\ŽiF‚Ń‚Ü‚ńŤ‚Ě“œ”A•a‰Š”Á•‚Žî‚Ƀ‹ƒZƒ“ƒeƒBƒX‚đ“Š—^‚ľ‚˝1—áD
  20. ‘ĺ‰z‹MŽuŽqF“œ”A•a–Ô–ŒÇ‚ÍŽŠŠoÇó‚ޏ­‚Č‚­AŽ¸–ž‚ˇ‚郊ƒXƒN‚𔺂¤•a‹C‚Ĺ‚ˇDƒoƒCƒGƒ‹ť–ň^ŽQ“Vť–ň@űŽqiŠÄCjA2015
  21. ‘ĺ‰z‹MŽuŽqF“œ”A•a‰Š”Á•‚Žî‚̐f—Â̐i•ŕ ƒŒ[ƒU[Œő‹ĂŒĹpDDM Network No.4iƒmƒoƒ‹ƒeƒBƒXƒtƒ@[ƒ}j, 2015
  22. ‘ĺ‰z‹MŽuŽqF•ŇWŽş‚ž‚ć‚čD“ú–{‚ĚŠá‰Č 86, 2015
  23. •˝Œ`–žlA–k–쎠•FAŒú“Œ—˛ŽuAŽR–{’őŽqFŽĄ—Ă‘I‘đŽˆ‚ŞL‚Ş‚Á‚˝ĄA“œ”A•a‰Š”Á•‚Žî‚ɂ‚˘‚ččl‚ˇ‚é‡@f’fEŒŸ¸•ŇDƒmƒoƒ‹ƒeƒBƒXŔ’k‰ď@űŽqA2015
2014”N
yŒ´’˜‰p•śziIF:68.169j
  1. Iida A, Iwagawa T, Kuribayashi H, Satoh S, Mochizuki Y, Baba Y, Nakauchi H, Furukawa T, Koseki H, Murakami A, Watanabe S. Histone demethylase Jmjd3 is required for the development of subsets of retinal bipolar cells. Proc Natl Acad Sci U S A 111(10):3751-3756, 2014. (IF:9.809)
  2. Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, Lorenz K, Honda M, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study GroupFIntravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology 121(1):202-208, 2014. (IF:6.170)
  3. Ishikawa K, Yoshida S, Nakao S, Nakama T, Kita T, Asato R, Sassa Y, Arita R, Miyazaki M, Enaida H, Oshima Y, Murakami N, Niiro H, Ono J, Matsuda A, Goto Y, Akashi K, Izuhara K, Kudo A, Kono T, Hafezi-Moghadam A, Ishibashi T. Periostin promotes the generation of fibrous membranes in proliferative vitreoretinopathy. FASEB J 28 (1):131-142, 2014. (IF:5.480)
  4. Okayama Y, Matsuda A, Kashiwakura JI, Sasaki-Sakamoto T, Nunomura S, Shimokawa T, Yamaguchi K, Takahashi S, Ra C. Highly expressed cytoplasmic FcεRIβ in human mast cells functions as a negative regulator of the FcRγ-mediated cell activation signal. Clin Exp Allergy 44(2):238-249, 2014. (IF:4.324)
  5. Mochizuki Y, Iida A, Lyons E, Kageyama R, Nakauchi H, Murakami A, Watanabe S. Use of cell type-specific transcriptome to identify genes specifically involved in Müller glia differentiation during retinal development. Dev Neurobiol 74(4):426-437, 2014. (IF:4.189)
  6. Hamanaka T, Omata T, Sekimoto S, Sugiyama T, Fujikoshi Y. Bleb analysis by using anterior segment optical coherence tomography in two different methods of trabeculectomy. Invest Ophthalmol Vis Sci 54(10):6536-6541, 2013. (IF:3.661)
  7. Hua J, Jin Y, Chen Y, Inomata T, Lee H, Chauhan SK, Petasis NA, Serhan CN, Dana R. The resolvin D1 analogue controls maturation of dendritic cells and suppresses alloimmunity in corneal transplantation. Invest Ophthalmol Vis Sci 55(9):5944-5951, 2014. (IF:3.661)
  8. Fukushima A, Ohashi Y, Ebihara N, Uchio E, Okamoto S, Kumagai N, Shoji J, Takamura E, Nakagawa Y, Namba K, Fujishima H, Miyazaki DFTherapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement.@Br J Ophthalmol 98(8):1023-1027, 2014. (IF:2.809)
  9. Ohta T, Toshida H, Murakami A. Simplified and safe method of sutureless intrascleral posterior chamber intraocular lens fixation: Y-fixation technique. J Cataract Refract Surg  40(1):2-7, 2014. (IF:2.552)
  10. Ohta T. Reply. J Cataract Refract Surg 40(5), 851-852, 2014. (IF:2.552)
  11. Fukushima A, Ebihara NFEfficacy of Olopatadine versus Epinastine for Treating Allergic Conjunctivitis Caused by Japanese Cedar Pollen: A Double-Blind Randomized Controlled TrialDAdv Ther 31(10):1045-1058, 2014. (IF:2.438)
  12. Nakatani S, Murakami A. Three-Year outcome of Descemet stripping automated endothelial keratoplasty for bullous keratopathy after argon laser iridotomy. Cornea 33(8):780–788, 2014. (IF:2.360)
  13. Asada Y, Ebihara N, Funaki T, Yokoi N, Murakami A, Matsuda A. Vernal keratoconjunctivitis with giant papillae on the inferior tarsal conjunctiva. Cornea 33(1):32-34, 2014. (IF:2.360)
  14. Arai R, Kimura I, Imamura Y, Shinoda K, Matsumoto CS, Seki K, Ishida M, Murakami A, Mizota A. Photoreceptor inner and outer segment layer thickness in multiple evanescent white dot syndrome. Graefes Arch Clin Exp Ophthalmol 252(10):1645-1651, 2014. (IF:2.333)
  15. Aung MN, Yuasa M, Lorga T, Moolphate S, Fukuda H, Kitajima T, Yokokawa H, Minematsu K, Tanimura S, Hiratsuka Y, Ono K, Naunboonruang P, Thinuan P, Kawai S, Suya Y, Chumvicharana S, Marui E. Evidence-based new service package vs. routine service package for smoking cessation to prevent high risk patients from cardiovascular diseases (CVD): study protocol for randomized controlled trial. Trials 14:419, 2013. (IF:2.117)
  16. Inagaki K, Ohkoshi K, Ohde S, Deshpande GA, Ebihara N, Murakami A. Subthreshold Micropulse Photocoagulation for Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion including Best-Corrected Visual Acuity Greater Than 20/40. J Ophthalmol  (in press) (IF:1.935)
  17. Gocho K, Kameya S, Akeo K, Kikuchi S, Usui A, Yamaki K, Hayashi T, Tsuneoka H, Mizota A, Takahashi HFHigh-Resolution Imaging of Patients with Bietti Crystalline Dystrophy with CYP4V2 MutationDJ Ophthalmol. Epub  Sep 3, 2014 (IF: 1.935)
  18. Hiratsuka Y, Yamada M, Akune Y, Murakami A, Okada AA, Yamashita H, Ohashi Y, Yamagishi N, Tamura H, Fukuhara S, Takura T. Eye Care Comparative Effectiveness Research Team (ECCERT) Assessment of vision-related quality of life among patients with cataract and the outcomes of cataract surgery using a newly developed visual function questionnaire; The VFQ-J11. Jpn J Ophthalmol 58(5):415-422, 2014. (IF:1.795)
  19. Arai E, Fujimaki T, Yanagawa A, Fujiki K, Yokoyama T, Okumura A, Shimizu T, Murakami A. Familial cases of Norrie disease detected by copy number analysis. Jpn J Ophthalmol 58(5):448-454, 2014. (IF:1.795)
  20. Suzuki T, Fujimaki T, Yanagawa A, Arai E, Fujiki K, Wada Y, Murakami A. A novel exon 17 deletion mutation of RPGRIP1 gene in two siblings with Leber congenital amaurosis. Jpn J Ophthalmol 58(6):528-535, 2014. (IF:1.795)
  21. Kobayashi H, Okamoto H, Murakami A, Iwata T. Plasma proteome analysis on cynomolgus monkey (macaca fascicularis) pedigrees with early onset drusen formation. Exp Anim 63(3):305-310, 2014. (IF:1.172)
  22. Hamanaka T, Otora K, Ono K, Ishida N. Long-term results of non-valved Glaucoma drainage implant surgery and glaucoma drainage implant combined with trabeculectomy. Indian J Ophthalmol 62(9):911-916, 2014. (IF:0.927)
  23. Sasaki H, Kokubun T. Alkali Burn Treated with 2% Rebamipide Ophthalmic Suspension: A Case Report. Case Rep Ophthalmol 5(3):380-385, 2014.
yŒ´’˜˜a•śz
  1. ’†’J@’qA‘şă@ťF‘S‘wŠp–ŒˆÚAŒăŠp–Œ“ŕ”ç‹@”\•s‘S‚Ö‚ĚŠp–Œ“ŕ”çˆÚAp. “úŠá‰ďŽ@117(12)F983-989, 2013.
  2. ’†’J’qA’J“ŕC‘ž˜YAM–؏rŹA‰Í–씎”VA‘şă@ťF“Eo‚Ü‚Ĺ‚É’ˇŠúŠÔŒo‰ß‚ľ‚˝Ź‘÷Šá“ŕƒŒƒ“ƒY‚Ě“EoŒđŠˇÇ—á‚ĚŒŸ. IOL•RS 28(4): 415-420, 2014
  3. –Ř‘şŽŠA’†ŕV—LŒáA“n糌dAŠC˜VŒ´LsFƒ`ƒ…[ƒuƒVƒƒƒ“ƒgŽčp(EX-PRESS)‚ĚŽĄ—ÐŹŃ‚ƏpŒă‡•šÇ‚ĚŒŸ“˘DŠá‰Č 56:79-83, 2014.
  4. •‹ “Ö‰pA‰Í–ě ”Ž”VA‘şă ťFŠá“ŕƒŒƒ“ƒYoptic captureŒĹ’č–@‚̏pŒă’ˇŠú‚Ě‹üÜ“x”•Ď“Ž‚ɂ‚˘‚Ä. —ŐŠá68(9): 1355-1361, 2014.
  5. ‰PˆäˆŸ—R”üC–Ř‘şŽŠC´ěł•qC˛‹vŠÔr˜YCˆÉ“Ą—ćCŠC˜VŒ´LsFŒŒŠÇVś—Γŕá‚đ‡•š‚ˇ‚édÇ‘B“œ”A•a–Ô–ŒÇ‚ĚŽĄ—ÐŹŃ‚Ć—\Œă•s—LjöŽq‚ɂ‚˘‚Ä‚ĚŒŸ“˘DŠá—Ő‹I12F928-933, 2014
  6. ă—ŃŒ÷Ž÷A‰ĄŽR—˜KF‹üÜ‹¸ł‚¨‚ć‚ŃŒ’ŠáŽŐ•Â‰ş‚ĚƒrƒfƒIƒQ[ƒ€‚É‚ć‚莋—͉ü‘P‚đ“ž‚˝Źl•s“ŻŽ‹ŽăŽ‹‚Ě1—á. Šá‰Č—Տ°‹I—v7(8): 620-622, 2014.
  7. ěŽç“cŽě—˘Aŕ_’†‹P•FA•S–ěˆÉŒbF‚“x‚̍‚Šáˆł‚đŽŚ‚ˇÇ—á‚ɑ΂ˇ‚éüˆŰ’Œ‘̐؏œp•š—pƒ`ƒ…[ƒuƒVƒƒƒ“ƒgŽčp\•a—Šw“IŒŸ¸‚Š‚甝–ž‚ľ‚˝ChandlerÇŒóŒQ\. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 31(8): 1215-1218.
  8. ‰ŹŒ´ĘŽqAˆîŠ_Œ\ŽiA–Ľ—Ö—LŽqA“Ą’JŽüŽqA‘ĺ‰z‹MŽuŽqA‘şăťF“œ”A•a‰Š”Á•‚Žî‚ĚŠiŽqóŒő‹ĂŒĹ‚đŽ{s‚ľ‚˝•”ˆĘ‚Ě–Ô–ŒŠ´“x‚ĚŒŸ“˘. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 31(2):289-294, 2014.
  9. “n糌dA–Ř‘şŽŠA’†ŕV—LŒáAŠC˜VŒ´LsFłíŠáˆł—ΓŕáŠłŽŇ‚É‚¨‚Ż‚éƒ^ƒtƒ‹ƒvƒƒXƒg“_Šá‰t‚É‚ć‚鎥—ÐŹŃ‚ĚŒŸ“˘DŠá—Ő‹I 7(8):597-602, 2014.
  10. ‹Ę’u—mA•˝’Ë‹`@A‰Ş–{‰xŽiAŒFěŽő˜YFƒŒƒZƒvƒgƒf[ƒ^“ˍ‡‚É‚ć‚éˆă—Ă”ď‘‰Á‚ĚƒŠƒXƒNˆöŽq‚ĚŒŸ“˘|“Á’čŒ’Nf¸‚É‚¨‚Ż‚鎿–â•\‚¨‚ć‚ŃŠeŒŸ¸€–Ú‚Ě•ŞÍ|Œúś‚ĚŽw•W 61:1-5, 2014.
y‘ŕz
  1. ‘şă ťA“ĄŠŞ ‘ń˜YA“Ą–Ř ŒcŽqA–öě ˆ¤AVˆä ‰p‰îA–]ŒŽ —SlA‰Pˆä ˆŸ—R”üA“nçł ‚ˇ‚ÝŽqAź“c ˛AŠâ“c •ś”T: ŠáŽžŠł‚Ćˆâ“`Žq@Šá‰Čˆâ“`Žqf—Ă‚đ‚ß‚´‚ľ‚˝ˆâ“`î•ń‰đÍ. “úŠá‰ďŽ118i3jF283-298A2014.
  2. ‘ž“cr•F: Šá“ŕƒŒƒ“ƒY‹­–Œ“ŕŒĹ’čp. ę–ĺˆă‚Ě‚˝‚ß‚ĚŠá‰Čf—ĂƒNƒIƒŠƒtƒ@ƒCu20 Šá“ŕƒŒƒ“ƒY‚ĚŽg‚˘‚Š‚˝v, 233-239, ’†ŽR‘“X, 2014”N1ŒŽ.
  3. ‘ž“cr•F: Šá“ŕƒŒƒ“ƒY‹­–Œ“ŕŒĹ’čp. “ú–{‚ĚŠá‰Č Šá‰Čˆă‚ĚŽčˆř 85ŠŞ6†783-784, “ú–{Šá‰Čˆă‰ď, 2014”N6ŒŽ.
  4. ‘ž“cr•F: Šá“ŕƒŒƒ“ƒY‹­–Œ“ŕŒĹ’čp. Šá‰ČƒOƒ‰ƒtƒBƒbƒN3ŠŞ5†541-548, ƒƒfƒBƒJo”Ĺ, 2014”N9ŒŽ.
  5. ‘ž“cr•F: V‚ľ‚˘pŽŽ‚đ•]‰ż‚ˇ‚é \ Šá“ŕƒŒƒ“ƒY‹­–Œ“ŕŒĹ’čp. —Տ°Šá‰Č68ŠŞ13†, ˆăŠw‘‰@, 2014”N12ŒŽ.
  6. ŠC˜VŒ´LsFƒAƒgƒs[”’“ŕáE—Γŕá‚ĆƒXƒeƒƒCƒhŠO—p–ňD–ň‹Ç(“ěŽR“°) 64(6):82-85, 2013.
  7. ŠC˜VŒ´LsFRƒAƒŒƒ‹ƒM[“_Šá–ň‚Ě‚˘‚낢‚ëDVisual Dermatology (GŽĐ) 12(2):176-177, 2013.
  8. ŠC˜VŒ´LsF‰Ô•˛ŤŒ‹–Œ‰Š‚ɑ΂ˇ‚é“_Šá–ň‚É‚ć‚鏉Šú—Ă–@Dç—tŒ§ˆăŽt‰ďŽGŽ65(3):135-136, 2013.
  9. ŠC˜VŒ´LsFRƒAƒŒƒ‹ƒM[“_Šá–ň‚É‚ć‚鏉Šú—Ă–@DNANO OPHTHALMOLOGY (“ú–{“_Šá–ňŒ¤‹†Š)43:5-7, 2013.
  10. ŠC˜VŒ´LsFƒAƒgƒs[ŠáÇŠłŽŇ‚Ě‘‰ÁDç—tŒ§ˆăŽt‰ďŽGŽ65(7): 331, 2013.
  11. ŠC˜VŒ´ LsFƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠłD–ň‹Ç(“ěŽR“°) 65(5):80-86, 2014.
  12. ŠC˜VŒ´ LsF”DP‚ĆŠáDę–ĺˆă‚Ě‚˝‚ß‚ĚƒAƒŒƒ‹ƒM[ŠwuŔ@ƒAƒŒƒ‹ƒM[(“ú–{ƒAƒŒƒ‹ƒM[Šw‰ď) 63(5):669-673, 2014.
  13. •˝’Ë ‹`@, ŽR“c š˜a, ˆ˘‹vŞ —zŽq, ‘şă ť, ŽR‰ş ‰pr, ‘ĺ‹´ —TˆęFŠá‰Č—Տ°‚É‚¨‚Ż‚éƒAƒEƒgƒJƒ€•]‰żFV‚ľ‚˘Ž‹ŠoŠÖ˜AQOLŽw•WVFQ-J11. “úŠá‰ďŽ. 118 (12): 1038-1042, 2014.
  14. ˛‹vŠÔr˜YAŠC˜VŒ´LsFÇ—á‚ÉŠw‚ԁ@“Ş’É‚Ćšq“f‚đŽĺ‘i‚ÉŽóf‚ľ‚˝‹}Ť•ÂÇ‹÷Šp—Γŕá(—Γŕá”­ě)‚Ě1—áD‡“V“°çΎ–ŽGŽ 59(6): 513-515, 2013.
  15. ˛‹vŠÔr˜YF^‹ŰŤŠá“ŕ‰Š@ƒJƒ“ƒWƒ_Šá“ŕ‰ŠD Š´őÇ“ŕ‰Č 2(6)F620-625, 2014.
  16. “yŽŠ“cG: ƒIƒ‹ƒ\ƒPƒ‰ƒgƒƒW[‚ĚŽŔŰD‘ć‚P‰ń@‹üÜ‹¸ł–@‚É‚¨‚Ż‚铃Iƒ‹ƒ\ƒPƒ‰ƒgƒƒW[”‚ĚˆĘ’u‚Ă‚Ż‚Ć‚ť‚ĚŠT—vD’†Šw•ŰŒ’ƒjƒ…[ƒXD2014”N5ŒŽ8“ú”­sDp11-12, 2014.
  17. –{“c”üŽ÷FRVEGFŽĄ—ĂƒZƒ~ƒi[@–ňÜ•Ę@ƒAƒtƒŠƒxƒ‹ƒZƒvƒgD‚ ‚˝‚ç‚ľ‚˘Šá‰Č 31(3)F375-376, 2014.
  18. M–؏rŹFŠp–ŒˆÚAŒŁŠá‚ĚŠá‹…“Eo. OCULISTA 16: 41-45, 2014.
  19. ŞŠÝ‹MŽu: śŠá‚̐ć“VŤăŽÎ‹Ř–ƒáƒ. Šá‰ČƒOƒ‰ƒtƒBƒbƒN 3(4): 444-447. 2014.
  20. ŞŠÝ‹MŽu: Šá‹…“Eop. Šá‰ČƒOƒ‰ƒtƒBƒbƒN 3(4): 390-393. 2014.
  21. ŞŠÝ‹MŽu: yƒ^[ƒQƒbƒg•ĘI‰ć‘œf’f‚¨•‚ŻƒKƒCƒh-Šî–{‰ć‘œ‚Š‚çĹVƒ‚ƒ_ƒŠƒeƒB‚܂Łz@ƒ^ƒCƒ~ƒ“ƒO•Ę@p’†EpŒă ŽÎŽ‹pŒă. —Տ°Šá‰Č 68(11): 288-292. 2014.
  22. ŞŠÝ‹MŽu: ŽÎŽ‹‚ĆŠÖ˜AŽžŠł ƒAƒgƒƒsƒ“‚É‚ć‚é‹ßŽ‹is—\–h‚ɂ‚˘‚Ä. Šá‰Č 56(12): 1455-1458. 2014.
  23. ŞŠÝ‹MŽu: ‹üÜ‹¸łnewest\•Ű‘ś—Ă–@‚ĆŽčp‚Ě”äŠr\ ŹŽ™‚ĚŠá‹žˆ•ű. Oculista 21: 18-21, 2014.
  24. ŞŠÝ‹MŽu: ’É‚­‚Č‚˘‹ÇŠ–ƒŒŽÎŽ‹Žčp. https://iseminar.net/e05200137 (2014.11.5)
  25. ŞŠÝ‹MŽu: ŒĹ’č“ŕŽÎŽ‹@‰ĄŽR–@m•ŇWĎE‰đŕ•tn. https://iseminar.net/e05200136 (2014.9.3)
  26. ŞŠÝ‹MŽu: “Ś‚ł‚¸f‚é‚É‚Í‚ą‚ą‚Ş‘ĺŘ! ŽÎŽ‹ŠO—ˆmƒnƒ“ƒhƒAƒEƒg•tn. https://iseminar.net/e05100166 (2014.8.8)
  27. ŞŠÝ‹MŽu: ŽÎŽ‹EŠáŽ‰‚Š‚ç‚ǂ̂悤‚ɏŹŽ™“ŕŠáŽžŠł‚đ”­ŒŠ‚ˇ‚é‚Š@Skiacope‚Š‚çŽn‚Ü‚éŹŽ™Šá‰Č‚Ö‚ĚƒAƒvƒ[ƒ`. https://iseminar.net/e05100164 (2014.6.18)
  28. ŞŠÝ‹MŽuAŽO—֓ޓߎq: Šá‹…‰^“Ž‚đ—‰đ‚ˇ‚é‚˝‚ß‚É•K—v‚Č1E2E3yę–ĺˆăŽŽŒą‘΍ôEƒ`ƒFƒbƒNƒeƒXƒg•t‚Ťz. https://iseminar.net/e05100163 (2014.6.4)
  29. ŞŠÝ‹MŽuAŽOŽ÷ˆŸ–í‰Ŕ: ‹üÜEŽ‹—ÍŒŸ¸‚ĚŠî–{ Ž‹—Í‚Á‚ÄC‚ž‚Ż‚ś‚á‚Č‚˘‚́H. https://iseminar.net/e05100161 (2014.3.12)
  30. ŞŠÝ‹MŽu: ŠO“]_Œo–ƒáƒ‚ɑ΂ˇ‚鐟“c–@m•ŇWĎE‰đŕ•tn. https://iseminar.net/e05200135 (2014.2.12)
  31. ŞŠÝ‹MŽuA‘ƒŽR ˆŸ‹IŽq: ‚ą‚ę‚ž‚Ż‚Í’m‚Á‚Ä‚¨‚Ť‚˝‚˘IFŠoˆŮí‚ĚŠî–{. https://iseminar.net/e05100155 (2013.11.26)
  32. ŞŠÝ‹MŽu: ‚â‚ł‚ľ‚˘‰şŽÎ‹ŘŘœpm•ŇWĎE‰đŕ‚ ‚čn. https://iseminar.net/e06200153 (2013.11.8)
  33. ŞŠÝ‹MŽu: ‰~ŠW•”ŹŘŠJ‚É‚ć‚éŠO’ź‹ŘŒă“]p m•ŇWĎE‰đŕ•tn. https://iseminar.net/e05200124 (2013.6.20)
  34. ŞŠÝ‹MŽu: –Ô–Œ‰č×–EŽî‚ɑ΂ˇ‚éŠá‹…“Eop m•ŇWĎE‰đŕ•tn. https://iseminar.net/e06200120 (2013.6.10)
  35. ŞŠÝ‹MŽu: ‹ƒ‚Š‚ł‚¸f‚é‚Ć‚ą‚ń‚Č‚ÉŠy‚ľ‚˘ŹŽ™Šá‰Č. https://iseminar.net/e05100110 (2013.3.18)
  36. ’J“ŕC‘ž˜Y: ‘B“œ”A•a–Ô–ŒÇ‚ĚŽĄ—ĂŽwj. https://iseminar.net/e04100159 (2014.8.20)
  37. ŽRŒűš‘ĺAˆÉ“Ą—DŽq: SCL‚ɂ‚˘‚Ä. https://iseminar.net/e01100172 (2014.10.22)
  38. ŽRŒűš‘ĺA‘ş“c’ź”ü: HCL‚ɂ‚˘‚Ä. https://iseminar.net/e01100171 (2014.10.8)
  39. ‚ŒK‰Á•c: Šá‰Č—Ěˆć‚É‚¨‚Ż‚éƒXƒeƒƒCƒh‚Ě‘Sg“Š—^. https://iseminar.net/e07100162 (2014.5.7)
  40. t“úrŒő, ’r“c’q‰›: Ž‹–ěŒŸ¸‚ĚŠî–{ GPEHFAEFDT. https://iseminar.net/e05100159 (2014.1.28)
  41. •˝’Ë‹`@AŹ–ě_ˆęF”’“ŕáŽčp‚̎ЉďvŒŁ:@ƒNƒIƒŠƒeƒBEƒAƒNƒZƒXEƒRƒXƒg‚Š‚ç”’“ŕáŽčp‚đl‚Ś‚éDIOL&RS, 27328-27334, 2013.
  42. ŕ_’†‹P•FFƒoƒ‹ƒxƒ‹ƒgƒ`ƒ…[ƒu‚đ‚Ç‚¤Žg‚¤H. OPHTHALMIC FORESIGHT 18(2)
  43. ‘ĺ‰z‹MŽuŽqFƒsƒ…ƒAƒCƒGƒ[ ƒŒ[ƒU[Œő‹ĂŒĹIQ577‚É‚ć‚éƒ}ƒCƒNƒƒpƒ‹ƒX臒l‰ş‹ĂŒĹ. TOMEY OPHTHALMOLOGY NEWS 50:6-9, 2014.
  44. ‘ĺ‰z‹MŽuŽqFƒ}ƒCƒNƒƒpƒ‹ƒX臒l‰ş‹ĂŒĹ. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 31(1):29-35.
  45. ‘ĺ‰z‹MŽuŽqFMicroPulseTM lazaer‚É‚ć‚é臒l‰şƒŒ[ƒU[ŽĄ—Ă. MEDICAL PHOTONIGS 18:38-44, 2014. iŠ”jƒIƒvƒgƒ[ƒNƒXŽĐA“Œ‹ž.
  46. źˆä–ƒ‹I, ‘ž“cr•F: Šá‹…”j—ô. —Տ°Šá‰Č68ŠŞ11†, 2014”N10ŒŽ.
  47. _•”—FFŹŽ™f’f‹@Ší‚ĚŽg—pƒ|ƒCƒ“ƒg. Šá‰ČƒOƒ‰ƒtƒBƒbƒN 3(6): 588-590, 2014.
  48. ‰PˆäˆŸ—R”üFŠá‰Čˆă‚Ě‚˝‚߂̐ć’[ˆă—Ă(‘ć159‰ń)@–Ô–Œ×–E•Ş‰ť‚É‚¨‚Ż‚éƒGƒsƒWƒFƒlƒeƒBƒbƒN‹@\‚ĆmicroRNA‚Ě–đŠ„D‚ ‚˝‚ç‚ľ‚˘Šá‰Č 31(3)F383-385, 2014.
  49. ‰Ş“c—L‰Â: Šá’ęŽĘ^‚ĚŽB‚č•ű. https://iseminar.net/e05100165 (2014.7.2)
  50. œAŁ—TŽq: Heidelberg Spectralis. https://iseminar.net/e04100158 (2014.6.18)
y’˜‘z
  1. ‰ĄŽR—˜KF‡U Œ´ˆö•s–ž‚ĚŽ‹_ŒoˆŢk‚đf‚˝‚ç ć“VˆŮí. _ŒoŠá‰Čf’fƒNƒ[ƒYƒAƒbƒv, •ŇW •~“‡ŒhŒĺ, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 42-47, 2014.
  2. ŠC˜VŒ´LsFƒAƒgƒs[ŠpŒ‹–Œ‰ŠDŠá‰Čf—ĂƒNƒIƒŠƒtƒ@ƒCiƒƒfƒBƒJƒ‹ƒIƒtƒTƒ‹ƒ‚ƒƒW[Šá‰Č–ň•¨ŽĄ—Ă‚Ě‚ˇ‚ׂājC•ŇW@‘ş“c•q‹KC’†ŽR‘“XC“Œ‹žC23-24C2013.
  3. ŠC˜VŒ´LsFŽ…óŠp–Œ‰ŠDŠá‰Čf—ĂƒNƒIƒŠƒtƒ@ƒCiƒƒfƒBƒJƒ‹ƒIƒtƒTƒ‹ƒ‚ƒƒW[Šá‰Č–ň•¨ŽĄ—Ă‚Ě‚ˇ‚ׂājC•ŇW@‘ş“c•q‹KC’†ŽR‘“XC“Œ‹žC95-96, 2013.
  4. ŠC˜VŒ´LsFŠp–Œ•ĎŤiŠp–ŒŽ‰–b•ĎŤATerrien•Ó‰Šp–Œ•ĎŤjDŠá‰Čf—ĂƒNƒIƒŠƒtƒ@ƒCiƒƒfƒBƒJƒ‹ƒIƒtƒTƒ‹ƒ‚ƒƒW[Šá‰Č–ň•¨ŽĄ—Ă‚Ě‚ˇ‚ׂājC•ŇW@‘ş“c•q‹KC’†ŽR‘“XC“Œ‹žC103-105, 2013.
  5. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠłDĄ“ú‚ĚŽĄ—ĂŽwjC•ŇW â–{‘דńCˆăŠw‘‰@C“Œ‹žC1251-1253, 2013.
  6. ŠC˜VŒ´LsA‘şăťFTerrienŠp–Œ•Ó‰•ĎŤDŠá‰ČŽžŠłĹV‚ĚŽĄ—Ă2013-2015C•ŇW ‘ĺ‹´—TˆęC“ě]“°C“Œ‹žC124, 2013.
  7. ŠC˜VŒ´LsFƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠłDƒCƒ`‚Š‚ç’m‚č‚˝‚˘ƒAƒŒƒ‹ƒM[f—ÁD•ŇW ‘ĺ‹v•ŰŒö—TC‘S“ú–{•a‰@o”ʼnďC“Œ‹žC116-121, 2014.
  8. ŠC˜VŒ´LsFt‹GƒJƒ^ƒ‹‚É‚¨‚˘‚ÄŒ‹–Œ‚ĆŠp–Œ‚̊Ԃłǂ̂悤‚Č•ŞŽq‚Ě‘ŠŒÝě—p‚Ş‚ ‚č‚Ü‚ˇ‚ŠDŠá‰Čf—ĂƒNƒIƒŠƒtƒ@ƒCiŠp–ŒŹ‘÷‚Ě‚ˇ‚ׂājC•ŇW ˆäăKŽŸC’†ŽR‘“XC“Œ‹žC154-155, 2014.
  9. •˝’Ë‹`@F”’“ŕáŽčp‚É‚¨‚Ż‚é”ď—pŒř—p•ŞÍ‚Ě•ű–@‚ĆŒ‹‰Ę@ˆă—ĂŒoĎ•]‰ż‚Ě‹ď‘Ě“I‚ČŠˆ—p–@@ˆă—ĂŒoĎ@‹Zpî•ń‹Ś‰ďA“Œ‹žA•iěA2014”N12ŒŽ
  10. ŞŠÝ‹MŽu: Žčp‚É•K—v‚ČŠí‹ď. Šá‰ČŽčpŠw3 Šá‹ŘE—ÜŠí: 88-93. 2014.
  11. ŞŠÝ‹MŽu: p–ě‚̏€”ő. Šá‰ČŽčpŠw3 Šá‹ŘE—ÜŠí: 109-112. 2014.
  12. ŞŠÝ‹MŽu: ŒĄˆřŽŽŒą. Šá‰ČŽčpŠw3 Šá‹ŘE—ÜŠí: 113-116. 2014.
  13. ŞŠÝ‹MŽu: Œ‹–ŒŘŠJ. Šá‰ČŽčpŠw3 Šá‹ŘE—ÜŠí: 117-119. 2014.
  14. ŞŠÝ‹MŽu: Œ‹–Œ–D‡. Šá‰ČŽčpŠw3 Šá‹ŘE—ÜŠí: 120-121. 2014.
  15. ŞŠÝ‹MŽu: ƒNƒŠƒjƒJƒ‹EƒNƒGƒXƒ`ƒ‡ƒ“ “ŕŽÎŽ‹pŒăŠOŽÎŽ‹‚͂ǂ̂悤‚ÉŽĄ—Ă‚ˇ‚ׂŤ‚Ĺ‚ľ‚傤‚ŠH. ę–ĺˆă‚Ě‚˝‚ß‚ĚŠá‰Čf—ĂƒNƒIƒŠƒtƒ@ƒC22 ŽÎŽ‹EŽăŽ‹f—Ă‚ĚƒXƒ^ƒ“ƒ_[ƒh: 173-174. 2014.
  16. _•”—FFŠáˆĘŒŸ¸. ŠáŽčpŠw 3.Šá‹ŘE—ÜŠí , •ŇW@˛“Ą”ü•Ű, •śŒő“°, “Œ‹ž, 54-58, 2014.
y•ń‚ť‚Ě‘źz
  1. ‘şă ť: Šá‰Čˆă‚ĚŽčˆř@ˆâ“`Šw“IŒŸ¸‚Ćˆâ“`ƒJƒEƒ“ƒZƒŠƒ“ƒO. “ú–{‚ĚŠá‰Č85(10): 1415-1416, 2014.
  2. ‰ĄŽR—˜K ‘źF“dŽqƒJƒ‹ƒeu‹Î–ąˆă‚̕Łv“Á•ĘŠé‰ćŔ’k‰ď. “ú–{‚ĚŠá‰Č 85(8):1167-1182.
  3. ‘ž“cr•F: ”’“ŕá‚ÉŠÖ‚ˇ‚éƒCƒ“ƒ^ƒrƒ…[ (Çó, Œ´ˆö, ’N‚Ĺ‚ŕ‚Č‚éH”NŠÔŽčpŒ”, •ú‚Á‚Ä‚¨‚­‚Ć…, ]—ˆ‚ĚŽčp–@, ‘ž“c‹łŽö‚̐V‚ľ‚˘Žčp–@). Ă‰Ş‘ćˆęƒeƒŒƒrwnews every. ‚ľ‚¸‚¨‚ŠxŒ’NƒR[ƒi[, 2014”N3ŒŽ12“ú.
  4. ‘ž“cr•F: ’ƒŠR157†, 2014”N12ŒŽ.
  5. Ohta T: Sutureless intrascleral posterior IOL fixation method may be safer than other fixation techniques. Ocular Surgery News (U.S. Edition, web magazine), March 25, 2014.
    http://www.healio.com/ophthalmology/cataract-surgery/news/print/ocular-surgery-news/%7Bc85bd659-d914-44f7-b566-20502ff15b7a%7D/sutureless-intrascleral-posterior-iol-fixation-method-may-be-safer-than-other-fixation-techniques
  6. ‘ž“cr•F: Šá“ŕŽ•œŽčp‚ɐVŽč–@. Ă‰ŞV•ˇ’ŠŠ§, 2014”N6ŒŽ22“ú.
  7. ‘ž“cr•F: Y-Fixation Technique, T-Fixation Technique <’ISRS Surgeon of the Month’‚Ć‚ľ‚ÄISRSƒEƒFƒuƒTƒCƒg‚É‚ÄĐ‰î>, International Society of Refractive Surgery (ISRS), July 7, 2014.
    yĐ‰îƒy[ƒWz
    https://www.facebook.com/ISRS.org/photos/a.479044495457024.95182054.148022648559212/877476405613829/?type=1
    yŽčp“Ž‰ć‚ĚĐ‰î (ISRS, AAO and AAOE members only)z
    http://www.aao.org/isrs/multimedialibrary.cfm?vid=c8c4bc6073ae43ecaa5935784103e2e2&app=b435b5fb0c8a4769b3068512c8a518bd
  8. ‘ž“cr•F: ’ƒŠR157†, 2014”N12ŒŽ‰ş{”­s—\’č
  9. ŠC˜VŒ´LsF•ń‘ć67‰ń“ú–{—Տ°Šá‰ČŠw‰ďSpeial Intrest Group Meeting (SIG). “ú–{Šá‰ČƒAƒŒƒ‹ƒM[Œ¤‹†‰ďC—ŐŠáiˆăŠw‘‰@jC68(6): 874-875, 2014.
  10. “yŽŠ“cG: CL‘•—p‚ĆŠ´őÇ. ‘ć27‰ń. ƒAƒNƒl‹ŰŠp–Œ‰Š. “úƒRƒŒŽ56: 61-62, 2014.
  11. “yŽŠ“cG: CL‘•—p‚ĆŠ´őÇ. ‘ć29‰ń. ƒuƒhƒE“œ”ń”­yƒOƒ‰ƒ€‰AŤž…‹ŰŠ´őÇ. “úƒRƒŒŽ56: (ˆóü’†), 2014.
  12. “yŽŠ“cG: CLƒoƒgƒ‹ƒƒCƒ„ƒ‹ƒT[ƒhƒXƒe[ƒW@‘ć36‰ń@Šp–ŒˆÚAŒăD“úƒRƒŒŽ56F109-110, 2014.
  13. “yŽŠ“cG: ƒhƒ‰ƒCƒAƒC‚Ƃ́H, news every. ‚ľ‚¸‚¨‚Š, Ă‰Ş‘ćˆęƒeƒŒƒr, 2014”N10ŒŽ15“ú.
  14. ŽRŒű’B•vF‹ßŽ‹ƒŒ[ƒU[Žčp‚̍Ą‚đ’Ç‚¤. NHK‚˝‚ß‚ľ‚ăKƒbƒeƒ“u–Ú‚Ě˜V‰ťv‚đ–h‚ŽVíŽŻ p124-126, Žĺ•w‚ƐśŠˆŽĐ.
  15. ‘ĺ‰z‹MŽuŽqF“‚ ‚č‚Ş‚Ć‚¤”‚ŞŒž‚Ś‚邨łŒŽ. “ú–{‚ĚŠá‰Č 85(1):9-10, 2014.
  16. ‘ĺ‰z‹MŽuŽqF’áNPƒŒ[ƒU[‚ĚŒťó‚Ć–˘—ˆ. ‹{éŒ§Šá‰Čćiˆă—ĂŒ¤‹†‰ď.
  17. ‘ĺ‰z‹MŽuŽqF“œ”A•a‰Š”ÁŽî‚Ě•a‘Ô‚ĆŽĄ—Ð헪. ƒmƒoƒ‹ƒeƒBƒX, ƒAƒ‹ƒRƒ“.
  18. ‘ĺ‰z‹MŽuŽqFNew Possibilities for Photo-thermal Laser Treatment of Macular Disease…Endpoint Management with PASCAL. TOPCON.
  19. “Ą–ŘŒcŽq: Jin H. Kinoshita ćś‚ĆNEI ‚Ĺ‚ĚŽv‚˘o. ‚ ‚˝‚ç‚ľ‚˘Šá‰Č@31(3):391-392, 2014.
  20. ŞŠÝ‹MŽu: 2014 Ophthalmic Surgery Film Award. Educational•”–ĺ Silver Award. 2014.11.14.
  21. ”~‰Ž—ćŽqFŽqˆç‚Ä‚Ěƒuƒ‰ƒ“ƒN‚đŒo‚Ä‘ĺŠw•‘Ž•a‰@‚Ö•œ‹A‚ľ‚˝“š‚Ě‚č‚ĆŒť‹ľ. ç—tŒ§Šá‰Čˆă‰ď’j—‹¤“ŻŽQ‰ć„i‚̉ď, ç—t, 2014”N2ŒŽ.
  22. źˆä–ƒ‹I: Ç—á”­•\. AMD‚Ě’ˇŠúŽĄ—Ð헪`‚ć‚č—Ç‚˘Ž‹—Í‚đ‹‚ß‚Ä, ‰Ą•lŽs, 2014”N9ŒŽ27“ú.
  23. •‹ “Ö‰pA‰Í–ě ”Ž”VA‘şă ťFŠá“ŕƒŒƒ“ƒYoptic captureŒĹ’č–@‚̏pŒă’ˇŠú‚Ě‹üÜ“x”•Ď“Ž‚ɂ‚˘‚Ä. —Տ°Šá‰Č68(9): 1355-1361, 2014.
  24. źč—LC: Šá“ŕŽ•œŽčp‚ɐVŽč–@. Ă‰ŞV•ˇ’ŠŠ§, 2014”N6ŒŽ22“ú.
  25. Šâ–{—ĺF•˝Ź25”N“x“ú–{Šá‰ČƒAƒŒƒ‹ƒM[Œ¤‹†‰ď—DGÜ‚đŽóÜ‚ľ‚Ä. “ú–{Šá‰ČƒAƒŒƒ‹ƒM[Œ¤‹†‰ď •˝Ź25”N“x”NŽŸ•ń‘, 5-6, 2014.
  26. –؉ş –Î(“ú–{ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYŠw‰ď)A‘ĺ‹´ —TˆęA‘şă ťAŽ…ˆä ‘fƒAˆî—t šŠŰAA“c ŠěˆęA‰F’ĂŒŠ ‹`ˆęAŠ“c ‰ë‹`A‹ŕˆä ~AŹ‹Ę —TŽiAŕV [A‰ş‘ş ‰ĂˆęA’Ř“c ˆę’jAŕ_–ě FA‘O“c ’ź”VA‹g–ě Œ’ˆęA“nçł Œ‰AŹě {ŽqAčŒł ’¨A˛–ě Œ¤“ńA‰–’J _A‚‘ş ‰xŽqAj’J –ž”üA•Ÿ“c š•FA…’J ‘A–öˆä —ş“ń: “ú–{ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYŠw‰ďƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYf—ĂƒKƒCƒhƒ‰ƒCƒ“•ŇWˆĎˆő‰ď yƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYf—ĂƒKƒCƒhƒ‰ƒCƒ“(‘ć2”Ĺ)z. “úŠá‰ďŽ118(7): 557-59, 2014.
  27. ‹g‘ş ’ˇ‹vA“Œ ”͍sA™ŽR ˜a‹vA’JŒ´ GMAŠâ“c ŠxA”Ń“c ’mOA•s“ń–ĺ ŽA’Ř“c ˆę’jA‘ĺ‹´ —TˆęAŽO‘ş ŽĄA–x“c Šě—TA‘şă ťAŽR‰ş ‰prA‘ĺ–ě ‹žŽqAŠO‰€ çŒbAˆî•x •×A‘ĺÎ –žś: “ŤŽžŠł‚ĚÇ—á”‚Ě‘S‘’˛¸. “úŠá‰ďŽ118(2): 134-13, 2014.
  28. ˆŔ“c–žOFŽčp‚ĹŽĄ‚š‚é‹ßŽ‹A‰“Ž‹A—Ž‹A‚ť‚ľ‚ĘVŠá. Œ’N‚Ö‚Ě“š, šƒ‹ƒJlŠÔƒhƒbƒN—F‚̉ď‰ď•ńŽ, 2014”N9ŒŽ.
 
Copyright © 2005 JUNTENDO All Rights Reserved.